ANNUAL REPORT OF THE PRESIDENT OF THE EXECUTIVE COMMITTEE

1. Presented below, in compliance with Article 9.C of the Constitution of the Pan American Health Organization (PAHO), is the report on the activities carried out by the Executive Committee and its Subcommittee on Program, Budget, and Administration (the Subcommittee) between September 2020 and September 2021. During that time, the Executive Committee held two sessions: the 167th Session, on 30 September 2020, and the 168th Session, from 21 to 25 June 2021. The Subcommittee on Program, Budget, and Administration held its 15th Session from 24 to 26 March 2021. Details of those sessions may be found in the respective final reports (Documents CE167/FR, CE168/FR and SPBA15/FR). Owing to the extraordinary and unprecedented circumstances presented by the COVID-19 pandemic, the sessions of the Governing Bodies in 2020 and 2021 were held online using a video conferencing platform.

2. The Members of the Executive Committee during the reporting period were Barbados, Brazil, Costa Rica, Cuba, Ecuador, Haiti, Mexico, Suriname, and the United States of America. The following Members were elected to serve as officers for the period: Costa Rica (President), Haiti (Vice President), and Ecuador (Rapporteur). The Members of the Subcommittee elected by the Executive Committee or designated by the Director were: Barbados, Canada, Ecuador, Guatemala, Mexico, United States of America, and Uruguay. The Subcommittee elected Uruguay as its President, Mexico as its Vice President, and Guatemala as its Rapporteur.

3. During the 167th Session, Barbados and Mexico were elected to serve on the Subcommittee on Program, Budget, and Administration on the expiration of the periods of office of Belize and Peru on the Executive Committee. In addition, as the Award Committee had not met in 2020, it was proposed that the members appointed at the 165th Session of the Executive Committee, Barbados, Costa Rica, and the United States of America, should continue to serve on the Award Committee as principal delegates, and that two new members, Brazil and Ecuador, should be appointed to serve as alternates, since the alternates appointed in 2019, Belize and Peru, were no longer Members of the Executive Committee. The Executive Committee also set the dates for the 15th Session of the Subcommittee on Program, Budget, and Administration, the 167th Session of the
Executive Committee, and the 58th Directing Council; and discussed the topics to be examined by the Governing Bodies during the year.

4. During its 167th Session, the Executive Committee also discussed a number of items that normally would have been discussed during its 166th Session in June 2020, but were deferred so that the Committee could focus exclusively on matters related to the COVID-19 pandemic and matters that had to be decided upon to ensure the Organization’s ability to properly discharge its functions. Those items included the following matters:

**Committee Matters**

- Engagement with non-State Actors
- Non-State Actors in Official Relations with PAHO
- Annual Report of the Ethics Office for 2019
- Report of the Audit Committee of PAHO

**Administrative and Financial Matters**

- Report of the Office of Internal Oversight and Evaluation Services for 2019

**Personnel Matters**

- PASB Human Resources Management
- Statement by the Representative of the PAHO/WHO Staff Association

**Matters for Information**

- PASB Management Information System (PMIS): Lessons Learned
- PAHO Governance Reform: Internal Assessment of the Approval Process of Projects Funded by Voluntary Contributions
- Emergency Loan from the Revolving Fund for Access to Vaccines to the Regional Revolving Fund for Strategic Public Health Supplies

5. At the 167th Session, the Executive Committee adopted one resolution and nine decisions, which appear, together with a summary of its deliberations, in the Final Report of the Session (Annex A to Document CD59/2).

6. During the 168th Session, the Executive Committee appointed the delegates of Costa Rica and Ecuador, its President and Rapporteur, respectively, to represent it at the 59th Directing Council, 73rd Session of the WHO Regional Committee for the Americas. Haiti and the United States of America were appointed as alternate representatives. The Committee also approved the provisional agenda for the 59th Directing Council. In
addition, the Committee appointed a member to the PAHO Audit Committee and selected the recipient of the PAHO Award for Health Services Management and Leadership 2021.

7. The following matters were also discussed during the 168th Session:

**Program Policy Matters**

- Proposed Program Budget of the Pan American Health Organization 2022-2023
- Scale of Assessed Contributions 2022-2023
- Roadmap for the Digital Transformation of the Health Sector in the Region of the Americas
- Policy on the Application of Data Science in Public Health Using Artificial Intelligence and Other Emerging Technologies
- Increasing Production Capacity for Essential Medicines and Health Technologies
- One Health: A Comprehensive Approach for Addressing Health Threats at the Human-Animal-Environment Interface
- Reinvigorating Immunization as a Public Good for Universal Health
- Strategy for Building Resilient Health Systems and Post COVID-19 Pandemic Recovery to Sustain and Protect Public Health Gains

**Administrative and Financial Matters**

- Report on the Collection of Assessed Contributions
- Appointment of the External Auditor of PAHO for 2022-2023
- Update on the Master Capital Investment Fund
- Update on the Working Capital Fund
- Report on the Status of the Emergency Loan from the Revolving Fund for Access to Vaccines to the Regional Revolving Fund for Strategic Public Health Supplies

**Personnel Matters**

- Amendments to the PASB Staff Regulations and Rules
- PASB Human Resources Management
- Statement by the Representative of the PAHO/WHO Staff Association

**Matters for Information**

- Update on COVID-19 in the Region of the Americas
- Report on Strategic Issues between PAHO and WHO
• Implementation of the International Health Regulations

8. At the 168th Session, the Executive Committee adopted 16 resolutions and two decisions, which appear, together with a summary of the presentations and discussions on each item, in the Final Report of the Session (Annex B to Document CD59/2).

Annexes
# CONTENTS

**Page**

**Opening of the Session**

**Procedural Matters**
- Election of Officers .......................................................... 4
- Adoption of the Agenda ....................................................... 5

**Committee Matters**
- Election of Two Members to the Subcommittee on Program, Budget, and Administration .................................................. 5
- Engagement with non-State Actors ........................................ 5
- Non-State Actors in Official Relations with PAHO ..................... 6
- Annual Report of the Ethics Office for 2019 ............................. 7
- Report of the Audit Committee of PAHO ................................. 10
- Appointment of the Award Committee for the PAHO Award for Health Services Management and Leadership 2021 .......... 14

**Administrative and Financial Matters**
- Report of the Office of Internal Oversight and Evaluation Services for 2019 ........ 15

**Personnel Matters**
- PASB Human Resources Management .................................... 17
- Statement by the Representative of the PAHO/WHO Staff Association ......... 17

**Governing Bodies Matters**
- Proposed Dates for Meetings of the Governing Bodies of PAHO in 2021 ........ 20
- Proposed Topics for Meetings of the Governing Bodies in 2021 ............... 21

**Matters for Information**
- PASB Management Information System (PMIS): Lessons Learned ............ 23
- PAHO Governance Reform: Internal Assessment of the Approval Process of Projects Funded by Voluntary Contributions .................................................. 24
- Emergency Loan from the Revolving Fund for Access to Vaccines to the Regional Revolving Fund for Strategic Public Health Supplies .................. 27

**Other Matters** ......................................................................... 27

**Closure of the Session** .......................................................... 28
CONTENTS (cont.)

Resolutions and Decisions

Resolutions
CE167.R1: Non-State Actors in Official Relations with PAHO ............... 28

Decisions
CE167(D1): Election of Officers ..................................................... 29
CE167(D2): Adoption of the Agenda .............................................. 29
CE167(D3): Election of Two Members to the Subcommittee on Program, Budget, and Administration ........................................ 30
CE167(D4): Appointment of the Award Committee for the PAHO Award for Health Services Management and Leadership 2021 .............................................. 30
CE167(D5): Dates of the 15th Session of the Subcommittee on Program, Budget, and Administration .............................................. 30
CE167(D6): Dates of the 168th Session of the Executive Committee .............. 30
CE167(D7): Dates of the 59th Directing Council, 73rd Session of the Regional Committee of WHO for the Americas ..................... 30
CE167(D8): Topics for Discussion during the 15th Session of the Subcommittee on Program, Budget, and Administration .......... 31
CE167(D9): Topics for Discussion during the 168th Session of the Executive Committee ................................................................. 31

Annexes
Annex A. Agenda
Annex B. List of Documents
Annex C. Proposed Topics for Meetings of the Governing Bodies of PAHO in 2021: 15th Session of the Subcommittee on Program, Budget, and Administration
Annex D. Revised List of Proposed Topics for Meetings of the Governing Bodies of PAHO in 2021: 15th Session of the Subcommittee on Program, Budget, and Administration
Annex E. Proposed Topics for Meetings of the Governing Bodies of PAHO in 2021: 168th Session of the Executive Committee
Annex F. Revised List of Proposed Topics for Meetings of the Governing Bodies of PAHO in 2021: 168th Session of the Executive Committee
Annex G. List of Participants
FINAL REPORT

Opening of the Session

1. The 167th Session of the Executive Committee was held on 30 September 2020. Owing to the extraordinary and unprecedented circumstances presented by the COVID-19 pandemic, the session was held online using a virtual meeting platform. The session was attended by representatives of the following nine members of the Executive Committee elected by the Directing Council: Barbados, Brazil, Costa Rica, Cuba, Ecuador, Haiti, Mexico, Suriname, and the United States of America. Delegates of the following Member States, Participating States, Associate Members, and Observer States attended in an observer capacity: Argentina, Aruba, Canada, Chile, Colombia, Dominican Republic, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, and Venezuela.

2. The Honorable Jeffrey Bostic (Barbados, Outgoing President of the Executive Committee) opened the session and welcomed the participants, extending a special welcome to the new members elected by the recently concluded 58th Directing Council: Brazil, Cuba, and Suriname.

3. Dr. Carissa Etienne (Director, Pan American Sanitary Bureau), adding her welcome to all participants, highlighted the important role of the Executive Committee in providing advice and guidance on matters critical for the transparent, effective, and efficient work of the Pan American Sanitary Bureau (PASB or the Bureau) in support of Member States. She noted that, in addition to deciding on the dates and topics for the 2021 sessions of the Governing Bodies, the Committee would be considering items that would ordinarily have been considered by the Governing Bodies earlier in the year, but that had been deferred owing to the circumstances surrounding the COVID-19 pandemic.

Procedural Matters

Election of Officers

4. Pursuant to Rule 15 of the Rules of Procedure of the Executive Committee, the Committee elected the following Member States to serve as officers for the period from September 2020 to September 2021 (Decision CE167[D1]):

    President: Costa Rica (Ms. Adriana Salazar González)
    Vice President: Haiti (Dr. Jean Patrick Alfred)
    Rapporteur: Ecuador (Mr. Fernando R. Jácome Gavilánez)

5. The Director of the Pan American Sanitary Bureau, Dr. Carissa Etienne, served as Secretary ex officio, and the Deputy Director, Ms. Mary Lou Valdez, served as Technical Secretary.
Adoption of the Agenda (Document CE167/1)

6. Pursuant to Rule 9 of its Rules of Procedure, the Committee adopted, without change, the provisional agenda prepared by the Director (Decision CE167[D2]).

Committee Matters

Election of Two Members to the Subcommittee on Program, Budget, and Administration

7. Pursuant to Rule 45 of its Rules of Procedure, the Committee elected Barbados and Mexico to serve on the Subcommittee on Program, Budget, and Administration on the expiration of the periods of office of Belize and Peru on the Executive Committee. The Committee expressed appreciation to the outgoing members of the Committee for their service (Decision CE167[D3]).

Engagement with non-State Actors (Document CE167/2)

8. Dr. Heidi Jiménez (Legal Counsel, PASB) recalled that the Framework of Engagement with non-State Actors (FENSA) had been adopted by the World Health Assembly in May 2016 and by the Directing Council of the Pan American Health Organization (PAHO) in September 2016, noting that the Directing Council had asked the Director to report to the Executive Committee each year on the Bureau’s implementation of the Framework. She informed the Committee that, as requested by the PAHO Member States, the Bureau continued to cooperate closely with the WHO Secretariat on the implementation of FENSA, while always taking into account PAHO’s Constitution and legal status. The Bureau’s focal point for FENSA kept staff updated on applicable procedures, conducted staff training and briefings, and frequently provided guidance and support during the initial stages of potential engagement with non-State actors. During 2019, the Bureau had conducted over 200 due diligence and risk assessments of non-State actors and hundreds of simplified reviews of low-risk engagements. Some examples were included in Document CE167/2.

9. Dr. Jiménez emphasized that the Bureau recognized the value and benefits of working with non-State actors and their contributions to public health and to the fulfillment of PAHO’s mission. She pointed out that PAHO had a long history of collaboration with non-State actors which pre-dated FENSA. Its engagement with non-State actors took various forms, including participating in one another’s meetings, conducting advocacy, exchanging information, and working together on technical cooperation activities, all in an effort to benefit PAHO Member States.

10. In the discussion that followed, it was noted that the Bureau had introduced a streamlined due diligence and risk assessment process as part of the response to the COVID-19 pandemic. While the need for flexibility and innovation in the face of the pandemic was acknowledged, it was emphasized that PAHO’s integrity and independence must be preserved. It was also noted that resource constraints remained an issue in relation to the implementation of FENSA, and the Bureau was asked to comment on what was being done to address that situation. Attention was drawn to the need to establish mechanisms to
facilitate training of staff and ensure that cooperation with non-State actors was cost-effective and beneficial. The Bureau was also asked to comment on the potential regional implications of the initial evaluation of FENSA commissioned by WHO in 2019 and on what steps the Bureau intended to take with regard to the findings.

11. Dr. Jiménez explained that the WHO Secretariat had only recently completed its review of the FENSA evaluation and that the Bureau expected to receive the WHO Secretariat’s report on the evaluation in January 2021, at which time it would determine whether any of PAHO’s mechanisms needed to be adjusted. She added that the Bureau had submitted reports and comments on WHO’s evaluation work.

12. The Director said that the Bureau had striven to balance risk management with ensuring that non-State actors could participate meaningfully in the Organization. It carried out strict assessments of such actors and had been proactive in engaging with those that met the criteria for engagement under FENSA. The Bureau looked forward to reviewing the WHO evaluation recommendations and looking at how they might be applied to improve the implementation of the Framework in PAHO.

13. The Committee took note of the report.

**Non-State Actors in Official Relations with PAHO** (Document CE167/3)

14. Mr. Alberto Kleiman (Director, Department of External Relations, Partnerships, and Resource Mobilization, PASB) introduced the document on this item, noting that under FENSA the Director was to report annually to the Executive Committee, through the Subcommittee on Program, Budget, and Administration (SPBA), on the non-State actors in official relations with PAHO. Ordinarily, the SPBA, after reviewing relevant documentation, would make recommendations to the Committee regarding the admission of new non-State actors seeking to enter into official relations with the Organization and the continuation of relations with organizations already in official relations. However, as the 14th Session of the SPBA had been cancelled due to the COVID-19 pandemic, it fell to the Executive Committee to consider applications for admission into official relations from three non-State actors and to review collaboration with eight non-State actors and decide whether to maintain official relations with them. Mr. Kleiman reported that all of the latter had submitted the necessary documentation and developed their 2020-2022 work plans and that the Bureau recommended the continuation of official relations with all of them.

15. The Executive Committee held a closed meeting in order to consider the information provided by the Bureau on each non-State actor being considered for admission into official relations and for continuation of official relations. Having reviewed that information, the Executive Committee decided to admit the following three non-State actors into official relations with PAHO: American Heart Association, Basic Health International, and Global Oncology.

16. The Executive Committee also decided to approve the continuation of official relations between PAHO and the following non-State actors: American Public Health Association, American Society for Microbiology, Inter-American Association of Sanitary
and Environmental Engineering, March of Dimes, Pan American Federation of Associations of Medical Schools, Pan American Federation of Nursing Professionals, United States Pharmacopeial Convention, and World Association for Sexual Health.

17. The Committee adopted Resolution CE167.R1, confirming the above-mentioned decisions.

**Annual Report of the Ethics Office for 2019 (Document CE167/4)**

18. Mr. Philip MacMillan (Manager, Ethics Office, PASB) introduced the annual report of the Ethics Office, observing that the Office played a key role in promoting a culture of integrity, transparency, and trust. He reported that in 2019 the Office had received 211 consultations from personnel, a record number for any one year and an increase of 37% with respect to 2018. In his view, the upward trend indicated an increased willingness on the part of PASB personnel to seek guidance on ethical matters and confidence in the quality of the advice provided. Among other activities, the Office had conducted training sessions on proper ethical behavior, conflicts of interest, fraud prevention and detection, whistleblower protection, and personal and sexual harassment. More than 1,200 staff had now completed the United Nations mandatory course on Prevention of Harassment, Sexual Harassment, and Abuse of Authority in the Workplace.

19. With regard to policies, Mr. MacMillan reported that the new comprehensive anti-fraud and corruption policy had been completed in 2019 and was in the final stages of internal review. Next on the agenda of the Ethics Office would be to review the Organization’s whistleblower policy, draft a more modern code of ethical principles and conduct, and implement an action plan to address sexual harassment in the workplace. The action plan would focus on providing mandatory regular training, fostering a safe and open environment where personnel could report incidents without fear of retaliation, and revising the Organization’s policy on preventing harassment in the workplace.

20. In the discussion that followed, the role of the Ethics Office in promoting a culture of ethics at PAHO was recognized. It was pointed out, however, that several recurring issues were raised in the report, such as conflicts of interest and the employment of family members. The Bureau was urged to implement the recommendations already provided in that regard, and the Ethics Office was encouraged to continue to raise awareness of policies on ethical behavior. An update was requested on the current status of the anti-fraud and corruption policy and the efforts that were planned by the Ethics Office to increase fraud awareness among staff.

21. A delegate inquired whether the 211 consultations received by the Ethics Office included multiple requests for guidance from single individuals and, if so, whether the Ethics Office had identified any trends that could be addressed through staff training or outreach. He noted that a claim of retaliation by a supervisor that had been submitted and requested more information, including about how that complaint had been dealt with by the Ethics Office and what action had been taken by the Investigations Office.
22. Another delegate noted that the Ethics Office had curtailed travel to PAHO/WHO representative offices (PWRs) owing to PAHO’s financial situation in 2019. He encouraged the Ethics Office to make use of virtual means to provide training sessions and one-on-one meetings for field personnel. He also encouraged the Bureau to strengthen the curriculum on its iLearn platform, in particular to address ethical issues related to teleworking, which had increased due to the COVID-19 pandemic.

23. Mr. MacMillan replied that the Ethics Office’s training programs were interactive—based on role-playing and storytelling—and were therefore more effective when delivered in person. However, in the current context of the pandemic and the concurrent rise in remote working, the Ethics Office was now reformatting its training for virtual platforms. As to the anti-fraud and corruption policy, he noted that it was in the final stages of review and due to be released imminently, adding that the policy would be backed by an awareness-raising program.

24. Concerning the 211 consultations, he reported that the vast majority had been submitted by different staff members, both at Headquarters and PWRs, although it was possible that one or two might have been multiple requests from the same individuals. He added that, in general, the trend pointed to an increasing willingness by staff to consult the Office in order to ensure that their actions were in line with ethical standards, which was a trend to be encouraged. He also pointed out that the transfer of the investigative function of the Ethics Office to the Investigations Office had freed the Ethics Office to focus on its core mandate of guiding and protecting staff.

25. With regard to the complaint of retaliation, he explained that the matter concerned a staff member who had sought advice from the Ethics Office about an interpersonal conflict with a supervisor. As a result of that consultation, the staff member had allegedly received an unfavorable performance evaluation. The case had prompted the Office to consider expanding its retaliation policy, which currently protected those persons who had reported misconduct or cooperated in an investigation but not those who had consultations with the Ethics Office or the Ombudsman. The case in question had largely been handled by the Ethics Office, but had later been referred to the Investigations Office. He noted that measures were being taken to define more clearly the division of roles of the Investigations Office and the Ethics Office when it came to dealing with complaints of retaliation.

26. The Director affirmed that, since the investigative function had been transferred to the Investigations Office in 2019, the Ethics Office was now able to focus on its core mandate of fostering a respectful working environment, providing guidance to staff, and expanding its training and awareness-raising programs. She noted that there had been a significant increase in requests for guidance by staff following in-country visits by the Ethics Office and the Ombudsman. That was a welcome development, and the Executive Management would continue to encourage staff to attend training and avail themselves of the services provided by the Ethics Office.

27. The Executive Committee took note of the report.
Annual Report of the Investigations Office for 2019 (Document CE167/5)

28. Mr. Alexander Lim (Chief Investigator, Investigations Office, PASB) explained that the Investigations Office, which was functionally independent, conducted administrative fact-finding investigations into allegations of wrongdoing involving PASB personnel or concerning activities contracted or financed by PAHO. In 2019, the Investigations Office had reviewed 68 reports of alleged wrongdoing, closing 58 of them and carrying the remaining 10 forward to the following year. In its capacity as the secretariat of the Standing Committee on Asset Protection and Loss Prevention (APLP), the Investigations Office had received 32 reports of fraud, theft, damage, and loss of PAHO assets and equipment, amounting to a net loss of $65,866\(^1\) to the Organization. More than half of that amount—$39,130—stemmed from six cases of alleged fraud by PAHO staff members, most of which were related to a single case of health insurance fraud.

29. During the course of its investigations, the Office often found issues or trends worth bringing to the attention of the Bureau’s Executive Management, which it did through observation letters. In 2019, one such letter had been issued to point out a possible loophole in travel entitlement rules. During the reporting period, the Office had also carried out awareness-raising activities involving more than 400 personnel. No allegations of sexual harassment had been reported in 2019, which might indicate the need for further awareness-raising, in particular in country offices.

30. In the ensuing discussion, delegates welcomed the detailed report of the Investigations Office, noting with satisfaction that increasing numbers of staff were demonstrating confidence in the Office by reporting suspected wrongdoing. The level of alleged fraud by staff was highlighted as a cause for concern, with one delegate calling on the Bureau to take firm measures to discourage such behavior. Another delegate suggested that, in future reports, the number of complaints or requests for support should be disaggregated by the category of staff involved. A third delegate sought clarification on the number of reports of alleged fraud received by the Investigations Office, given that 15 were mentioned in paragraph 21, while another 32 were referred to in paragraph 26 of annual report of the Ethics Office. He noted that 14 reports of alleged wrongdoing were categorized as “miscellaneous” and requested further information in that regard.

31. Concern was expressed at the possible underreporting of sexual harassment or sexual exploitation in the Bureau. A delegate noted that, according to the 2018 United Nations “Safe Space: Survey on Sexual Harassment” report, 36% of respondents had experienced sexual harassment in the past two years. She urged the Director to ensure that the relevant recommendations of the External Auditor were implemented, in particular recommendation 16, which called on the Bureau to ensure that a culture of zero tolerance was clearly communicated by senior management.\(^2\) In a similar vein, another delegate wished to know what steps were being taken to enforce mandatory training on sexual harassment and

---

\(^1\) Unless otherwise indicated, all monetary figures in this report are expressed in United States dollars.


implement compulsory performance evaluations in order to ensure accountability. The same
delegate voiced concerns about the limited resources of the Investigations Office and
recommended that the Office review the recent report of the Joint Inspection Unit of the
United Nations system on the progress made in strengthening the investigation function.3

32. Mr. Lim explained that the 32 reports mentioned in paragraph 26 concerned the loss
of laptops or other valuable equipment; those cases, which had been dealt with by the
Standing Committee on Asset Protection and Loss Prevention, had resulted in the net loss to
the Organization of $65,866. Six of those cases had been investigated for alleged fraud, most
notably the case of health insurance fraud. He clarified that so-called miscellaneous reports
of alleged wrongdoing were those that did not necessarily pertain to investigative matters;
in some cases, they did not even relate to the Organization, since the Investigations Office’s
helpline was also open to the general public. Although the Investigations Office did not have
any jurisdiction to investigate such cases, it often provided guidance or made referrals. He
affirmed that more information about miscellaneous items would be included in future
reports. Lastly, he noted that the Investigations Office was aware of the Joint Inspection
Unit’s report and intended to use it as a guide during the planned update of its investigations
protocol.

33. The Director underscored her commitment to embedding a zero-tolerance approach
to sexual harassment in the Organization, recalling that one of her first actions as Director
had concerned a case of sexual harassment that had long been pending. She recognized,
however, the need for more awareness-raising and training to prevent both sexual harassment
and fraud. She highlighted the fact that, as a result of the separation of the functions of the
Ethics Office and the Investigations Office, the latter had been able to deal with more cases
in a timely manner, had increased the number of investigations completed annually, and had
more time to conduct training and awareness-raising. She also welcomed the increase in the
number of staff reporting alleged wrongdoing to the Investigations Office, which she took
as a sign that the Bureau was building a culture of trust, accountability, and respect. Lastly,
she pointed out that the Investigations Office currently had two full-time investigators plus
support staff, adding that the need for further resources would have to be weighed against
the volume of work and the costs associated with an increased workforce.

34. The Executive Committee took note of the report.

Report of the Audit Committee of PAHO (Document CE167/6)

35. Mr. Martin Guozden (Chair, PAHO Audit Committee) reported that the Audit
Committee had met once during the reporting period, in December 2019. Its April 2020
session had been cancelled owing to the circumstances surrounding the COVID-19
pandemic. After reviewing the history and functions of the Audit Committee, Mr. Guozden
outlined the topics examined and summarized the recommendations made by the Audit
Committee during the reporting period. He expressed thanks to the Director and the Bureau

3 Review of the state of the investigation function: progress made in the United Nations system organizations
staff, and also to the External Auditor, for their cooperation and support in the work of the Audit Committee.

36. He reported that the Audit Committee had made three recommendations during its 19th Session in December 2019, one concerning the PASB Management Information System (PMIS) and two relating to the Office of Internal Oversight and Evaluation Services (IES). With regard to the former, after receiving an update from the Bureau on the status of the PMIS roadmap and on the progress made towards addressing previous recommendations concerning PMIS, the Audit Committee had closed one of the open recommendations and had recommended that the redesign of financial data models should be considered as a priority and applied in all financial reports, including those used in daily operations.

37. With regard to IES, the Audit Committee had closed one earlier recommendation after hearing an explanation from the Auditor General regarding the methodology for the selection of country offices to be audited and subjects for thematic audits. The Audit Committee recommended that the IES should conduct an interim internal audit quality assessment as required by the International Professional Practices Framework of the Institute of Internal Auditors and should update its Charter to reflect its changed mandate regarding evaluation. In relation to the latter, Mr. Guozden noted that the Audit Committee had been informed that the evaluation function was being transferred to the Department of Planning and Budget, the aim being to ensure that evaluation was included in the Bureau’s planning cycle and to enable the Bureau to utilize the findings of future evaluations in an active manner.

38. The Audit Committee had also discussed the topics of information technology (IT) security, investigation, and program and budget performance monitoring assessment. Mr. Guozden pointed out that the issue of IT security had taken on increasing importance in the context of remote working during the pandemic.

39. In conclusion, Mr. Guozden reported that the Audit Committee had reviewed the actions taken on its previous recommendations and had found that, the Bureau was implementing the recommendations. Regarding future work, at its 20th Session in November 2020, the Committee planned to focus on internal controls and internal audit, ethics and integrity, project evaluation, governance and risk management, financial reports and external audit, and the Organization’s planning and budgeting.

40. In the Executive Committee’s discussion of the report, Committee members recognized the contribution of the Audit Committee to strengthening governance, transparency, and accountability and expressed support for its recommendations. Particular support was voiced for the Audit Committee’s recommendations and suggestions concerning risk assessment and management, internal control, cybersecurity, travel expenditures, and

---

4 As of 16 July 2020, the Office of Internal Oversight and Evaluation Services (IES) was renamed the Office of Internal Audit (OIA) given that the Evaluation function previously assigned to IES was transferred to the Department of Planning and Budget (PBU).
fraud. It was considered essential to strengthen risk management and internal control in order to protect the Organization from financial, legal, and reputational risks.

41. The Bureau was asked to indicate what steps were being taken to address the concerns raised by the Audit Committee in relation to the Organization’s travel policy and travel expenditures and to automate financial and program performance monitoring processes that were still being carried out manually. It was also asked to explain how the independence of the evaluation function would be maintained following the transfer of that function to the Department of Planning and Budget. The Bureau was encouraged to issue its anti-fraud policy and provide fraud awareness training to staff throughout the Organization. It was considered essential to have procedures and personnel in place to address complaints, particularly of sexual harassment, in a swift, effective, and professional manner. A delegate requested further information on the pending payments and the lawsuit relating to the Mais Médicos project.

42. It was noted that the Audit Committee intended to propose revisions to its terms of reference, and the Audit Committee was encouraged to review the United Nations Joint Inspection Unit report on audit and oversight committees when considering those revisions. Mr. Guozden was asked to comment on the Audit Committee’s involvement in supporting the implementation of the recommendations of the External Auditor concerning the development of a methodology to monitor actual costs, savings, and revenues against the business case for the purchase of the building located at 2121 Virginia Avenue, the simplification of the Organization’s financial statements to provide strategic information to the Governing Bodies, and the review of the real estate condition survey to assess risks, future costs, and lessons learned from ways of working during the pandemic and the possible impacts on demand for office space.

43. Mr. Guozden explained that the Audit Committee normally reviewed and discussed the recommendations of the External Auditor during its April session. It had been unable to do so in April 2020, as that session had been cancelled, but the Audit Committee planned to discuss the External Auditor’s recommendations at its upcoming November session. With regard to risk analysis and management, he noted that the Audit Committee would receive an update during its November session on the Bureau’s implementation of the recommendations made. It would also receive a report on the transfer of the evaluation function to the Department of Planning and Budget. In that connection, he noted that the Audit Committee shared the Executive Committee’s concern about the independence of the evaluation function.

44. Regarding the anti-fraud policy, Mr. Guozden clarified that the Audit Committee’s approach was to look first at the Organization’s policy and then to review the protocol that the Bureau was following in implementing the policy. The same approach was applied in the Audit Committee’s work in relation to other issues, such as travel expenditure and

---

investigations. With respect to the revision of the Committee’s terms of reference, he pointed out that any changes must be initiated and approved by the Governing Bodies.

45. Mr. Gerald Anderson (Director of Administration, PASB) said that the Bureau had taken action on numerous recommendations since the 19th Session of the Audit Committee in November 2019 and would be submitting updated information to the Audit Committee during its 20th Session in November 2020. He reported that all but one of the five recommendations made in connection with the 2019 internal audit of travel expenditures had been implemented and that the fifth was in the final stages of policy review. During 2020, the Bureau had implemented phase 1 of a project aimed at automating the production of financial statements. The second and final phase would be completed in 2021. The questionnaire for the most recent program management review exercise had also been automated, which had significantly reduced the manual effort associated with that exercise. The Bureau would continue to improve the level of automation in 2021. A recent review of internal controls in the country office in Haiti had verified that all related audit recommendations had been implemented. Responding to the comments on the purchase of the Virginia Avenue building, Mr. Anderson said that information on the impact of that purchase would be reported to Member States as part of the annual report on the Master Capital Investment Fund submitted to the Subcommittee on Program, Budget, and Administration.

46. Dr. Heidi Jiménez (Legal Counsel, PASB) recalled that the Bureau had informed the Audit Committee twice a year on the status of the Mais Médicos project since its inception in 2013. The Bureau continued to closely monitor the status of all outstanding payables for the project and was currently negotiating directly with the Member States involved in its implementation. Regarding the lawsuit, she noted that it was a civil action filed in United States in December 2018, after the project and PAHO’s participation therein had concluded. Since the matter was ongoing, she was not at liberty to present details. However, she assured the Committee that the Bureau continued to actively defend the case and would continue to inform Member States and the Audit Committee on its status as necessary.

47. The Director expressed thanks to the Audit Committee for its invaluable work in ensuring good oversight and responsible management of resources. She assured the Executive Committee that the Bureau took the recommendations of the various oversight bodies seriously and would continue to ensure that all recommendations were addressed.

48. Concerning the comments on evaluation, she noted that there were two levels: evaluation as part of the planning cycle and evaluation as part of independent oversight processes. She explained that the need for an evaluation was generally identified during the program implementation monitoring exercises conducted twice yearly. Under the existing approach, it was the entity responsible for the program that was responsible for organizing and managing the evaluation, although it received guidance and recommendations concerning possible evaluators from IES. When the evaluation was complete, IES would extract lessons learned and make them available online. The Bureau believed that approach was not having sufficient impact on the program and entity evaluated. By bringing the evaluation function under the Department of Planning and Budget, the Bureau considered
that it could maintain the same independence but ensure that the evaluation findings were taken into account in the planning cycle and acted upon in a timely manner, thus enabling programs and the entities responsible for them to deliver more effectively and efficiently on their priorities.

49. The Committee took note of the report.

Appointment of the Award Committee for the PAHO Award for Health Services Management and Leadership 2021 (Document CE167/7)

50. Dr. James Fitzgerald (Director, Department of Health Systems and Services, PASB) recalled that the annual PAHO Award for Health Services Management and Leadership was conferred on a candidate who had made a significant contribution in his/her home country and/or throughout the Region of the Americas. He noted that the Award had not been conferred in 2020 owing to the circumstances presented by the COVID-19 pandemic.

51. According to procedures adopted during the Executive Committee at its 158th Session in 2016, the Award Committee was to be selected each year during the first session held by the Executive Committee following the election of new Members by the Directing Council. The Award Committee was to consist of the President of the Executive Committee and a representative and alternate from each subregion. For the award to be conferred in 2021, the Director proposed to include the four nominations received in 2020 to the list of candidates for the 2021 Award and to invite Member States to submit further nominations beginning in November 2020. The deadline for receipt of nominations would be 31 March 2021. Copies of the documentation submitted on candidates would be forwarded to members of the Award Committee no fewer than 45 days before the date of the opening of the 168th Session of the Executive Committee in June. The Award Committee would then meet to consider the information on the candidates nominated and would submit its recommendation to the Executive Committee at its 168th Session.

52. The President of the Executive Committee said that, in the light of the fact that the Award Committee had not met in 2020, it was proposed that the members appointed at the Committee’s 165th Session, Barbados, Costa Rica, and the United States of America, should continue to serve on the Award Committee as principal delegates, and that two new members, Brazil and Ecuador, should be appointed to serve as alternates, since the alternates appointed in 2019, Belize and Peru, were no longer Members of the Executive Committee.

53. The Executive Committee reappointed Barbados, Costa Rica, and the United States of America as members and appointed Brazil and Ecuador as alternate members of the Award Committee for the PAHO Award for Health Services Management and Leadership 2021 (Decision CE167[D4]).
Administrative and Financial Matters

Report of the Office of Internal Oversight and Evaluation Services for 2019
(Document CE167/8)

54. Mr. David O’Regan (Auditor General, Office of Internal Audit, PASB), presented the report, which summarized the work undertaken by the Office of Internal Oversight and Evaluation Services (IES) in 2019, outlined its main findings, and set out its overall opinion on the Bureau’s internal control environment. He noted that, as detailed in paragraphs 41 to 45, the overall opinion of the Office of Internal Audit (OIA) was that the internal control framework was satisfactory to meet the needs of the Organization. There was, however, scope for further improvement of the second line of defense—the monitoring of internal controls by management—in particular through the enhanced analytical capabilities of the Workday system.

55. Among the main activities of the Office of Internal Audit in 2019, Mr. O’Regan reported OIA had undertaken seven internal audits—three thematic audits at PAHO Headquarters and four country-level audits in Brazil, Ecuador, Honduras, and Trinidad and Tobago—none of which had been rated as unsatisfactory. OIA had also continued to provide advice to management by participating in various working committees and groups and had supplied ad hoc advice to the Director of PASB on emerging risks.

56. At the request of Member States, the report included information on internal audit recommendations that had been pending implementation for more than two years. He noted that, as of December 2019, two such recommendations remained pending. Overall, the implementation rate of audit recommendations was 88%, which was consistent with previous years and comparable with that of other international organizations. Lastly, Mr. O’Regan pointed out that a decision had been made at the end of 2019 to transfer the evaluation function from OIA to the Department of Planning and Budget in order to link it more closely with the planning cycle as previously presented in this report.

57. In the discussion that followed, delegates commended the work of the Office of Internal Audit, welcomed the absence of unsatisfactory internal audit findings, and voiced support for the internal audit recommendations. The Director was requested to provide an update on the status of the two pending priority recommendations and the reasons for the delay in their implementation. The Bureau was encouraged to implement the internal audit recommendations in a timely manner, particularly those relating to the authorization of duty travel and the centralization of IT asset procurement, which could generate cost-savings for the Organization.

58. Concern was voiced about the potential security risks created when PAHO personnel elected to stay in non-standard accommodation while on duty travel, presumably in order to retain a larger portion of their per diem allowance. A delegate emphasized the need to review the relevant rules and prioritize the OIA recommendation intended to address that issue. Another suggested that travelers should be reimbursed the actual cost of hotel accommodation.
59. The Bureau was urged to take measures to improve transparency in procurement transactions and in the hiring of consultants, including by reducing the practice of employing retirees on consulting contracts. It was also encouraged to ensure that robust risk management and compliance measures were in place in PAHO Country Offices. The views OIA on the transfer of its evaluation functions to the Department of Planning and Budget were sought.

60. In response, Mr. O'Regan emphasized that OIA had made a number of recommendations concerning duty travel, all of which had been closed, as the Office had received satisfactory evidence of implementation. He noted, however, that duty travel had been reduced almost to nil in recent months as a result of the financial constraints on the Bureau and the circumstances presented by the COVID-19 pandemic. Once travel returned to normal, OIA intended to assess the situation again to ensure that implementation of those recommendations was maintained.

61. As far as the transfer of the evaluation function was concerned, he pointed out that, while it was unconventional to locate that function outside an internal oversight office, it was not unheard of, including in the United Nations system. The key consideration was the maintenance of the function’s independence and objectivity, which could be achieved wherever it was ultimately positioned, provided that the appropriate framework was in place. With regard to the implementation of recommendations, he noted that OIA followed up on its recommendations three times a year. The Director herself chaired annual meetings to discuss each pending recommendation and encourage their speedy implementation. From an internal audit perspective, he considered that follow-up on recommendations was effective, regular, and benefited from the supportive tone set by the Bureau’s Executive Management.

62. Mr. Gerald Anderson (Director of Administration, PASB) added that several measures had been taken with regard to staff travel. The first measure had been to require that any travel request submitted outside the set time frame must be approved by a member of the Executive Management, a step that had been successfully implemented prior to the pandemic and had improved compliance. Another measure had been to contract with a global travel agency through which hotels would be booked and paid for by the Bureau, rather than reimbursing travelers. That measure would facilitate cost-savings and ensure that the accommodation safety requirements were respected.

63. Turning to the issue of risk management, he explained that a working group, composed of various stakeholders, including the Risk Management Advisor, had been formed to establish an automated project management workflow, which would incorporate a mandatory risk assessment component. A number of measures were also being taken to improve the Organization’s Enterprise Risk Management Program, such as updating the risk register for each biennium. The current version of the risk register included mandatory risk mitigation plans and monitoring of their implementation. In addition, steps had been taken to develop capacity with regard to risk assessment and risk tolerance.

64. The Director expressed her gratitude for the work of the Office of Internal Audit and the advice of the Auditor General. She pointed out that over the past five years the Bureau
had made significant advances in terms of risk management. Executive Management met annually to identify the 10 highest risks to the Organization and followed up regularly to share progress and identify any risk mitigation measures to be taken. On the issue of the two outstanding audit recommendations, she confirmed that both would be implemented by the end of 2020.

65. The Executive Committee took note of the report.

**Personnel Matters**

*PASB Human Resources Management (Document CE167/9)*

66. Dr. Luz Marina Barillas (Director, Department of Human Resources Management, PASB) introduced the report on human resources management, which described the actions taken to implement the Bureau’s human resources strategy, known as the “People Strategy,” during 2019. She reported that an advisory committee had been established in 2019 to analyze the Strategy and identify needed revisions in order to support the implementation of PAHO’s Strategic Plan 2020-2025. Outlining the content of the report, she noted that it described the staffing reviews conducted in the country offices in Barbados, Brazil, and Guatemala and the human resources planning exercise undertaken for the 2020-2021 biennium—an exercise that had been especially relevant in the light of the anticipated financial situation for the biennium. Among the initiatives carried out in the area of staff development, she highlighted the merging of management, leadership, and coaching programs into a comprehensive program aimed at building the capacity of current and emerging PASB leaders.

67. Dr. Barillas also reported that the Bureau had adopted the WHO competency model, which would serve as the basis for competency-based human resources management. In the first quarter of 2019, a personnel engagement survey had been conducted. The results had been shared with all staff and managers and would serve as the basis for developing an action plan for each department and office. In order to further efforts to foster a working environment conducive to staff well-being, the policy on telework had been reviewed and mental health counselling had been offered to support staff during the time of financial uncertainty that the Organization was experiencing. All human resources records had been digitized and moved to cloud-based storage, which had enabled the Bureau to continue to provide services to staff working remotely during the pandemic.

68. She concluded by noting that the last part of the document described the administrative and disciplinary measures taken in cases of staff misconduct and that the annex presented staffing statistics.

69. In the Executive Committee’s discussion of the report, delegates welcomed the efforts to adjust the People Strategy to better support the implementation of the Strategic Plan and to transform organizational processes, policies, and culture in order to ensure that PAHO was fit for purpose. The Bureau was asked to provide more information on the recommendations made by the Advisory Committee on the Implementation of the People Strategy and on the findings of the review of the policy and procedure for the hiring
of consultants. Additional information was also requested on the status of the geographic mobility policy and efforts to encourage mobility between PAHO Headquarters and field offices. The Bureau was encouraged to adopt more rigorous and transparent processes for the recruitment of non-staff personnel and to make needed changes in recruitment practices so as to reduce reliance on the rehiring of retirees.

70. It was emphasized that staff were the Organization’s most important asset, and the need for a robust succession plan was underscored. Such a plan was considered critical to ensure the preservation of existing capacity and institutional memory when staff retired. Several delegates drew attention to the need for continued effort to achieve gender parity, especially at the higher levels of the professional category. The Bureau was encouraged to implement the recommendations of the External Auditor with regard to human resources management, in particular those relating to strategic planning, recruitment and hiring, training, and performance evaluation. The Bureau was also urged to take action to ensure compliance with mandatory training requirements, especially in relation to issues such as harassment, for which there should be zero tolerance. Information was requested on what action would be taken on the External Auditor’s recommendations concerning strengthening of governance relating to human resources through more comprehensive and clear reporting to Member States and through the development of human resources management information and cost data using PMIS functionality.

71. Dr. Barillas explained that, in response to the recommendations of the Advisory Committee and the External Auditor, a series of actions and remedial measures had been proposed to adapt the People Strategy to the Organization’s budgetary reality and to current and future technical cooperation priorities. Among other actions, the Bureau would conduct an assessment of staff abilities and competencies with a view to identifying learning gaps and training needs and drawing up a learning plan. The Bureau would also take steps to strengthen human resources planning, not only to ensure that the staff composition was aligned with the Organization’s needs, but also as the basis for succession planning. In relation to the latter, she pointed out that the Bureau had been working on succession planning for a couple of bienniums as part of the overall human resources planning process, during which the Bureau identified staff approaching retirement age and determined which of those staff would need to be replaced and whether any change in the post profile was required.

72. The Bureau also planned to put in place an accountability framework to ensure that all managers applied good human resources practices, including regular performance evaluations and monitoring of staff participation in mandatory training courses. With regard to the hiring of consultants, Dr. Barillas reported that a policy had been developed and was in the process of being approved. As to measures envisaged to improve reporting to Member States on human resources, she commented that the Bureau planned to carry out a comparative evaluation of the methods of reporting metrics used by other organizations in the United Nations system. Concerning gender parity, she said that the revision of the People Strategy would include the identification of initiatives to advance both gender equity and gender parity. She noted that the Bureau had already implemented policies that were
conducive to the recruitment and employment of women, including teleworking arrangements and comprehensive policies on maternity and paternity leave.

73. The Director affirmed that the Bureau had launched an organizational development initiative, as part of which it was looking at a number of issues related to human resources management, including the adjustments needed to enable the staff to deliver on the Strategic Plan and the reprofiling required to ensure that PAHO remained fit for purpose. The Bureau was aware that it was essential to have a workforce that was knowledgeable, experienced, and well prepared and to create a working environment in which staff could function at their highest capacity.

74. With regard to gender parity, she noted that the Bureau had identified a need to provide staff at the P4 level with managerial training and the opportunity to engage in more managerial functions in order to prepare them to apply for P5 positions, including PAHO/WHO representative posts. The Bureau was working with the United Nations System Staff College to provide such training, and it had also consulted the PAHO/WHO Staff Association about what needed to be done to enable more women to be represented at the P6, D1, and D2 levels. She pointed out, however, that the number of posts at those levels was limited.

75. She explained that, as a consequence of the hiring freeze put in place in response to the financial constraints that the Organization had faced, the Bureau had been unable to fill some fixed-term positions and therefore had to rely more heavily on contingent staff, particularly consultants. Nevertheless, the Bureau had taken measures to reduce the number of consultants over time.

76. The Committee took note of the report.

Statement by the Representative of the PAHO/WHO Staff Association (Document CE167/10)

77. Ms. Pilar Vidal (Representative of the PAHO/WHO Staff Association) began her statement by expressing condolences to all families who had lost a loved one to COVID-19 and paying tribute to all the frontline workers who had maintained essential activities during the pandemic in all countries of the Region of the Americas and worldwide. She reaffirmed the commitment of the Bureau’s staff to the mission of the Organization and stressed that the staff were focused on service to Member States, noting that they had reoriented their efforts both to support the COVID-19 emergency response and to continue delivering technical cooperation virtually.

78. Although the unprecedented financial challenges that the Bureau had faced had been alleviated by Member States’ efforts to pay their assessed contributions, in the Staff Association’s view, the crisis had not been fully resolved. The Staff Association believed it was necessary to seek opportunities to rationalize expenses and modernize work processes. At the same time, it would strive to guard against any erosion of working conditions. Ms. Vidal pointed out that PAHO could not have achieved its reputation as the leading public health agency in the Region without its staff, who brought a wealth of knowledge and
experience to serve Member States. She called on Member States to preserve the Bureau’s capacities and ensure that the Organization would emerge strengthened from the current crisis so that it could continue to respond to current and future demands.

79. Noting that the Staff Association was participating in the Bureau’s organizational development initiative, she said that the Staff Association concurred with the External Auditor’s recommendations on the importance of improving transparency and accountability in the hiring of consultants and other short-term staff. The Staff Association also believed that the Organization’s commitment to gender parity and diversity should be reinforced in the revision of the People Strategy. She added that the Staff Association considered it important to implement a competency-based professional development model, promote the development of managerial and leadership competencies, and implement a mental health strategy or program for staff that would foster greater well-being and enhance staff motivation and commitment.

80. In the ensuing discussion, Executive Committee Members affirmed that human resources were the most precious resource of any organization and expressed appreciation for the staff’s unstinting dedication to the Organization’s work, particularly in the context of the COVID-19 pandemic. The importance of a clear and transparent mechanism for the replacement of retiring staff was underlined, as was the need for a new approach to training, oriented towards generational replacement and transformation of the Organization to respond to the new reality created by the pandemic.

81. Ms. Vidal thanked the Executive Committee Members for their expressions of support and appreciation for the staff.

82. The Director said that she firmly believed that staff were the Organization’s greatest resource. She affirmed that the Bureau’s Executive Management viewed the Staff Association as an important partner and valued its members’ institutional knowledge and memory. The Executive Management sought the Staff Association’s comments on many matters dealt with on a daily basis and welcomed the input the Staff Association provided. She was deeply grateful to the staff for their hard work particularly during the COVID-19 pandemic and pledged that the Executive Management would continue to work with the Staff Association to ensure the staff’s welfare, career development, and advancement.

83. The Committee took note of the report.

**Governing Bodies Matters**

*Proposed Dates for Meetings of the Governing Bodies of PAHO in 2021 (Document CE167/11)*

15th Session of the Subcommittee on Program, Budget, and Administration

84. The Committee decided that the 15th Session of the Subcommittee on Program, Budget, and Administration would be held from 24 to 26 March 2021 (Decision CE167[D5]).
168th Session of the Executive Committee

85. The Committee decided to hold its 168th Session from 21 to 25 June 2021 (Decision CE167[D6]).

59th Directing Council, 73rd Session of the Regional Committee of WHO for the Americas

86. The Committee decided that the 59th Directing Council, 73rd Session of the Regional Committee of WHO for the Americas, would be held from 20 to 24 September 2021 (Decision CE167[D7]).

Proposed Topics for Meetings of the Governing Bodies in 2021 (Documents CE167/12 and CE167/13)

15th Session of the Subcommittee on Program, Budget, and Administration

87. The Director introduced the list of topics proposed for discussion by the Subcommittee on Program, Budget, and Administration during its 15th Session (Document CE167/12), noting that the topics were those customarily considered by the Subcommittee.

88. In the discussion of this item, it was suggested that a report on the use of the cash flows from the Working Capital Fund should be added to the agenda, in line with Resolution CD58.R1, adopted by the 58th Directing Council. This resolution approved an increase in the authorized level of the Working Capital Fund and requested that the Director report regularly to the Governing Bodies on the manner in which cashflows from the Working Capital Fund are covered and the programmatic areas that are financed from it.

89. The Executive Committee endorsed the list of topics contained in Document CE167/12, with the addition of the report on the use of cash flows from the Working Capital Fund (Decision CE167[D8]).

168th Session of the Executive Committee

90. The Director drew attention to Document CE167/13, which listed the topics proposed for discussion by the Executive Committee during its 168th Session, together with tentative lists of topics for discussion by the Governing Bodies in 2022 and 2023. She noted that most of the proposed topics were those customarily considered by the Committee, some of which had initially been scheduled for discussion in 2020 but had been postponed due to the COVID-19 pandemic. Under program policy matters, there were a number of new topics relating to the response to the COVID-19 pandemic and the post-COVID era. She highlighted, in particular, the policy for rebuilding pharmaceutical production capacity in the Americas, the strategy and plan of action on strengthening public health functions, and the strategy and plan of action on health security. The plan of action on health, environment, and climate change was another item that was highly relevant in the current context. She pointed out that a new policy on gender equality in health had been proposed since the previous policy on this issue dated of 2006. Lastly, she noted that the plan of action on malaria elimination was being proposed following a number of setbacks in that area.
91. In the discussion that followed, several delegates voiced concern about the proliferation of strategies, plans of action, and policy documents submitted to the Governing Bodies for consideration. It was pointed out that the Strategic Plan and the Sustainable Health Agenda for the Americas provided a comprehensive mandate and that specific strategies or plans were not needed in order to deliver technical assistance. It was also pointed out that some of the proposed program policy matters were already covered by existing plans.

92. The Bureau was encouraged to reconsider the topics for the Governing Bodies in 2021 and present an agenda with a greater focus on the response to and lessons learned from the COVID-19 pandemic. A delegate pointed out the Bureau had agreed to establish a technical advisory group pursuant to a recommendation made during the 58th Directing Council and suggested that the group might be helpful in reviewing the topics to be discussed, as well as in enabling PAHO to function more effectively and efficiently.

93. Another delegate recalled that, during the 58th Directing Council, the Bureau had agreed to draw up a definition of the concept of “institutional risk” as part of the governance reform initiative relating to technical cooperation projects funded by voluntary contributions. Her delegation believed that Member States should have the opportunity to consider and contribute to that definition and therefore suggested that the information item concerning lessons learned on PAHO governance reform should become a program policy item.

94. The Director said it was true that many strategies and plans were proposed to the PASB Executive Management for which mandates from the Governing Bodies were not necessarily required. However, in some areas, the commitment of Member States was needed in order to achieve the targets set in the Strategic Plan and the biennial work plans. She affirmed that the Bureau would revisit the proposed list of topics, bearing in mind the suggestions made. She noted that the Bureau had agreed to the establishment of a technical advisory group, as had been requested, but pointed out that the responsibility for ensuring the effective functioning of PAHO lay with the Bureau’s Director and Executive Management. She was concerned that the proposal to put in place a technical advisory group might indicate that Member States felt that the Bureau’s leadership was not adequately fulfilling that responsibility.

95. The delegate who had made the comment regarding the technical advisory group clarified that the group’s aim would be to find potential ways to improve PAHO and make it more efficient. The group’s creation did not reflect any lack of confidence in the Director or the staff of the Bureau.

96. The Executive Committee endorsed the list of proposed topics contained in Document CE167/13; it was agreed that the Bureau would revise the list of program policy items proposed for consideration (Decision CE167[D9]).

**Matters for Information**

*PASB Management Information System (PMIS): Lessons Learned (Document CE167/INF/1)*

97. Mr. Gerald Anderson (Director of Administration, PASB) introduced the report on the lessons learned from the implementation of the PMIS, noting that it covered the period from February 2015 to December 2019. He pointed out that the report included a detailed annex organized on the basis of the four core guiding principles endorsed by Member States at the time that the PMIS project was approved in 2010. He also noted that, although the report indicated that, as of the end of 2019, PAHO had not entered into any partnership arrangements with other United Nations organizations, in fact it did have formal arrangements with WHO for the processing of staff health insurance claims and the administration of recruitment processes. The Bureau and the WHO Secretariat also had an arrangement that enabled PASB staff to access the WHO intranet and vice versa. In addition, a number of PAHO/WHO country offices were participating in and utilizing services available through the United Nations business operations network. Furthermore, the Bureau was sharing lessons learned from the implementation of the PMIS with WHO and other international organizations that were considering replacing their management information systems.

98. Highlighting some of the benefits resulting from the implementation of the PMIS, Mr. Anderson noted that the number of fixed-term posts in administrative departments had decreased by 16%. He added that many of the benefits produced by the PMIS derived from the migration to a single, integrated cloud-based system that covered most administrative processes, including accounting processes. The PMIS provided a single source of data that could be accessed securely from any device anywhere. That feature had been especially effective in maintaining seamless business continuity throughout the COVID-19 pandemic. A roadmap had been established to implement a series of additional streamlining measures through the PMIS that were expected to further reduce workloads for administrative processes.

99. Mr. Anderson pointed out that the PMIS had also had benefits for Member States. For example, a recently deployed feature allowed ministries of health to access data from the PMIS relating to shipments of vaccines ordered through the Revolving Fund for Access to Vaccines. With regard to costs, he pointed out that the principal expenses associated with the introduction of any enterprise resource planning (ERP) system related to change

---

7 The list of topics was subsequently revised and presented to the Members of the Executive Committee by the Director in a note verbale sent in December 2020. The revised list of topics is attached to this report as Annex F.

8 See Document CD50/7 and Resolution CD50.R10 (2010).
management and staff training. However, since the PMIS allowed the continuous implementation of new features, the change management process had now been institutionalized, thereby eliminating the need for significant one-time expenditures.

100. In the discussion that followed, delegates welcomed the report and the information on the benefits derived from the implementation of the PMIS. It was pointed out, however, that the report included little information on quantification of the benefits and few details regarding the lessons learned from the System’s implementation or the next steps to be taken to further improve it. Additional information was requested on lessons learned that had been identified in the 2019 external assessment of the PMIS and on the recommendations arising from that assessment.

101. The need for ongoing training of both Headquarters and PWR staff, particularly in the handling of accounting adjustments, was underscored, as was the need for attention to matters relating to cybersecurity. The Bureau was encouraged to implement the recommendations of the external evaluators, the PAHO Auditor General, and the External Auditor regarding using the PMIS to strengthen internal controls. A delegate suggested that greater use could be made of PMIS functionalities to enhance compliance in the area of human resources management.

102. Mr. Anderson, responding to the comment on quantification of benefits, said that the Bureau had developed a roadmap for the implementation of streamlining measures and had prepared an innovation assessment template that would enable it to determine how much staff time was saved as a result of any innovations introduced. The information generated as a result of those initiatives would be systematized so as to present an overall picture of the impact of PMIS efficiencies in terms of the human resources assigned to administrative processes. The Bureau would thus be able to provide a more granular assessment of the impact of the PMIS in 2021 and subsequent years.

103. The Bureau also had a detailed roadmap for implementing the recommendations arising from the 2019 external assessment of the PMIS, and many had already been implemented. A major one was the establishment of a shared services center in one of the country offices, a measure that was expected to generate cost-savings and efficiencies.

104. Concerning the use of the PMIS for compliance purposes, he noted that a compliance dashboard was already in place and that the monthly compliance certification process operated fully within the PMIS. The Bureau continued striving to add additional functionality to improve compliance processes, in line with the recommendations of the various oversight bodies.

105. Noting that the staff had been trained in how to handle accounting adjustments in the PMIS, Mr. Anderson explained that such adjustments were made when expected funding did not arrive in a timely manner and it became necessary to move expenditures from one account to another. He added that most such adjustments related to voluntary contribution grants and that it might therefore be necessary to work with donors to improve the timing of payments. In any case, the Bureau was seeking to minimize such adjustments because they had to be made manually.
The Director said that the Bureau would continue to explore and expand the capabilities of the PMIS for the benefit of the Organization. It would also strive to document lessons learned more explicitly. She noted that one of the lessons learned thus far was the need for continuous updating, training, and monitoring.

The Committee took note of the report.

**PAHO Governance Reform: Internal Assessment of the Approval Process of Projects Funded by Voluntary Contributions (Document CE167/INF/2)**

Mr. Alberto Kleiman (Director, Department of External Relations, Partnerships, and Resource Mobilization, PASB) introduced the report, pointing out that projects funded by voluntary contributions played an important role in achieving the targets set in PAHO’s Strategic Plan. He also noted that the Bureau had made important progress in project and risk management, including through the establishment of a project management framework, standard operating procedures for the management of projects funded by voluntary contributions, the PAHO Enterprise Risk Management Policy, and the updated Policy on the Review Process for Voluntary Contributions and Agreements.

Through the Office of Internal Audit, the Bureau had undertaken an internal assessment of the approval and oversight processes for projects funded by voluntary contributions. The assessment highlighted many satisfactory structures and working practices for the approval and management of such projects and proposed six recommendations for strengthening current systems and processes. Mr. Kleiman noted that the assessment findings and recommendations were consistent with several initiatives already under way to strengthen the management of projects funded by voluntary contributions, and said that the Bureau would continue to study the recommendations and prepare a plan to operationalize relevant findings of the assessment.

Executive Committee Members expressed support for the recommendations put forward in the report, which, together with the recommendations made by the independent consultant⁹ and the resolution adopted by the 58th Directing Council on governance reform,¹⁰ were considered a good foundation for improving the review process for projects funded by voluntary contributions. It was felt that the implementation of the recommendations would enhance transparency and accountability in relation to voluntary contributions and projects funded by them, although it was pointed out that, to date, there had not been any information to indicate that there had been any misappropriation or misuse of funds in connection with such projects. It was stressed that, while the Bureau already had tools for more effective project management, the use of those tools should be made mandatory at all levels of the Organization in order to address the concerns raised by the External Auditor in relation to risk management. The need for a clear definition of the concept of “institutional risk” was reaffirmed (see paragraph 93 above).

---

111. A delegate suggested that the Bureau should seek advice and insight from Member States on operationalizing the recommendations and the resolution adopted by the 58th Directing Council in order to ensure that they were implemented effectively and in line with the concerns of Member States. Another delegate sought information on how the Bureau would implement the recommendation calling for a broader role for the Office of Investigations, particularly in light of the limited resources available to expand the Office, as noted in the report of the Audit Committee. A third delegate pointed out that the potential need to hire additional personnel, coupled with the Organization’s recent financial difficulties and the austerity measures called for by Member States, might limit the Bureau’s ability to implement the recommendations.

112. The Bureau was asked to report regularly to Member States on progress achieved, lessons learned and challenges encountered in implementing the governance reform initiative. It was emphasized that the countries involved in the implementation of projects funded by voluntary contributions should be kept updated throughout the process of approval, execution, and evaluation of those projects.

113. Mr. Kleiman emphasized that the Bureau had begun work immediately after the Executive Committee adopted Resolution CE166.R9 to put in place the elements needed to fulfill the request from Member States with regard to governance reform. He explained that an internal working group met weekly to explore how to further develop and enhance the various project and risk management mechanisms. One of the group’s tasks was to define the criteria for identifying which projects needed to be further analyzed in terms of risk. The group was also looking at how to improve the connection between project management and risk management and ensure that risk assessment was part of the corporate review process for all project proposals. A checklist and online tool were being developed for that purpose. The Bureau had also reviewed and updated the numerous policies related to project management in order to bring them into line with the project management framework adopted in 2018. Those policies were available on the Bureau’s intranet and were known to staff, but the Bureau was seeking to make them even more visible and easier to access.

114. The Director pointed out that the Bureau had received the report on the internal assessment only recently and was therefore not in a position to provide much detail on the action to be taken on the findings. She assured the Committee that the Bureau intended to move quickly to implement the recommendations and the other actions related to governance reform and would provide additional information in 2021. She added that she personally, along with the other members of the Bureau’s Executive Management, would oversee the implementation of the recommendations.

115. The Committee took note of the report.

11 Document CE167/6 (2020).
116. Dr. James Fitzgerald (Director, Department of Health Systems and Services, PASB) recalled that the Executive Committee had adopted Resolution CESS1.R1 during its Special Session in May 2020. The Committee had thereby authorized a short-term emergency loan of up to $50 million from the capital account of the Revolving Fund for Access to Vaccines (the Revolving Fund) to the capital account of the Revolving Fund for Strategic Public Health Supplies (the Strategic Fund). The Bureau had requested authorization of the loan in order to meet the expected demand for COVID-19-related medical supplies to be procured through the Strategic Fund. Document CE167/INF/3 reported on the status of the emergency loan and on the actions taken to support Member States and facilitate access to critical supplies.

117. Dr. Fitzgerald noted that, as of 31 August 2020, medicines and supplies valued at a total of $151 million had been procured on behalf of 25 Member States through the Strategic Fund, a threefold increase in the use of the Fund in comparison with 2019. The increased use of the Strategic Fund had raised the amount in its capital account to $24 million as of 31 August. That increase, combined with effective management of the capital account, had meant that it had not been necessary to use the emergency loan. Nonetheless, the emergency loan provision was an important mechanism that would enable the Bureau to meet potential future urgent needs of Member States.

118. The Committee took note of the report.

Other Matters

119. A delegate requested that the Bureau organize a meeting on the humanitarian and health situation in Venezuela, featuring Dr. Julio Castro, health advisor to the Venezuelan National Assembly. Two delegates supported the proposal, but one delegate voiced strong opposition, pointing out that it was the Ministry of Health of Venezuela that was represented in PAHO and that any discussion of health matters in Venezuela must therefore involve the Ministry. A fourth delegate expressed support for a gathering that would allow the voices of the National Assembly and other players in Venezuela and in bordering countries to be heard. She cautioned Member States about introducing political issues into a multilateral organization that had a specific focus on health. Although she understood the reasons that had given rise to the request, she stressed that PAHO had to be able to work with every country in the
Region in order to continue improving the health and well-being of the peoples of the Americas.

121. After further discussion, it was agreed that the Bureau would organize a meeting including a variety of spokespersons to bring greater understanding of the health situation in Venezuela and neighboring countries.

Closure of the Session

122. Following the customary exchange of courtesies, the President declared the 167th Session closed.

Resolutions and Decisions

123. The following are the resolutions and decisions approved by the Executive Committee in the course of the 167th Session:

Resolutions

CE167.R1: Non-State Actors in Official Relations with PAHO

THE 167th SESSION OF THE EXECUTIVE COMMITTEE,

Having reviewed the report Non-State Actors in Official Relations with PAHO (Document CE167/3);

Mindful of the provisions of the Framework of Engagement with Non-State Actors, adopted by the 55th Directing Council through Resolution CD55.R3 (2016), which governs official relations status between the Pan American Health Organization (PAHO) and such entities,

RESOLVES:

1. To renew official relations between PAHO and the following non-State actors for a period of three years:
   a) American Public Health Association;
   b) American Society for Microbiology;
   c) Inter-American Association of Sanitary and Environmental Engineering;
   d) March of Dimes;
   e) Pan American Federation of Associations of Medical Schools;
   f) Pan American Federation of Nursing Professionals;
   g) United States Pharmacopeial Convention, and
h) World Association for Sexual Health.

2. To admit the following non-State actors into official relations with PAHO for a period of three years:
   
a) American Heart Association;
b) Basic Health International, and
c) Global Oncology.

3. To request the Director to:
   
a) advise the respective non-State actors of the decisions taken by the Executive Committee;
b) continue developing dynamic working relations with inter-American non-State actors of interest to the Organization in areas that fall within the program priorities that the Governing Bodies have adopted for PAHO;
c) continue fostering relationships between Member States and non-State actors working in the field of health.

(First meeting, 30 September 2020)

Decisions

CE167(D1): Election of Officers

Pursuant to Rule 15 of the Rules of Procedure of the Executive Committee, the Committee elected the following Member States to serve as officers for the period from September 2020 to September 2021:

President: Costa Rica
Vice President: Haiti
Rapporteur: Ecuador

(First meeting, 30 September 2020)

CE167(D2): Adoption of the Agenda

Pursuant to Rule 9 of the Rules of Procedure of the Executive Committee, the Committee adopted the agenda submitted by the Director (Document CE167/1).

(First meeting, 30 September 2020)
CE167(D3): Election of Two Members to the Subcommittee on Program, Budget, and Administration

The Executive Committee elected Barbados and Mexico to serve on the Subcommittee on Program, Budget, and Administration.

(First meeting, 30 September 2020)

CE167(D4): Appointment of the Award Committee for the PAHO Award for Health Services Management and Leadership 2021

The Executive Committee appointed Barbados, Costa Rica, and the United States of America as members and Brazil and Ecuador as alternate members of the Award Committee for the PAHO Award for Health Services Management and Leadership 2021.

(First meeting, 30 September 2020)

CE167(D5): Dates of the 15th Session of the Subcommittee on Program, Budget, and Administration

The Executive Committee decided that the 15th Session of the Subcommittee on Program, Budget, and Administration would be held from 24 to 26 March 2021.

(Second meeting, 30 September 2020)

CE167(D6): Dates of the 168th Session of the Executive Committee

The Executive Committee decided that the 168th Session of the Executive Committee would be held from 21 to 25 June 2021.

(Second meeting, 30 September 2020)

CE167(D7): Dates of the 59th Directing Council, 73rd Session of the Regional Committee of WHO for the Americas

The Executive Committee decided that the 59th Directing Council, 73rd Session of the Regional Committee of WHO for the Americas, would be held from 20 to 24 September 2021.

(Second meeting, 30 September 2020)
CE167(D8):  Topics for Discussion during the 15th Session of the Subcommittee on Program, Budget, and Administration

The Executive Committee endorsed the list of topics proposed for discussion by the Subcommittee on Program, Budget, and Administration (Document CE167/12), with the addition of a report on the use of cash flows from the Working Capital Fund.

(Second meeting, 30 September 2020)

CE167(D9):  Topics for Discussion during the 168th Session of the Executive Committee

The Executive Committee endorsed the list of topics proposed for discussion by the Executive Committee during its 168th Session (Document CE167/13); it was agreed that the Bureau would revise the list of program policy items proposed for consideration.

(Second meeting, 30 September 2020)
IN WITNESS WHEREOF, the President of the Executive Committee, Delegate of Costa Rica, and the Secretary ex officio, Director of the Pan American Sanitary Bureau, sign the present Final Report in the Spanish language.

DONE in Washington, D.C., United States of America, on this thirtieth day of September in the year two thousand twenty. The Secretary shall deposit the original texts in the archives of the Pan American Sanitary Bureau. The Final Report will be published on the webpage of the Pan American Health Organization once approved by the President.

__________________________
Adriana Salazar González
President of the 167th Session of the Executive Committee
Delegate of Costa Rica

__________________________
Carissa Etienne
Secretary ex officio of the
167th Session of the Executive Committee
Director of the
Pan American Sanitary Bureau
AGENDA

1. OPENING OF THE SESSION

2. PROCEDURAL MATTERS
   2.1 Election of Officers
   2.2 Adoption of the Agenda

3. COMMITTEE MATTERS
   3.1 Election of Two Members to the Subcommittee on Program, Budget, and Administration on the Expiration of the Period of Office on the Executive Committee of Belize and Peru
   3.2 Engagement with non-State Actors
   3.3 Non-State Actors in Official Relations with PAHO
   3.4 Annual Report of the Ethics Office for 2019
   3.5 Annual Report of the Investigations Office for 2019
   3.6 Report of the Audit Committee of PAHO
   3.7 Appointment of the Award Committee for the PAHO Award for Health Services Management and Leadership 2021

4. ADMINISTRATIVE AND FINANCIAL MATTERS
   4.1 Report of the Office of Internal Oversight and Evaluation Services for 2019

5. PERSONNEL MATTERS
   5.1 PASB Human Resources Management
   5.2 Statement by the Representative of the PAHO/WHO Staff Association
6. GOVERNING BODIES MATTERS

6.1 Proposed Dates for Meetings of the Governing Bodies of PAHO in 2021:
   a) 15th Session of the Subcommittee on Program, Budget, and Administration
   b) 168th Session of the Executive Committee
   c) 59th Directing Council of PAHO, 73rd Session of the Regional Committee of WHO for the Americas

6.2 Proposed Topics for Meetings of the Governing Bodies of PAHO in 2021:
   a) 15th Session of the Subcommittee on Program, Budget, and Administration
   b) 168th Session of the Executive Committee

7. MATTERS FOR INFORMATION

7.1 PASB Management Information System (PMIS): Lessons Learned

7.2 PAHO Governance Reform: Internal Assessment of the Approval Process of Projects Funded by Voluntary Contributions

7.3 Emergency Loan from the Revolving Fund for Access to Vaccines to the Regional Revolving Fund for Strategic Public Health Supplies

8. OTHER MATTERS

9. CLOSURE OF THE SESSION
LIST OF DOCUMENTS

Working Documents

CE167/1  Agenda
CE167/2  Engagement with non-State Actors
CE167/3  Non-State Actors in Official Relations with PAHO
CE167/4  Annual Report of the Ethics Office for 2019
CE167/5  Annual Report of the Investigations Office for 2019
CE167/6  Report of the Audit Committee of PAHO
CE167/7  Appointment of the Award Committee for the PAHO Award for Health Services Management and Leadership 2021
CE167/8  Report of the Office of Internal Oversight and Evaluation Services for 2019
CE167/9  PASB Human Resources Management
CE167/10 Statement by the Representative of the PAHO/WHO Staff Association
CE167/11 Proposed Dates for Meetings of the Governing Bodies of PAHO in 2021
CE167/12 Proposed Topics for Meetings of the Governing Bodies of PAHO in 2021: 15th Session of the Subcommittee on Program, Budget, and Administration
CE167/13 Proposed Topics for Meetings of the Governing Bodies of PAHO in 2021: 168th Session of the Executive Committee

Matters for Information

CE167/INF/1  PASB Management Information System (PMIS): Lessons Learned
CE167/INF/2  PAHO Governance Reform: Internal Assessment of the Approval Process of Projects Funded by Voluntary Contributions
Matters for Information (cont.)

CE167/INF/3    Emergency Loan from the Revolving Fund for Access to Vaccines to the Regional Revolving Fund for Strategic Public Health Supplies
PROPOSED TOPICS FOR MEETINGS OF THE GOVERNING BODIES OF PAHO FOR 2021:
15th SESSION OF THE SUBCOMMITTEE ON PROGRAM, BUDGET, AND ADMINISTRATION

Procedural Matters
1. Election of Officers
2. Adoption of the Agenda

Program Policy Matters
3. Outline of the Program Budget of the Pan American Health Organization 2022-2023
4. Scale of Assessed Contributions for 2022-2023
5. Engagement with non-State Actors
6. Non-State Actors in Official Relations with PAHO
7. Appointment of One Member to the Audit Committee of PAHO

Administrative and Financial Matters
10. Update on the Appointment of the External Auditor of PAHO for 2022-2023
11. Amendments to the PASB Staff Regulations and Rules (if any)
12. PASB Human Resources Management
13. Update on the Master Capital Investment Fund

Matters for Information
14. Report on Strategic Issues between PAHO and WHO
Matters for Information *(cont.)*


16. Draft Provisional Agenda for the 168th Session of the Executive Committee
REVISED LIST OF PROPOSED TOPICS FOR MEETINGS OF THE GOVERNING BODIES OF PAHO FOR 2021:
15th SESSION OF THE SUBCOMMITTEE ON PROGRAM, BUDGET, AND ADMINISTRATION

Procedural Matters

1. Election of Officers
2. Adoption of the Agenda

Program Policy Matters

3. Outline of the Program Budget of the Pan American Health Organization 2022-2023
4. Scale of Assessed Contributions for 2022-2023
5. Engagement with non-State Actors
6. Non-State Actors in Official Relations with PAHO
7. Appointment of One Member to the Audit Committee of PAHO

Administrative and Financial Matters

9. Update on the Appointment of the External Auditor of PAHO for 2022-2023
10. Amendments to the PASB Staff Regulations and Rules (if any)
11. PASB Human Resources Management
12. Update on the Master Capital Investment Fund
Matters for Information

14. Report on Strategic Issues between PAHO and WHO


16. Draft Provisional Agenda for the 168th Session of the Executive Committee
PROPOSED TOPICS FOR MEETINGS
OF THE GOVERNING BODIES OF PAHO IN 2021:
168th SESSION OF THE EXECUTIVE COMMITTEE

Procedural Matters

1. Adoption of the Agenda and Program of Meetings
2. Representation of the Executive Committee at the 59th Directing Council of PAHO, 73rd Session of the Regional Committee of WHO for the Americas
3. Draft Provisional Agenda of the 59th Directing Council of PAHO, 73rd Session of the Regional Committee of WHO for the Americas

Committee Matters

4. Report on the 15th Session of the Subcommittee on Program, Budget, and Administration
5. PAHO Award for Health Services Management and Leadership 2021
6. Engagement with non-State Actors
7. Non-State Actors in Official Relations with PAHO
10. Report of the Audit Committee of PAHO
11. Appointment of One Member to the Audit Committee of PAHO

Program Policy Matters

12. Proposed Program Budget of the Pan American Health Organization 2022-2023
13. Scale of Assessed Contributions 2022-2023
14. Policy for rebuilding pharmaceutical production capacity in the Americas
15. Policy on Gender Equality in Health
16. Strategy and Plan of Action on Strengthening Public Health Functions
Program Policy Matters (cont.)

17. Strategy and Plan of Action on Health Security
18. Plan of Action on Health, Environment, and Climate Change 2021-2030
19. Plan of Action on Malaria Elimination
20. Plan of Action on Noncommunicable Disease Prevention and Control

Administrative and Financial Matters

26. Update on the Master Capital Investment Fund

Personnel Matters

27. Amendments to the PASB Staff Regulations and Rules (if any)
28. PASB Human Resources Management
29. Statement by the Representative of the PAHO/WHO Staff Association

Matters for Information

30. Update on COVID-19 in the Region of the Americas
31. Report on Strategic Issues between PAHO and WHO
32. Lessons Learned on PAHO Governance Reform
Matters for Information (cont.)

34. Implementation of the International Health Regulations

35. Report of the Advisory Committee on Health Research (if any meeting in 2020)

36. Status of the Pan American Centers (if necessary)

37. PAHO/WHO Collaborating Centers (if necessary)


42. Health and Tourism: Final Report (Resolution CD49.R20 [2009])

43. Plan of Action on Mental Health: Final Report (Resolution CD53.R7 [2014])

44. Persistent Organic Pollutants: Final Report (Resolution CD41.R1 [1999])

45. Influenza Pandemic: Preparation in the Hemisphere: Final Report (Resolution CD44.R8 [2003])

46. Coordination of International Humanitarian Assistance in Health in Case of Disasters: Final Report (Resolution CSP28.R19 [2012])

Matters for Information (cont.)

Progress Reports on Technical Matters

   (Resolution CD56.R5 [2018])
   (Resolution CD52.R13 [2013])
   (Resolution CD45.R9 [2004])

49. Chronic Kidney Disease in Agricultural Communities in Central America: Progress Report
   (Resolution CD52.R10 [2013])

50. Strategy and Plan of Action on Strengthening the Health System to Address Violence against Women: Progress Report
   (Resolution CD54.R12 [2015])

   (Resolution CD48.R11 [2008])

   (Resolution CSP29.R11 [2017])

53. Plan of Action on Entomology and Vector Control 2018-2023: Midterm Review
   (Resolution CD56.R2 [2018])

54. Cooperation for Health Development in the Americas: Progress Report
   (Resolution CD52.R15 [2013])

Matters for Information

Resolutions and other Actions of Intergovernmental Organizations of Interest to PAHO

55. Seventy-fourth World Health Assembly

56. Subregional Organizations

Annexes
Annex A

PROPOSED TOPICS FOR MEETINGS OF THE GOVERNING BODIES OF PAHO IN 2022:
170th SESSION OF THE EXECUTIVE COMMITTEE

Procedural Matters

1. Adoption of the Agenda and Program of Meetings
2. Representation of the Executive Committee at the 30th Pan American Sanitary Conference, 74th Session of the Regional Committee of WHO for the Americas
3. Draft Provisional Agenda of the 30th Pan American Sanitary Conference, 74th Session of the Regional Committee of WHO for the Americas

Committee Matters

4. Report on the 16th Session of the Subcommittee on Program, Budget, and Administration
5. PAHO Award for Health Services Management and Leadership 2022
6. Engagement with non-State Actors
7. Non-State Actors in Official Relations with PAHO
10. Report of the Audit Committee of PAHO
11. Appointment of One Member to the Audit Committee of PAHO

Program Policy Matters

13. Men’s Health: Concept Paper
14. Strategy on Equity in Health
15. Plan of Action on Health of Migrants
16. Plan of Action on Immunization
Program Policy Matters (cont.)

17. Plan of Action on Mental Health
18. Plan of Action for an Integrated Multi-disease Approach on HIV, Tuberculosis, and Viral Hepatitis
19. Plan of Action on Healthy Aging

Administrative and Financial Matters

23. Programming of the Budget Surplus (if any)
24. Programming of the Revenue Surplus (if any)
25. Update on the Appointment of the External Auditor of PAHO for 2024-2025 and 2026-2027
27. Update on the Master Capital Investment Fund

Personnel Matters

28. Amendments to the PASB Staff Regulations and Rules (if any)
29. PASB Human Resources Management
30. Statement by the Representative of the PAHO/WHO Staff Association

Matters for Information

31. Process for the Election of the Director of the Pan American Sanitary Bureau and the Nomination of the Regional Director of the World Health Organization for the Americas
32. WHO Programme Budget 2024-2025
33. Report on Strategic Issues between PAHO and WHO
34. Implementation of the International Health Regulations
Matters for Information (cont.)

35. Report of the Advisory Committee on Health Research
    (if any meeting in 2021)

36. Monitoring of the Resolutions and Mandates of the Pan American
    Health Organization

37. Strategy and Plan of Action on Substance Use and Public Health:
    Final Report
    (Resolution CD50.R2 [2010])
    (Resolution CD51.R7 [2011])

38. Strategy and Plan of Action on Epilepsy: Final Report
    (Resolution CD51.R8 [2011])

39. Plan of Action to Reduce the Harmful Use of Alcohol: Final Report
    (Resolution CD51.R14 [2014])

40. Strategy and Plan of Action on Urban Health: Final Report
    (Resolution CD51.R4 [2011])

41. Plan of Action for Disaster Risk Reduction 2016-2021: Final Report
    (Resolution CD55.R10 [2016])

42. Access and Rational Use of Strategic and High-cost Medicines
    and Other Health Technologies: Final Report
    (Resolution CD55.R12 [2016])

Progress Reports on Technical Matters

43. Plan of Action for Cervical Cancer Prevention and Control 2018-2030:
    Progress Report
    (Resolution CD56.R9 [2018])

44. Plan of Action for Women’s, Children’s, and Adolescents’ Health 2018-2030:
    Progress Report
    (Resolution CD56.R8 [2018])

45. Plan of Action for Strengthening Information Systems for Health 2019-2023:
    Progress Report
    (Resolution CD57.R9 [2019])

46. Plan of Action for the Elimination of Industrially Produced Trans-Fatty Acids
    2020-2025: Midterm Review
    (Resolution CD57.R12 [2019])
Progress Reports on Technical Matters (cont.)

47. Health Technology Assessment and Incorporation into Health Systems: Progress Report
   (Resolution CSP28.R9 [2012])

   (Resolution CD52.R12 [2013])

Resolutions and other Actions of Intergovernmental Organizations of Interest to PAHO

49. Seventy-fifth World Health Assembly

50. Subregional Organizations
Annex B

PROPOSED TOPICS FOR MEETINGS
OF THE GOVERNING BODIES OF PAHO IN 2023:
172nd SESSION OF THE EXECUTIVE COMMITTEE

Procedural Matters

1. Adoption of the Agenda and Program of Meetings
2. Representation of the Executive Committee at the 60th Directing Council of PAHO, 75th Session of the Regional Committee of WHO for the Americas
3. Draft Provisional Agenda of the 60th Directing Council of PAHO, 75th Session of the Regional Committee of WHO for the Americas

Committee Matters

4. Report on the 17th Session of the Subcommittee on Program, Budget, and Administration
5. PAHO Award for Health Services Management and Leadership 2023
6. Engagement with non-State Actors
7. Non-State Actors in Official Relations with PAHO
10. Report of the Audit Committee of PAHO
11. Appointment of One Member to the Audit Committee of PAHO

Program Policy Matters

12. Proposed Program Budget of the Pan American Health Organization 2024-2025
13. Scale of Assessed Contributions 2024-2025
Administrative and Financial Matters

17. Appointment of the External Auditor of PAHO for 2024-2025 and 2026-2027
19. Update on the Master Capital Investment Fund

Personnel Matters

20. Amendments to the PASB Staff Regulations and Rules (if any)
21. PASB Human Resources Management
22. Statement by the Representative of the PAHO/WHO Staff Association

Matters for Information

23. Report on Strategic Issues between PAHO and WHO
24. Implementation of the International Health Regulations
25. Report of the Advisory Committee on Health Research (if any meeting in 2022)
Matters for Information (cont.)

**Progress Reports on Technical Matters**

29. Chronic Kidney Disease in Agricultural Communities in Central America: Progress Report  
   *(Resolution CD52.R10 [2013])*

30. PAHO Disease Elimination Initiative: A Policy for an Integrated Sustainable Approach to Communicable Diseases in the Americas: Progress Report  
   *(Resolution CD57.R7 [2019])*

   *(Resolution CD57.R11 [2019])*

32. Strategy and Plan of Action to Improve Quality of Care in Health Service Delivery 2020-2025: Midterm Review  
   *(Resolution CD57.R13 [2017])*

   *(Resolution CD57.R14 [2019])*

**Resolutions and other Actions of Intergovernmental Organizations of Interest to PAHO**

34. Seventy-sixth World Health Assembly

35. Subregional Organizations
REVISED LIST OF PROPOSED TOPICS FOR MEETINGS
OF THE GOVERNING BODIES OF PAHO IN 2021:
168th SESSION OF THE EXECUTIVE COMMITTEE

Procedural Matters
1. Adoption of the Agenda and Program of Meetings
2. Representation of the Executive Committee at the 59th Directing Council of PAHO, 73rd Session of the Regional Committee of WHO for the Americas
3. Draft Provisional Agenda of the 59th Directing Council of PAHO, 73rd Session of the Regional Committee of WHO for the Americas

Committee Matters
4. Report on the 15th Session of the Subcommittee on Program, Budget, and Administration
5. PAHO Award for Health Services Management and Leadership 2021
6. Engagement with non-State Actors
7. Non-State Actors in Official Relations with PAHO
10. Report of the Audit Committee of PAHO
11. Appointment of One Member to the Audit Committee of PAHO

Program Policy Matters
12. Proposed Program Budget of the Pan American Health Organization 2022-2023
13. Scale of Assessed Contributions 2022-2023
14. Policy for Rebuilding Pharmaceutical Production Capacity in the Americas
15. Policy on Gender Equality in Health
Program Policy Matters (cont.)

16. **Strategy and Plan of Action on Strengthening Public Health Functions**

17. **Strategy and Plan of Action on Health Security**

18. **Plan of Action on Health, Environment, and Climate Change 2021-2030**

19. **Plan of Action on Malaria Elimination**

20. **Plan of Action on Noncommunicable Disease Prevention and Control**


15. **Policy on the Application of Data Science in Public Health Using Artificial Intelligence and Other Emerging Technologies**

16. **Increasing Production Capacity for Essential Medicines and Health Technologies**

17. **One Health: A Comprehensive Approach for Addressing Zoonotic Diseases, Antimicrobial Resistance, Environmental Determinants of Health and Food Safety**

18. **Reinvigorating Immunization as a Public Good for Universal Health**


Administrative and Financial Matters


22. **Appointment of the External Auditor of PAHO for 2022-2023**


24. **Update on the Master Capital Investment Fund**

**Personnel Matters**

26. Amendments to the PASB Staff Regulations and Rules (if any)

27. PASB Human Resources Management

28. Statement by the Representative of the PAHO/WHO Staff Association

**Matters for Information**

29. Update on COVID-19 in the Region of the Americas

30. Report on Strategic Issues between PAHO and WHO

31. Lessons Learned on PAHO Governance Reform


33. Implementation of the International Health Regulations

35. Report of the Advisory Committee on Health Research (if any meeting in 2020)

36. Status of the Pan American Centers (if necessary)

34. PAHO/WHO Collaborating Centers (if necessary)


Matters for Information (cont.)

40. Persistent Organic Pollutants: Final Report
   (Resolution CD41.R1 [1999])

41. Influenza Pandemic: Preparation in the Hemisphere: Final Report
   (Resolution CD44.R8 [2003])

42. Coordination of International Humanitarian Assistance in Health
    in Case of Disasters: Final Report
   (Resolution CSP28.R19 [2012])

   (Resolution CD50.R16 [2010])

Progress Reports on Technical Matters

44. Plan of Action of Human Resources for Universal Access to Health
   (Resolution CD56.R5 [2018])
   (Resolution CD52.R13 [2013])
   (Resolution CD45.R9 [2004])

45. Chronic Kidney Disease in Agricultural Communities in Central America:
    Progress Report
   (Resolution CD52.R10 [2013])

46. Strategy and Plan of Action on Strengthening the Health System to Address
    Violence against Women: Progress Report
   (Resolution CD54.R12 [2015])

47. Preventing Violence and Injuries and Promoting Safety: A Call for Action
    in the Region: Progress Report
   (Resolution CD48.R11 [2008])

48. Plan of Action for the Sustainability of Measles, Rubella, and Congenital
    Rubella Syndrome Elimination 2018-2023: Progress Report
   (Resolution CSP29.R11 [2017])

49. Plan of Action on Entomology and Vector Control 2018-2023:
    Midterm Review
   (Resolution CD56.R2 [2018])

50. Cooperation for Health Development in the Americas: Progress Report
    (Resolution CD52.R15 [2013])
Matters for Information (cont.)

Resolutions and other Actions of Intergovernmental Organizations of Interest to PAHO

51. Seventy-fourth World Health Assembly
52. Subregional Organizations

Annexes
Annex A

REVISED LIST OF PROPOSED TOPICS FOR MEETINGS OF THE GOVERNING BODIES OF PAHO IN 2022: 170th SESSION OF THE EXECUTIVE COMMITTEE

Procedural Matters

1. Adoption of the Agenda and Program of Meetings

2. Representation of the Executive Committee at the 30th Pan American Sanitary Conference, 74th Session of the Regional Committee of WHO for the Americas

3. Draft Provisional Agenda of the 30th Pan American Sanitary Conference, 74th Session of the Regional Committee of WHO for the Americas

Committee Matters

4. Report on the 16th Session of the Subcommittee on Program, Budget, and Administration

5. PAHO Award for Health Services Management and Leadership 2022

6. Engagement with non-State Actors

7. Non-State Actors in Official Relations with PAHO


10. Report of the Audit Committee of PAHO

11. Appointment of One Member to the Audit Committee of PAHO

Program Policy Matters


13. Men’s Health: Concept Paper
Program Policy Matters (cont.)

14. Strategy on Equity in Health
15. Plan of Action on Health of Migrants
16. Plan of Action on Immunization
17. Plan of Action on Mental Health
18. Plan of Action for an Integrated Multi-disease Approach on HIV, Tuberculosis, and Viral Hepatitis
19. Plan of Action on Healthy Aging

Administrative and Financial Matters

23. Programming of the Budget Surplus (if any)
24. Programming of the Revenue Surplus (if any)
25. Update on the Appointment of the External Auditor of PAHO for 2024-2025 and 2026-2027
27. Update on the Master Capital Investment Fund

Personnel Matters

28. Amendments to the PASB Staff Regulations and Rules (if any)
29. PASB Human Resources Management
30. Statement by the Representative of the PAHO/WHO Staff Association
Matters for Information

31. Process for the Election of the Director of the Pan American Sanitary Bureau and the Nomination of the Regional Director of the World Health Organization for the Americas

32. WHO Programme Budget 2024-2025

33. Report on Strategic Issues between PAHO and WHO

34. Implementation of the International Health Regulations

35. Report of the Advisory Committee on Health Research (if any meeting in 2021)

36. Monitoring of the Resolutions and Mandates of the Pan American Health Organization

37. Strategy and Plan of Action on Substance Use and Public Health: Final Report
   (Resolution CD50.R2 [2010])
   (Resolution CD51.R7 [2011])

38. Strategy and Plan of Action on Epilepsy: Final Report
   (Resolution CD51.R8 [2011])

39. Plan of Action to Reduce the Harmful Use of Alcohol: Final Report
   (Resolution CD51.R14 [2014])

40. Strategy and Plan of Action on Urban Health: Final Report
   (Resolution CD51.R4 [2011])

41. Plan of Action for Disaster Risk Reduction 2016-2021: Final Report
   (Resolution CD55.R10 [2016])

42. Access and Rational Use of Strategic and High-cost Medicines and Other Health Technologies: Final Report
   (Resolution CD55.R12 [2016])

Progress Reports on Technical Matters

   (Resolution CD56.R9 [2018])
Matters for Information (cont.)

Progress Reports on Technical Matters (cont.)

44. Plan of Action for Women’s, Children’s, and Adolescents’ Health 2018-2030: Progress Report
   (Resolution CD56.R8 [2018])

   (Resolution CD57.R9 [2019])

46. Plan of Action for the Elimination of Industrially Produced Trans-Fatty Acids 2020-2025: Midterm Review
   (Resolution CD57.R12 [2019])

47. Health Technology Assessment and Incorporation into Health Systems: Progress Report
   (Resolution CSP28.R9 [2012])

   (Resolution CD52.R12 [2013])

Resolutions and other Actions of Intergovernmental Organizations of Interest to PAHO

49. Seventy-fifth World Health Assembly

50. Subregional Organizations
Annex B

REVISED LIST OF PROPOSED TOPICS FOR MEETINGS OF THE GOVERNING BODIES OF PAHO IN 2023: 172nd SESSION OF THE EXECUTIVE COMMITTEE

Procedural Matters

1. Adoption of the Agenda and Program of Meetings

2. Representation of the Executive Committee at the 60th Directing Council of PAHO, 75th Session of the Regional Committee of WHO for the Americas

3. Draft Provisional Agenda of the 60th Directing Council of PAHO, 75th Session of the Regional Committee of WHO for the Americas

Committee Matters

4. Report on the 17th Session of the Subcommittee on Program, Budget, and Administration

5. PAHO Award for Health Services Management and Leadership 2023

6. Engagement with non-State Actors

7. Non-State Actors in Official Relations with PAHO


10. Report of the Audit Committee of PAHO

11. Appointment of One Member to the Audit Committee of PAHO

Program Policy Matters

12. Proposed Program Budget of the Pan American Health Organization 2024-2025

13. Scale of Assessed Contributions 2024-2025
Administrative and Financial Matters


17. Appointment of the External Auditor of PAHO for 2024-2025 and 2026-2027


19. Update on the Master Capital Investment Fund

Personnel Matters

20. Amendments to the PASB Staff Regulations and Rules (if any)

21. PASB Human Resources Management

22. Statement by the Representative of the PAHO/WHO Staff Association

Matters for Information

23. Report on Strategic Issues between PAHO and WHO

24. Implementation of the International Health Regulations

25. Report of the Advisory Committee on Health Research (if any meeting in 2022)


Matters for Information (cont.)

Progress Reports on Technical Matters

29. Chronic Kidney Disease in Agricultural Communities in Central America: Progress Report
   (Resolution CD52.R10 [2013])

30. PAHO Disease Elimination Initiative: A Policy for an Integrated Sustainable Approach to Communicable Diseases in the Americas: Progress Report
   (Resolution CD57.R7 [2019])

   (Resolution CD57.R11 [2019])

32. Strategy and Plan of Action to Improve Quality of Care in Health Service Delivery 2020-2025: Midterm Review
   (Resolution CD57.R13 [2017])

   (Resolution CD57.R14 [2019])

Resolutions and other Actions of Intergovernmental Organizations of Interest to PAHO

34. Seventy-sixth World Health Assembly

35. Subregional Organizations
# List of Participants / Lista de Participantes

## Officers / Mesa Directiva

<table>
<thead>
<tr>
<th>Role</th>
<th>Name and Designation</th>
</tr>
</thead>
<tbody>
<tr>
<td>President / Presidente</td>
<td>Lic. Adriana Salazar González (Costa Rica)</td>
</tr>
<tr>
<td>Vice-President / Vicepresidente</td>
<td>Dr. Jean Patrick Alfred (Haiti)</td>
</tr>
<tr>
<td>Rapporteur / Relator</td>
<td>Lic. Fernando R. Jácome Gavilánez (Ecuador)</td>
</tr>
</tbody>
</table>

## Members of the Executive Committee / Miembros del Comité Ejecutivo

### Barbados

**Head of Delegation – Jefe de Delegación**

- Lt. Col. Hon. Jeffrey D. Bostic  
  Minister of Health and Wellness  
  Ministry of Health and Wellness  
  St. Michael  

**Delegates – Delegados**

- Dr. Kenneth George  
  Chief Medical Officer  
  Ministry of Health and Wellness  
  St. Michael  

- Dr. Anton Best  
  Senior Medical Officer  
  Ministry of Health and Wellness  
  St. Michael  

### Brazil / Brasil (cont.)

**Delegates – Delegados (cont.)**

- Sr. Matheus Machado de Carvalho  
  Primeiro Secretário, Assessor da Divisão de Ciudadania do Ministério de Relações Exteriores  
  Rio de Janeiro  

- Sra. Cristina Alexandre  
  Primeira Secretária, Chefe da assessoria de Assuntos Internacionais em Saúde  
  Ministério da Saúde  
  Brasília  

- Sra. Maria Clara de Paula Tusco  
  Primeira-Secrétaria, Representante Alterna do Brasil junto à Organização dos Estados Americanos  
  Washington, D.C.  

### Brazil / Brasil

**Head of Delegation – Jefe de Delegación**

- Sr. Eduardo Pazuello  
  Ministro de Estado da Saúde  
  Ministério da Saúde  
  Brasília  

**Delegates – Delegados**

- Sr. Flávio Werneck Noce dos Santos  
  Assessor Especial para Assuntos Internacionais de Saúde  
  Ministério da Saúde  
  Brasília  

- Sr. Carlos Fernando Gallinal Cuenca  
  Conselheiro, Representante Alterno do Brasil junto à Organização dos Estados Americanos  
  Washington, D.C.  

### Costa Rica

**Head of Delegation – Jefe de Delegación**

- Lic. Adriana Salazar González  
  Jefe de Relaciones Internacionales  
  Ministerio de Salud  
  San José  

---
MEMBERS OF THE EXECUTIVE COMMITTEE / MIEMBROS DEL COMITÉ EJECUTIVO (cont.)

COSTA RICA (cont.)

Delegates – Delegados

Dra. Andrea Garita Castro
Directora de Planificación
Ministerio de Salud
San José

Sr. Antonio Alarcón Zamora
Ministro Consejero, Representante Alterno de Costa Rica ante la Organización de los Estados Americanos
Washington, D.C.

ECUADOR (cont.)

Delegates – Delegados

Lic. Fernando Roberto Jácome Gavilánez
Director Nacional de Cooperación y Relaciones Internacionales
Ministerio de Salud Pública
Quito

Sr. Marco Ponce
Ministro, Representante Alterno del Ecuador ante la Organización de los Estados Americanos
Washington, D.C.

CUBA

Head of Delegation – Jefe de Delegación

Dr. José Ángel Portal Miranda
Ministro de Salud Pública
Ministerio de Salud Pública
La Habana

Delegates – Delegados

Dra. Marcia Cobas Ruiz
Viceministra de Salud
Ministerio de Salud Pública
La Habana

Dr. Néstor Marimón Torres
Director de Relaciones Internacionales
Ministerio de Salud Pública
La Habana

Sr. Dariel Quintana Fraga
Tercer Secretario
Embajada de Cuba
Washington, D.C.

HAITI/HAITÍ

Head of Delegation – Jefe de Delegación

H.E. Léon Charles
Ambassador, Permanent Representative of Haiti to the Organization of American States
Washington, D.C.

Delegates – Delegados

Lic. Luisa Albertina Noboa Paz y Miño
Analista de Cooperación y Relaciones Internacionales
Ministerio de Salud
Quito

Sr. Martín Tamayo
Analista Legal
Dirección del Sistema Interamericano de Relaciones Exteriores y Movilidad Humana
Quito

ECUADOR

Head of Delegation – Jefe de Delegación

Excmo. Sr. Carlos A. Jácome Naranjo
Embajador, Representante Permanente del Ecuador ante la Organización de los Estados Americanos
Washington, D.C.
### MEMBERS OF THE EXECUTIVE COMMITTEE / MIEMBROS DEL COMITÉ EJECUTIVO (cont.)

#### MEXICO/MÉXICO

**Head of Delegation – Jefe de Delegación**

- **Mtro. Marcos Cantero Cortes**
  - Titular de la Unidad de Análisis Económico
  - Secretaría de Salud
  - México, D.F.

**Delegates – Delegados**

- **Lic. Martha Leticia Caballero Abraham**
  - Encargada de la Dirección General de Relaciones Internacionales
  - Secretaría de Salud
  - México, D.F.

- **Lic. José Gustavo Valle Mendoza**
  - Subdirector de Gestión Interamericana
  - Secretaría de Salud
  - México, D.F.

- **Lic. Zulema Guerra Carpio**
  - Jefa del Departamento para el Sistema Interamericano
  - Secretaría de Salud
  - México, D.F.

- **Lic. Maite Narvaéz Abad**
  - Segunda Secretaria, Representante Alterna de México ante la Organización de los Estados Americanos
  - Washington, D.C.

#### UNITED STATES OF AMERICA/ESTADOS UNIDOS DE AMÉRICA (cont.)

**Head of Delegation – Jefe de Delegación**

- **Hon. Alex M. Azar II**
  - Secretary of Health
  - Department of Health and Human Services
  - Washington, D.C.

**Delegates – Delegados**

- **Mr. Garrett Grigsby**
  - Director
  - Office of Global Affairs
  - Department of Health and Human Services
  - Washington, D.C.

- **Mr. Nelson Arboleda**
  - Director, Americas Office
  - Office of Global Affairs
  - Department of Health and Human Services
  - Washington, D.C.

- **Mrs. Mara Burr**
  - Director Multilateral Relations
  - Department of Health and Human Services
  - Washington, D.C.

- **Ms. Nerissa Cook**
  - Deputy Assistant Secretary
  - Bureau of International Organization Affairs
  - Department of State
  - Washington, D.C.

- **Ms. Carrie Filipetti**
  - Deputy Assistant Secretary
  - Bureau of Western Hemisphere Affairs
  - Department of State
  - Washington, D.C.

- **Ms. Adriana Gonzalez**
  - Health Advisor
  - Office of Economic and Development Assistance
  - Bureau of International Organization Affairs
  - Department of State
  - Washington, D.C.
MEMBERS OF THE EXECUTIVE COMMITTEE /
MIEMBROS DEL COMITÉ EJECUTIVO (cont.)

UNITED STATES OF AMERICA/ESTADOS UNIDOS DE AMÉRICA (cont.)

Delegates – Delegados (cont.)

Mr. Joshua Hodges
Senior Deputy Assistant Administrator
Bureau for Latin America and the Caribbean
U.S. Agency for International Development
Washington, D.C.

Mr. Michael Kozak
Acting Assistant Secretary
Bureau of Western Hemisphere Affairs
Department of State
Washington, D.C.

Mr. Colin McIlff
Deputy Director
Office of Global Affairs
Department of Health and Human Services
Washington, D.C.

Ms. Kristen Pisani
Director
Office of Economic and Development Assistance
Bureau of International Organization Affairs
Department of State
Washington, D.C.

Ms. Monique Wubbenhorst
Senior Deputy Assistant Administrator
Bureau for Global Health
U.S. Agency for International Development
Washington, D.C.

Mr. Jose Fernandez
Deputy Director for Global Health Security
Office of Global Affairs
Department of Health and Human Services
Washington, D.C.

Ms. Brittany Hayes
Global Health Officer for Multilateral Relations
Office of Global Affairs
Department of Health and Human Services
Washington, D.C.

UNITED STATES OF AMERICA/ESTADOS UNIDOS DE AMÉRICA (cont.)

Delegates – Delegados (cont.)

Ms. Meghan Holohan
Senior Analyst
Bureau for Policy, Planning and Learning
U.S. Agency for International Development
Washington, D.C.

Ms. Mackenzie Klein
Global Health Officer
Office of the Americas
Office of Global Affairs
Department of Health and Human Services
Washington, D.C.

Ms. Gabrielle Lamoureille
Deputy Director, Multilateral Relations
Office of Global Affairs
Department of Health and Human Services
Washington, D.C.

Ms. Maya Levine
Senior Global Health Officer for Multilateral Relations
Office of Global Affairs
Department of Health and Human Services
Washington, D.C.

Ms. Marcela Lievano-Martinez
Global Health Officer
Office of the Americas
Office of Global Affairs
Department of Health and Human Services
Washington, D.C.

Ms. Ella Nudell
Intern, Multilateral Relations
Office of Global Affairs
Department of Health and Human Services
Washington, D.C.

Ms. Leandra Olson
Senior Global Health Officer, Multilateral Relations
Office of Global Affairs
Department of Health and Human Services
Washington, D.C.
OTHER MEMBERS NOT SERVING IN THE EXECUTIVE COMMITTEE/
OTROS MIEMBROS QUE NO FORMAN PARTE DEL COMITÉ EJECUTIVO

ARGENTINA

Dra. Carla Moretti
Directora Nacional de Relaciones Internacionales
Ministerio de Salud
Buenos Aires

Lic. Andrea Polach
Asesora
Dirección Nacional de Relaciones Internacionales
Ministerio de Salud
Buenos Aires

CANADA/CANADÁ

His Excellency Hugh Adsett
Ambassador, Permanent Representative of Canada to the Organization of American States
Washington, D.C.

Mr. William Wang
Policy Analyst
Office of International Affairs for the Health Portfolio
Government of Canada, Ottawa

Ms. Charlotte McDowell
Senior Development Officer and Alternate Representative of Canada to the Organization of American States
Washington, D.C.

CHILE

Sra. Carolina Horta
Consejera, Representante Alterna de Chile ante la Organización de los Estados Americanos
Washington, D.C.

COLOMBIA

Dr. Fernando Ruiz Gómez
Ministro de Salud y Protección Social
Ministerio de Salud y Protección Social
Bogotá

Excmo. Sr. Alejandro Ordoñez Maldonado
Embajador, Representante Permanente de Colombia ante la Organización de los Estados Americanos
Washington, D.C.

Ms. Monica Palak
Senior Policy Analyst
Multilateral Relations Division
Office of International Affairs for the Health Portfolio
Government of Canada, Ottawa

Ms. Jennifer Izaguirre
Policy Analyst
Office of International Affairs for the Health Portfolio
Government of Canada, Ottawa
OTHER MEMBERS NOT SERVING IN THE EXECUTIVE COMMITTEE/
OTROS MIEMBROS QUE NO FORMAN PARTE DEL COMITÉ EJECUTIVO
(cont.)

DOMINICAN REPUBLIC/REPÚBLICA DOMINICANA

Excmo. Sr. Josué Fiallo
Embajador, Representante Alterno de la República Dominicana ante la Organización de los Estados Americanos Washington, D.C.

Lic. Dania Guzmán Sánchez
Directora de Planificación Institucional
Ministerio de Salud Pública
Santo Domingo

NICARAGUA

Excmo. Sr. Luis E. Alvarado Ramírez
Embajador, Representante Alterno de Nicaragua ante la Organización de los Estados Americanos Washington, D.C.

Dr. Christian Toledo
Director General de Vigilancia para la Salud
Ministerio de Salud
Managua

Sr. Arturo McFields
Primer Secretario, Representante Alterno de Nicaragua ante la Organización de los Estados Americanos Washington, D.C.

PARAGUAY

Sra. Lorena Patiño
Consejera, Representante Alterna de Paraguay ante la Organización de los Estados Americanos Washington, D.C.

PERU/PERÚ

Dr. Víctor Cuba Ore
Director General
Oficina de Cooperación Técnica Internacional
Ministerio de Salud Lima

SAINT KITTS AND NEVIS/SAINT KITTS Y NEVIS

Hon. Akilah Byron-Nisbett
Minister of Health et al.
Ministry of Health
Basseterre

Dr. Delores Stapleton-Harris
Permanent Secretary
Ministry of Health
Basseterre

SAINT LUCIA/SANTA LUCÍA

Senator Hon. Mary Issac
Minister for Health and Wellness
Ministry of Health and Wellness
Waterfront, Castries

VENEZUELA (BOLIVARIAN REPUBLIC OF/REPUBLICA BOLIVARIANA DE)

Dr. Carlos Humberto Alvarado González
Ministro del Poder Popular para la Salud
Ministerio del Poder Popular para la Salud Caracas

Dra. Marisela Bermúdez
Viceministra de Redes de Salud Colectiva
Ministerio del Poder Popular para la Salud Caracas
OTHER MEMBERS NOT SERVING IN THE EXECUTIVE COMMITTEE/
OTROS MIEMBROS QUE NO FORMAN PARTE DEL COMITÉ EJECUTIVO
(cont.)

VENEZUELA (BOLIVARIAN REPUBLIC OF/
REPÚBLICA BOLIVARIANA DE) (cont.)

Dr. Julio Francisco Colmenares
Director de Relaciones Multilaterales
Oficina de Integración y Asuntos Internacionales
Ministerio del Poder Popular para la Salud
Caracas

ASSOCIATE MEMBERS/MIEMBROS ASOCIADOS

ARUBA

Hon. Danguillaume Oduber
Minister of Tourism, Public Health and Sport
Ministry of Tourism, Public Health and Sport
Oranjestad

PUERTO RICO

Dr. Raúl G. Castellanos Bran
Coordinador de OPS/OMS
Departamento de Salud
Puerto Rico

REPRESENTATIVES OF INTERGOVERNMENTAL ORGANIZATIONS/
REPRESENTANTES DE ORGANIZACIONES INTERGUBERNAMENTALES

Caribbean Public Health Agency/Agencia de Salud Pública del Caribe

Dr. Joy St. John

Organisation of Eastern Caribbean States/Organización de Estados del Caribe Oriental

Dr. Lydia Atkins

REPRESENTATIVES OF NON-STATES ACTORS IN OFFICIAL RELATIONS
WITH PAHO / REPRESENTANTES DE ACTORES NO ESTATALES EN
RELACIONES OFICIALES CON LA OPS

Drug for Neglected Diseases Initiative/Iniciativa Medicamentos para Enfermedades Olvidadas

Sr. Francisco Viegas Neves da Silva

Latin American Society of Nephrology and Hypertension/ Sociedad Latinoamericana de Nefrología e Hipertensión

Sra. María Carlota González Bedat

Mundo Sano Foundation/ Fundación Mundo Sano

Sr. Marcelo Abril
SPECIAL GUESTS/
INVITADOS ESPECIALES

PAHO Audit Committee/
Comité de Auditoría de la OPS

Mr. Martin Guozden

PAN AMERICAN HEALTH ORGANIZATION/
ORGANIZACIÓN PANAMERICANA DE LA SALUD

Director and Secretary ex officio of the Conference/Directora y Secretaria ex officio de la Conferencia

Dr. Carissa F. Etienne

Advisors to the Director/Asesores de la Directora

Ms. Mary Lou Valdez
Deputy Director
Directora Adjunta

Dr. Jarbas Barbosa da Silva Jr.
Assistant Director
Subdirector

Advisors to the Director/Asesores de la Directora (cont.)

Mr. Gerald Anderson
Director of Administration
Director de Administración

Dr. Heidi Jiménez
Legal Counsel, Office of the Legal Counsel
Asesora Jurídica, Oficina del Asesor Jurídico

Ms. Mónica Zaccarelli Davoli
Senior Advisor, Governing Bodies Office
Asesora Principal, Oficina de los Cuerpos Directivos
FINAL REPORT
## CONTENTS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opening of the Session</td>
<td>5</td>
</tr>
<tr>
<td><strong>Procedural Matters</strong></td>
<td></td>
</tr>
<tr>
<td>Officers</td>
<td>6</td>
</tr>
<tr>
<td>Adoption of the Agenda and Program of Meetings</td>
<td>7</td>
</tr>
<tr>
<td>Representation of the Executive Committee at the</td>
<td></td>
</tr>
<tr>
<td>59th Directing Council of PAHO, 73rd Session of the</td>
<td></td>
</tr>
<tr>
<td>Regional Committee of WHO for the Americas</td>
<td>7</td>
</tr>
<tr>
<td>Draft Provisional Agenda of the 59th Directing Council of PAHO,</td>
<td></td>
</tr>
<tr>
<td>73rd Session of the Regional Committee of WHO for the Americas</td>
<td>7</td>
</tr>
<tr>
<td><strong>Committee Matters</strong></td>
<td></td>
</tr>
<tr>
<td>Report on the 15th Session of the Subcommittee on Program, Budget,</td>
<td>8</td>
</tr>
<tr>
<td>and Administration</td>
<td></td>
</tr>
<tr>
<td>PAHO Award for Health Services Management and Leadership 2021</td>
<td>9</td>
</tr>
<tr>
<td>Non-State Actors in Official Relations with PAHO</td>
<td>9</td>
</tr>
<tr>
<td>Appointment of One Member to the Audit Committee of PAHO</td>
<td>10</td>
</tr>
<tr>
<td><strong>Program Policy Matters</strong></td>
<td></td>
</tr>
<tr>
<td>Proposed Program Budget of the Pan American Health Organization 2022-2023</td>
<td>11</td>
</tr>
<tr>
<td>Scale of Assessed Contributions for 2022-2023</td>
<td>14</td>
</tr>
<tr>
<td>Roadmap for the Digital Transformation of the Health Sector in the Region of the Americas</td>
<td>15</td>
</tr>
<tr>
<td>Policy on the Application of Data Science in Public Health Using Artificial Intelligence and Other Emerging Technologies</td>
<td>16</td>
</tr>
<tr>
<td>Increasing Production Capacity for Essential Medicines and Health Technologies</td>
<td>18</td>
</tr>
<tr>
<td>One Health: A Comprehensive Approach for Addressing Health Threats at the Human-Animal-Environment Interface</td>
<td>21</td>
</tr>
<tr>
<td>Reinvigorating Immunization as a Public Good for Universal Health</td>
<td>23</td>
</tr>
<tr>
<td>Strategy for Building Resilient Health Systems and Post COVID-19</td>
<td></td>
</tr>
<tr>
<td>Pandemic Recovery to Sustain and Protect Public Health Gains</td>
<td>25</td>
</tr>
<tr>
<td><strong>Administrative and Financial Matters</strong></td>
<td></td>
</tr>
<tr>
<td>Report on the Collection of Assessed Contributions</td>
<td>28</td>
</tr>
<tr>
<td>Appointment of the External Auditor of PAHO for 2022-2023</td>
<td>33</td>
</tr>
<tr>
<td>Update on the Master Capital Investment Fund</td>
<td>34</td>
</tr>
<tr>
<td>Update on the Working Capital Fund</td>
<td>35</td>
</tr>
</tbody>
</table>
**CONTENTS (cont.)**

<table>
<thead>
<tr>
<th>Administrative and Financial Matters (cont.)</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Report on the Status of the Emergency Loan from the Revolving Fund for Access to Vaccines to the Regional Revolving Fund for Strategic Public Health Supplies</td>
<td>36</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Personnel Matters</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amendments to the PASB Staff Regulations and Rules</td>
<td>38</td>
</tr>
<tr>
<td>PASB Human Resources Management</td>
<td>39</td>
</tr>
<tr>
<td>Statement by the Representative of the PAHO/WHO Staff Association</td>
<td>41</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Matters for Information</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Update on COVID-19 in the Region of the Americas</td>
<td>43</td>
</tr>
<tr>
<td>Report on Strategic Issues between PAHO and WHO</td>
<td>46</td>
</tr>
<tr>
<td>Implementation of the International Health Regulations</td>
<td>49</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Closure of the Session</th>
<th>Page</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Resolutions and Decisions</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Resolutions</strong></td>
<td></td>
</tr>
<tr>
<td>CE168.R1: Collection of Assessed Contributions</td>
<td>52</td>
</tr>
<tr>
<td>CE168.R2: Policy on the Application of Data Science in Public Health Using Artificial Intelligence and Other Emerging Technologies</td>
<td>53</td>
</tr>
<tr>
<td>CE168.R4: Increasing Production Capacity for Essential Medicines and Health Technologies</td>
<td>56</td>
</tr>
<tr>
<td>CE168.R5: Scale of Assessed Contributions 2022-2023</td>
<td>61</td>
</tr>
<tr>
<td>CE168.R6: Proposed Program Budget of the Pan American Health Organization 2022-2023</td>
<td>63</td>
</tr>
<tr>
<td>CE168.R7: Assessed Contributions of the Member States, Participating States, and Associate Members of the Pan American Health Organization for 2022-2023</td>
<td>66</td>
</tr>
<tr>
<td>CE168.R8: PAHO Award for Health Services Management and Leadership 2021</td>
<td>69</td>
</tr>
<tr>
<td>CE168.R9: Appointment of One Member to the Audit Committee of PAHO</td>
<td>70</td>
</tr>
</tbody>
</table>
CONTENTS (cont.)

Resolutions and Decisions (cont.)

Resolutions (cont.)

CE168.R10: Emergency Loan from the Revolving Fund for Access to Vaccines to the Regional Revolving Fund for Strategic Public Health Supplies .......................................................... 70

CE168.R11: One Health: A Comprehensive Approach for Addressing Health Threats at the Human-Animal-Environment Interface ................................................. 72


CE168.R13: Amendments to the PASB Staff Regulations and Rules ....... 76

CE168.R14: Non-State Actors in Official Relations with PAHO ............ 79

CE168.R15: Reinvigorating Immunization as a Public Good for Universal Health .................................................................................. 80

CE168.R16: Provisional Agenda of the 59th Directing Council of PAHO, 73rd Session of the Regional Committee of WHO for the Americas ................................................. 82

Decisions

CE168(D1): Adoption of the Agenda ............................................................................. 83

CE168(D2): Representation of the Executive Committee at the 59th Directing Council, 73rd Session of the Regional Committee of WHO for the Americas ............................................................................. 83

Annexes

Annex A. Agenda

Annex B. List of Documents

Annex C. List of Participants
Opening of the Session

1. The 168th Session of the Executive Committee of the Pan American Health Organization (PAHO) was held on 21 to 24 June 2021. The session was held using a virtual meeting platform owing to the ongoing COVID-19 pandemic.

2. The Session was attended by delegates of the following nine Members of the Executive Committee elected by the Directing Council: Barbados, Brazil, Costa Rica, Cuba, Ecuador, Haiti, Mexico, Suriname, and the United States of America. Delegates of the following Member States, Participating States, and Observer States also attended in an observer capacity: Argentina, Bahamas, Belize, Bolivia (Plurinational State of), Canada, Chile, Colombia, Dominican Republic, El Salvador, France, Grenada, Guatemala, Guyana, Honduras, Nicaragua, Panama, Paraguay, Saint Kitts and Nevis, Saint Lucia, Spain, Trinidad and Tobago, Uruguay, and Venezuela (Bolivarian Republic of). In addition, 2 intergovernmental organizations and 10 nongovernmental organizations were represented.

3. Ms. Adriana Salazar González (Costa Rica, President of the Executive Committee) opened the session and welcomed the participants. She noted that the Committee had an extensive agenda before it and, with a view to reaching consensus, she appealed to participants to approach the deliberations on the various items in the spirit of Pan Americanism that had always characterized the Organization.

4. Dr. Carissa Etienne (Director, Pan American Sanitary Bureau) also welcomed the participants, expressing thanks to Member States for their sustained and active engagement with the Pan American Sanitary Bureau (PASB or Bureau) as the Americas had grappled with the worst health crisis in a hundred years. She noted that, not only had the pandemic claimed almost 1.9 million lives, but it had upended economies and led to an unprecedented rise in poverty levels, exacerbating inequalities. Highlighting some of the work that the Bureau had undertaken in the fight against the COVID-19 pandemic, she reported that, in collaboration with the COVID-19 Vaccines Global Access (COVAX) Facility, the Bureau had supported the delivery of more than 20 million doses of COVID-19 vaccines in Latin America and the Caribbean, developed and/or adapted 153 technical guidelines and recommendations, conducted more than 249 training exercises and 57 weekly press briefings, and delivered 162 shipments of personal protective equipment (PPE) and 19.5 million polymerase chain reaction (PCR) tests to countries and territories throughout the Region of the Americas.

5. The Director emphasized that, while the Region must turn the tide of the pandemic, it must also protect hard-won public health gains, including the elimination of indigenous transmission of vaccine-preventable diseases such as measles, rubella, and poliomyelitis; the elimination of mother-to-child transmission of HIV and congenital syphilis; and the elimination of Chagas disease and malaria in many countries. The Region must not neglect
essential public health services, including childhood immunization, screening for noncommunicable diseases, management of chronic conditions such as diabetes, and critically needed mental health services. Otherwise, it risked paying a very high toll in terms of increased morbidity, excess mortality, and exorbitant opportunity costs.

6. The Americas must begin immediately to plan for recovery from the pandemic and the post-pandemic era. During its 168th Session, the Committee would be addressing crucial and far-reaching policy matters, including the digital transformation of the health care sector in the Americas, increasing production capacity for essential medicines and health technologies in the Region, and building resilient health systems and post-pandemic recovery to sustain and protect public health gains. The fundamental strategic direction underpinning the various policies and strategies to be discussed would be to recover and rebuild with equity and solidarity. She looked forward to receiving Member States’ astute guidance on those and other vital issues.

7. Ms. Loyce Pace (Director of Global Affairs, Department of Health and Human Services, United States of America), welcoming the participants on behalf of the host country, thanked the Organization for its leadership in the response to the pandemic and the staff of the Bureau for their tireless efforts to improve health and well-being in spite of the current crisis. She stressed that build back better must be more than a political slogan and that steps must be taken to strengthen both PAHO and the World Health Organization (WHO), national health systems, and the broader global health architecture. The United States of America was committed to working in partnership and solidarity with the Bureau and with other Member States to support the COVID-19 response and mitigate the impact of the pandemic while also strengthening institutions and advancing epidemic preparedness for the future. Working together, the countries of the Region could improve health and well-being throughout the Region, advance equity, and help all people to realize their right to health.

Procedural Matters

Officers

8. The following Members elected to office at the 167th Session of the Executive Committee in September 2020 continued to serve in their respective capacities during the 168th Session:

   President:  Costa Rica (Ms. Adriana Salazar González)
   Vice President:  Haiti (Dr. Jean Patrick Alfred)
   Rapporteur:  Ecuador (Dr. Fernando Jácome Gavilánez)

9. The Director of the Pan American Sanitary Bureau, Dr. Carissa Etienne, served as Secretary ex officio, and the Deputy Director, Ms. Mary Lou Valdez, served as Technical Secretary.
Adoption of the Agenda and Program of Meetings (Document CE168/1, Rev. 2)

10. The Committee adopted the provisional agenda proposed by the Director without change (Document CE168/1, Rev. 2); the Committee also adopted a program of meetings (CE168/WP/1) (Decision CE168[D1]).

Representation of the Executive Committee at the 59th Directing Council of PAHO, 73rd Session of the Regional Committee of WHO for the Americas (Document CE168/2)

11. In accordance with Rule 54 of its Rules of Procedure, the Executive Committee appointed Costa Rica and Ecuador, its President and Rapporteur, respectively, to represent the Committee at the 59th Directing Council of PAHO, 73rd Session of the Regional Committee of WHO for the Americas. Haiti and the United States of America were appointed as alternate representatives (Decision CE168[D2]).

Draft Provisional Agenda of the 59th Directing Council of PAHO, 73rd Session of the Regional Committee of WHO for the Americas (Documents CE168/3 and CE168/3, Rev. 1)

12. Ms. Mônica Zaccarelli Davoli (Senior Advisor, Governing Bodies Office, PASB) introduced the draft provisional agenda of the 59th Directing Council of PAHO, 73rd Session of the Regional Committee of WHO for the Americas (Document CE168/3), pointing out that it would most likely not be possible for the Directing Council to resume meeting in Washington, D.C., owing to ongoing travel and public health restrictions necessitated by the pandemic. It was therefore proposed that session should be held virtually and that the agenda for the session should include only items related to the COVID-19 pandemic and matters that must be decided upon to ensure the Organization’s ability to properly discharge its functions. It was also proposed that progress and final reports on policies, strategies, and plans of action that were due for consideration in 2021 should be posted on the webpage of the 59th Directing Council for information, but that they not be discussed during the session. Ms. Zaccarelli Davoli noted that, in addition to the matters for information considered by the Executive Committee, the agenda for the Directing Council would include a discussion on the draft report of the Working Group on Sustainable Financing established by the Executive Board of WHO.

13. In the discussion that followed, it was suggested that an item should be added on the World Health Assembly resolution on strengthening WHO preparedness for and response to health emergencies in order to assist Member States in preparing for the special session of the World Health Assembly to be held in November 2021. It was also suggested that consideration should be given to holding a “hybrid” session, with in-person participation by some and virtual participation by others, in the event that the COVID-19 pandemic situation improved sufficiently before September 2021.

---

1 See Resolution WHA74.7 (2021).
14. The Director welcomed the proposal to add a specific item on WHO preparedness for and response to health emergencies. She was open to the possibility of a hybrid format, but pointed out that the epidemiological situation was constantly evolving and that ongoing travel restrictions might prevent some Member State representatives from participating in person. She suggested that the Officers of the Executive Committee, in consultation with the Bureau, should make a decision on the matter closer to the date of the 59th Directing Council.

15. The Executive Committee adopted Resolution CE168.R16, approving the provisional agenda as amended (Document CE168/3, Rev. 1) and requesting the Officers of the Executive Committee, in consultation with the Bureau, to decide on the format for the session.

Committee Matters

Report on the 15th Session of the Subcommittee on Program, Budget, and Administration (Document CE168/4)

16. Dr. Daniel Salinas (Uruguay, President of the Subcommittee on Program, Budget, and Administration) reported that the Subcommittee on Program, Budget, and Administration had held its 15th Session from 24 to 26 March 2021. Owing to the extraordinary and unprecedented circumstances presented by the COVID-19 pandemic, the Session had been held online using a virtual meeting platform. The Subcommittee had discussed a number of important financial, administrative, and other issues, including an outline of the Program Budget of PAHO for the 2022-2023 biennium and an overview of the Financial Report of the Director for 2020.

17. Dr. Salinas noted that only one of the matters discussed by the Subcommittee was not on the agenda for the 168th Session of the Executive Committee: a report on PAHO’s engagement with non-State actors (NSAs). In that connection, the Subcommittee had been informed that PAHO continued to cooperate closely with the WHO Secretariat to ensure the coherent and consistent implementation of the Framework of Engagement with non-State Actors (FENSA). It had also been informed that the Bureau had instituted special procedures to expedite the review of engagements with NSAs as part of the response to the COVID-19 pandemic. The Subcommittee had noted that the pandemic had highlighted the critical role played by NSAs in responding to health emergencies and recommended that PAHO should further expand its outreach and engagement with NSAs in the Region. The Bureau had been asked to provide Member States with recommendations or procedural guidelines for use at the national level to assess, mitigate, and manage conflicts of interest in potential engagements with non-State actors.

18. Noting that all of the other matters discussed by the Subcommittee were also on the agenda of the Executive Committee, Dr. Salinas indicated that he would report on them as they were taken up by the Committee.

19. The Executive Committee thanked the Subcommittee for its work and took note of the report.
PAHO Award for Health Services Management and Leadership 2021 (Documents CE168/5 and Add. I)

20. Dr. Kenneth George (Barbados, Representative of the Award Committee) reported that the Award Committee for the PAHO Award for Health Services Management and Leadership 2021, comprising the delegates of Barbados, Costa Rica, and the United States of America, had met on 22 June to examine the information on the candidates nominated by Member States. The Award Committee had decided to recommend that the PAHO Award for Health Services Management and Leadership 2021 should be awarded to Dr. Joanne Liu, of Canada, for her dedicated work assisting communities affected by the earthquake and cholera epidemic in Haiti, her efforts to support the strengthening of the health system in Honduras, her leadership in health emergencies and crisis response, and her commitment to delivering health care services to those living in the situations of greatest vulnerability—all of which embodied the key PAHO values of health equity and solidarity. He emphasized that Dr. Liu’s work and advocacy in the fields of medical humanitarianism, crisis response, and health emergencies had been influential regionally and globally, not least in the context of the COVID-19 pandemic and as the world prepared to build back better.

21. The Delegate of Canada applauded the Award Committee’s decision and expressed her admiration for the dedication and achievements of Dr. Liu, whose work in medical humanitarianism and crisis response was renowned in the Americas and globally.

22. The Executive Committee adopted Resolution CE168.R8, conferring the PAHO Award for Health Services Management and Leadership 2021 on Dr. Joanne Liu, of Canada.

Non-State Actors in Official Relations with PAHO (Document CE168/6)

23. Ms. Gabriela Gómez (Uruguay, Representative of the Subcommittee on Program, Budget, and Administration) reported that the Subcommittee had considered a report and a packet of confidential information provided by the Bureau on one non-State actor that had applied for admission into official relations with PAHO and nine organizations in official relations which were due for their triennial review. After considering the information provided by the Bureau, the Subcommittee had decided to recommend that the Executive Committee should approve the admission of Campaign for Tobacco Free Kids into official relations with PAHO and the continuation of official relations between PAHO and Action on Smoking and Health, the American Speech-Language-Hearing Association, the Drugs for Neglected Diseases Initiative–Latin America, the Framework Convention Alliance, the InterAmerican Heart Foundation, the Latin American Federation of the Pharmaceutical Industry, the Latin American Society of Nephrology and Hypertension, the National Alliance for Hispanic Health, and the Sabin Vaccine Institute.

24. In the ensuing discussion, support was expressed for the Subcommittee’s recommendations and the benefits of collaboration with NSAs was underlined. The Bureau was encouraged to continue working in a transparent and accountable manner to improve
engagement with NSAs and to enhance opportunities for NSAs to contribute to global public health work and to participate in the PAHO Governing Bodies.

25. A representative of the Latin American Society of Nephrology and Hypertension described various aspects of his organization’s work with PAHO and emphasized the need to ensure the continuity and quality of care for individuals with kidney disease, particularly among those who had been most impacted by the COVID-19 pandemic. A representative of the Pan American Federation of Nursing Professionals highlighted the critical role played by nurses during the pandemic and stressed the need to ensure that nurses had a voice in decision-making within the health care team. She also stressed the need to ensure access to COVID-19 vaccines for all nurses. A representative of the American Speech-Language-Hearing Association noted that her organization had been collaborating with PAHO since 2014 and looked forward to continuing that collaboration in order to support Member States in the areas of speech pathology and audiology.

26. Ms. Regina Campa (Advisor, Department of External Relations, Partnerships, and Resource Mobilization, PASB) said that the Bureau was firmly convinced of the value of collaboration with non-State actors and of the significant contribution they could make to the achievement of public health objectives.

27. The Director affirmed that the Bureau frequently sought to tap the knowledge and expertise of NSAs and relied on them as partners in expanding the Organization’s technical cooperation. She also noted that NSAs had contributed to some of the documents considered by the Executive Committee during the session.

28. The Executive Committee adopted resolution CE168.R14, endorsing the recommendations of the Subcommittee.

Appointment of One Member to the Audit Committee of PAHO (Document CE168/7)

29. Ms. Gabriela Gómez (Representative of the Subcommittee on Program, Budget, and Administration) reported that the Subcommittee, having been informed that the term of office of one member of the Audit Committee was set to expire in June 2021, had established a working group to review the list of candidates proposed by the Director. The working group had evaluated the proposed candidates on the basis of the criteria for membership set out in Section 4 of the Terms of Reference of the Audit Committee and had decided to recommend that Mr. Martín Guozden should be reappointed to the Audit Committee. The Subcommittee had endorsed the working group’s recommendation.

30. In the ensuing discussion, a delegate expressed support for Mr. Guozden’s reappointment and observed that the Audit Committee played a critical role in providing oversight of PAHO, thereby strengthening accountability and improving governance within the Organization.

31. The Director said that she would welcome Mr. Guozden’s reappointment, affirming that his contribution during his first term on the Committee had been invaluable.
32. The Executive Committee endorsed the recommendation of the Subcommittee and adopted Resolution CE168.R9, appointing Mr. Martín Guozden to serve as a member of the PAHO Audit Committee for a second term of three years, from June 2021 to June 2024.

Program Policy Matters

Proposed Program Budget of the Pan American Health Organization 2022-2023 (Documents CE168/8 and Add. I and Add. II)

33. Ms. Gabriela Gómez (Representative of the Subcommittee on Program, Budget, and Administration) reported that the Subcommittee had reviewed an outline of the proposed program budget for the 2022-2023 biennium during its 15th Session. The Subcommittee had welcomed the Bureau’s efforts to incorporate lessons learned from the previous biennium and from the pandemic response in the program budget proposal and its work with Member States to review and refocus the Organization’s objectives and priorities to reflect current needs. The Bureau had been asked to provide the Executive Committee with a report on the trends and patterns observed in the reprioritization exercise. It had been pointed out that Member States face unprecedented financial pressures as a result of the pandemic, and it had been emphasized that the Bureau should develop a realistic budget proposal that reflected that context of resource constraints. The Bureau had been encouraged to continue to seek economies through increased efficiency.

34. Mr. Rony Maza (Director, Department of Planning, Budget, and Evaluation, PASB) introduced the program budget proposal for 2022-2023 (Document CE168/8), noting that it was the first full draft of the program budget to be presented to the Governing Bodies and that the proposal had been updated to reflect recent developments at the country, regional, and global levels. He pointed out that, in preparing the proposal, the Bureau had carefully considered the current situation, existing commitments, the review of the strategic priorities undertaken in collaboration with Member States, and lessons learned during the current biennium. The proposal had been crafted with a view to providing the strategic direction, approaches, and areas of focus for the biennium, with special attention to risks and mitigation actions for 2022-2023. A key consideration had been the need to continue responding to the current pandemic situation, while not losing focus on medium- and long-term commitments for sustainable health development. The principles of equity and solidarity underpinned the proposal.

35. Mr. Maza noted that the programmatic structure of the program budget would remain largely the same as in the current 2020-2021 biennium, with 28 outcomes and 102 outputs, as approved under the PAHO Strategic Plan 2020-2025. It was aligned with various regional and global mandates, including the Sustainable Health Agenda for the Americas 2018-2030 (SHAA30), the WHO Thirteenth General Programme of Work (GPW13), and WHO program budget for 2022-2023. The process of preparing the program budget 2022-2023 had offered an opportunity to review the strategic priorities defined in the PAHO Strategic Plan 2020-2025 in the light of the current situation in order to ensure that the Bureau’s technical cooperation remained responsive and aligned with Member States’ needs. Consultation with Member States on the review of strategic priorities was
ongoing but would be concluded prior to the 59th Directing Council, to be held in September 2021. Planning and budgeting at country level would be guided by the results of the prioritization review conducted with each country.

36. The proposal called for a total budget of US$ 688 million, including $640 million for base programs and $48 million for special programs, $20 million and $18 million more, respectively, than in the 2020-2021 biennium. The increases would be financed entirely from the increase in the WHO allocation to the Regional Office for the Americas (AMRO). The budget allocation from WHO for AMRO amounted to $252.6 million for base programs and $17.3 million for special programs. PAHO net assessed contributions would remain unchanged under the Program Budget 2022-2023. Acknowledging that there had traditionally been a sizable gap between WHO allocated funding and the amount actually received, Mr. Maza emphasized that every effort had been made to ensure that the proposal was realistic, balancing the needs identified in a bottom-up planning and costing exercise, existing corporate commitments, and the technical cooperation priorities identified by Member States against historical trends and prospects for financing. He also noted that PAHO assessed contributions had not increased since 2012-2013, which meant that, in real terms, predictable, flexible financing for technical cooperation activities had declined, while dependence on voluntary contributions had grown.

37. Like the Subcommittee, the Executive Committee welcomed the Bureau’s efforts to incorporate lessons learned from the previous biennium and from the pandemic response in the budget proposal and to work with Member States to review the Organization’s priorities. The Executive Committee expressed appreciation to the Bureau for the effort made to present a proposed program budget that not only clearly showed the alignment between the global and regional mandates, but also a results chain indicating how collectively established objectives would be achieved. To facilitate future evaluation of the achievement of those objectives, the Bureau was urged to carefully validate baselines and targets for the output indicators. It was also encouraged to review the wording of some of the key technical cooperation interventions identified under each outcome to make it clear that those activities would be carried out in close collaboration with national health authorities.

38. The cost-efficiency measures implemented by the Bureau were applauded; at the same time, however, it was hoped that those measures would not affect the deployment of technical cooperation at the country level. It was pointed out in that regard that the recovery of essential health services in the post-pandemic period would require a redoubling of efforts at the country level, and the Bureau was encouraged to review the proposed 3% increase in the allocation to the regional level with an eye to channeling more resources to the country level. The Bureau was also encouraged to strengthen the PAHO/WHO representative offices in order to strengthen technical cooperation at country level and facilitate the achievement of both collective and individual country objectives.

3 Unless otherwise indicated, all monetary figures in this report are expressed in United States dollars.
39. It was pointed out that, going forward, it would be critical to continue implementing lessons learned from the COVID-19 pandemic and making adjustments as needed. In that connection, the Bureau was asked to include in the document to be prepared for the Directing Council more specific information on the synergies between outcomes 23 (Health emergency preparedness and risk reduction) and 24 (Epidemic and pandemic prevention and control) and the Health Emergencies Program.

40. More information was requested on the interprogrammatic actions that would offset reductions in the allocations for some outcomes, such as outcome 7 (Health workforce). Further detail was also requested on how the Bureau planned to address the External Auditor’s recommendations on improving the costing of activities under the program budget and agreeing with Member States a methodology to establish a target level of retained program support funds for financing subsequent biennium program budget activities and transferring any surplus over the agreed level to fund other priority or strategic funding requirements (see paragraphs 114 to 132 below).

41. The Committee recognized that the Bureau’s ability to continue providing critical support during the pandemic and to implement the technical cooperation planned for the coming biennium would depend on the availability of financial resources, and Member States were urged to pay their assessed contributions on time and in full. In view of the historical shortfall in the receipt of the WHO allocation to the Region, the Bureau was encouraged to plan around potential gaps in WHO funding. It was also encouraged to identify new strategies for resource mobilization. Clarification was sought regarding what strategies were being considered to achieve the Bureau’s stated objective of strategically positioning PAHO as the partner of choice for health in the Americas. The Bureau’s efforts to strengthen accountability through the PAHO Program Budget Portal were applauded. It was noted that the portal enabled Member States to identify areas where there were funding gaps and where technical cooperation results might therefore be limited.

42. Mr. Maza thanked delegates for their suggestions for the improvement of the program budget document, affirming that the Bureau strove to present information in the clearest manner possible. Regarding the questions on outcomes 23 and 24, he pointed out that there were synergies among all the outcomes having to do with emergency preparedness and response and those related to health systems and services, since effective emergency response required comprehensive action across health systems and services. Similarly, as outcome 7 (Health workforce) was closely linked to other outcomes relating to health systems and services, the reduction in the former could be offset through an integrated interprogrammatic approach to the latter. With regard to the distribution of the budget by functional level, he pointed out that the 40% allocated to the country level was the minimum under the PAHO Budget Policy; in reality, however, substantially more than that went to countries, since a large portion of the budget for technical programs and for enabling and support functions at the regional level supported technical cooperation with countries. He assured the Executive Committee that, in preparing the budget proposal, the Bureau had taken into consideration the gap between the amount allocated and the funding received from WHO. It was grateful for Member States’ continued advocacy within WHO aimed at ensuring that the Region received the entire budget allocation of the WHO budget.
43. The Director explained that the Bureau had already made significant headway towards positioning PAHO as the preferred partner and the lead public health agency in the Region. It had significantly ramped up its communications, including through weekly press briefings, with a view to raising awareness of the Organization and its work, not just in Latin America and the Caribbean but globally. At the same time, the Bureau had stepped up its resource mobilization efforts and its outreach to potential new partners, including philanthropic organizations and private-sector entities, always ensuring that any such fund-raising efforts were fully in accordance with the Framework of Engagement with non-State Actors (FENSA). PASB aimed to ensure that all members of staff, including staff in the country offices, saw themselves as resource mobilizers.

44. She thanked Member States for their engagement in the budgetary process and for their many recommendations on how to improve the process and the information provided. She assured the Executive Committee that the Bureau would do its best to incorporate the suggestions made with regard to the proposed PAHO Program Budget 2022-2023 and to ensure effectiveness, efficiency, and transparency, not only in the process of developing the program budget but also in implementing it. She noted, however, that the Bureau faced heavy demand for technical cooperation services related to the COVID-19 pandemic and its ability to respond to other demands was therefore limited.

45. The Executive Committee adopted Resolution CE168.R6, recommending that the Directing Council approve the PAHO Program Budget 2022-2023 as proposed in Document CE168/8. The Committee also adopted Resolution CE168.R7, recommending that the Directing Council establish the assessed contributions of Member States, Participating States, and Associate Members for the biennium 2022-2023.

Scale of Assessed Contributions for 2022-2023 (Document CE168/9)

46. Ms. Gabriela Gómez (Representative of the Subcommittee on Program, Budget, and Administration) reported that the Subcommittee had been informed that the PAHO scale of assessed contributions for 2022-2023 would be based on the scale adopted by the General Assembly of the Organization of American States (OAS) in October 2018, which covered the period from 2019 to 2023. As the OAS scale would apply different percentage calculations for 2022 and 2023, the PAHO scale would also differ in the two years of the biennium. The changes in the percentage calculation would entail an increase for all OAS Member States except the United States of America.

47. The Delegate of the United States pointed out that it was not in the Organization’s best interest to be overly reliant on a single donor and that the equitable sharing of assessed contributions among Member States would encourage financial sustainability.

48. Mr. Rony Maza (Director, Department of Planning, Budget, and Evaluation, PASB) noted that, pursuant to the PAHO Constitution, the Organization’s scale of assessed contributions was tied to the scale formally adopted by the OAS.

49. The Director said she appreciated that the new OAS scale would require some PAHO Member States to pay a higher contribution to the Organization at a time when
many faced economic difficulties due to the pandemic. Nevertheless, the importance of timely payment of assessed contributions could not be understated. Indeed, it was critical to the Organization’s ability to deliver technical cooperation. She appealed to Member States to ensure that their payments were made in a timely manner.

50. The Executive Committee adopted Resolution CE168.R5, recommending that the Directing Council approve the scale of assessed contributions for 2022-2023 as set out in Document CE168/9.

Roadmap for the Digital Transformation of the Health Sector in the Region of the Americas (Document CE168/10)

51. Dr. Sebastián García Saiso (Director, Department of Evidence and Intelligence for Action in Health, PASB) introduced the proposed roadmap for the digital transformation of the health sector in the Region, noting that it was related to the proposed policy on the application of data science in public health using artificial intelligence and other emerging technologies (see paragraphs 60 to 68 below), but that it called for distinct policy actions. He also noted that both the roadmap and the policy had been discussed at a conference on information systems for health (IS4H) held in February 2021.

52. Pointing out that telemedicine and other digital health solutions had proved crucial to the delivery of health services and the continuity of care during the COVID-19 pandemic, he explained that the aim of the roadmap was to support Member States in participating in a safe, ethical, equitable, inclusive, and cost-effective way in the digital transformation processes with a view to accelerating the adoption and implementation of interoperable digital health solutions through a multistakeholder approach and in collaboration with key partners.

53. The roadmap built on existing mandates and plans and on the experience of PAHO, WHO, and other relevant organizations in supporting interventions that employed an innovative approach to the development and use of interoperable and interconnected information systems for health and digital health solutions. Its eight lines of action were aligned with the eight principles for digital transformation of the health sector adapted from the United Nations Roadmap for Digital Cooperation and agreed with Member States during the IS4H conference in February 2021.

54. The Executive Committee voiced strong support for the roadmap and thanked the Bureau for involving Member States in the deliberative process leading to its development. The Committee felt that the roadmap clearly laid out the actions required to bring about the digital transformation of the health sector in the Region. It was emphasized that the digital transformation process must ensure the availability, accessibility, and interoperability of information, with high security standards to protect the confidentiality of patient information, while also making information available for evidence-based decision- and policy-making. The Committee also stressed the importance of a multisectoral approach and of ensuring interoperable, equitable, and inclusive digital health solutions. The need to adapt such solutions to the reality, priorities, and needs of each country was highlighted.
55. It was pointed out that the technology required for digital transformation was not available to everyone in the Region, which could create a new gap between those who did and did not have access to resources. It was also pointed out that those who had access to digital technologies did not necessarily know how to use them and that appropriate training was therefore essential. The importance of training in the ethical use of data and in digital literacy, both for health personnel and for the general public, was underscored. In order to achieve the objectives of the roadmap, it was considered essential for governments to invest in its implementation, including through investment in universal connectivity and mobile telephone coverage, especially in remote and vulnerable communities.

56. It was suggested that the document would benefit from the inclusion of information on successful digital health initiatives under way in various countries of the Region. The important role of PASB in sharing information on such experiences and promoting cooperation and collaboration between countries was noted. As the policy document comprehensively addressed the issues involved in digital transformation processes, it was not considered necessary to develop a subsequent strategy and plan of action on the matter.

57. Dr. García Saiso acknowledged the value of sharing experiences and information and thanked Member States for their contributions to the roadmap and to the IS4H initiative. He assured the Executive Committee that the Bureau was keenly aware of the need to bridge digital gaps between and within countries and avoid exacerbating existing inequities, noting that the issue was addressed in a cross-cutting manner throughout the roadmap. The Bureau also recognized the need to adapt the actions taken under the roadmap to the needs and priorities of each country and stood ready to work with Member States to that end.

58. The Director noted that digital transformation had been recognized as key to the attainment of the Sustainable Development Goals and universal health coverage. She pointed out that, in many countries, significant progress in digital transformation had been made in other sectors, but that the health sector had lagged behind, and it was therefore important for the sector to catch up. She affirmed that, in the Bureau’s work to advance digital transformation in the Region, it would place emphasis on equity, and on ensuring the use of technologies that were already widely available, while also expanding access to other health technologies. The Bureau recognized the value of harnessing the knowledge and experience existing in the Region, and she assured Member States that there would be ample opportunity for them to share information and best practices.

59. The proposed resolution on this item was revised to reflect comments and suggestions made during the discussion, and the Executive Committee subsequently adopted Resolution CE168.R3, recommending that the 59th Directing Council approve the roadmap.

Policy on the Application of Data Science in Public Health Using Artificial Intelligence and Other Emerging Technologies (Document CE168/11)

60. Dr. Sebastián García Saiso (Director, Department of Evidence and Intelligence for Action in Health, PASB), introducing the proposed policy, pointed out that the COVID-19
pandemic had highlighted the importance of access to timely and secure access to accurate data and information for decision-making and had also revealed the limitations that existed with regard to health statistics. He explained that the aim of the proposed policy on the application of data science was to provide strategic and technical guidance to enable Member States to create an enabling environment to support general and predictive analysis for modeling, forecasting, and identification of public health trends and for devising practical solutions to improve health outcomes.

61. He reported that an analysis of IS4H maturity in the countries and territories of the Region had shown that there was great opportunity for better health data management, but also major challenges in relation to governance and regulatory issues, critical levels of aggregation, cybersecurity, and ethical use of information and data. The proposed policy was intended to help Member States tackle those challenges through eight priority actions, which were described in Document CE168/11.

62. The Executive Committee expressed solid support for the proposed policy and priority actions and agreed on the need to develop and implement policies and initiatives for the use of data science in order to strengthen public health data and surveillance, facilitate a better understanding of complex public health problems, and increase the availability of evidence-based information for decision-making. The Committee also recognized the challenges existing in this area, including the need to strengthen regulatory systems and to protect privacy and ensure ethical and transparent use of data, the need to address differences in health information systems between and within countries and put in place standards for interoperability and information-sharing, and the need to ensure training for health personnel in the appropriate use of data science tools and methods. In relation to the latter, a delegate drew attention to the importance of presenting data science technologies to health workers as a means of enhancing their current activities and not as a replacement for traditional methods.

63. It was pointed out that implementing the policy would require action beyond the health sector and that the policy should therefore be accompanied by broad national policies and efforts aimed at fostering the development of the necessary capacities. The proposed policy was seen as a means of promoting the exchange of experiences and good practices and strengthening capacities through international cooperation. The Bureau’s role in that regard was highlighted. As with the roadmap for digital transformation of the health sector, it was not considered necessary to develop a subsequent strategy and plan of action, as the policy document comprehensively addressed the issues involved in the application of data science in public health.

64. It was emphasized that care must be taken to ensure that data science tools were used in a way that did not exacerbate existing health disparities but rather served to reveal inequalities in health status and health determinants in order to provide a basis for addressing them. The importance of representative datasets that included information on vulnerable and underserved populations was stressed.
65. It was suggested that the policy could be improved by clarifying the distinction between the concepts of “open data” and “open algorithms” and by better nuancing and contextualizing the references to them. In that regard, it was pointed out that there could be legal and ethical barriers to the sharing of many types of health data openly, coupled with technical barriers to data anonymization, and that many data science initiatives used proprietary algorithms or software that could not be shared openly.

66. Dr. García Saiso thanked the Executive Committee for its suggestions for improving the document and affirmed that the policy would continue to be broadened and strengthened as it was implemented. The Bureau was convinced that the policy would provide a sound basis for enhancing capacity to collect and analyze data in order to generate the information and intelligence required for decision-making for the benefit of the Region’s populations.

67. The Director agreed that the policy had the potential to catapult health information into the 21st century and enable the optimal use of relevant data for public health decision-making. It was an ambitious policy, but also, in her view, a necessary one. The Bureau did not intend to develop a subsequent strategy and plan of action, but it would need to continue working closely with experts and institutions in Member States to plot the way forward and realize the policy’s objectives.

68. The Executive Committee adopted Resolution CE168.R2, recommending that the 59th Directing Council approve the policy.

**Increasing Production Capacity for Essential Medicines and Health Technologies (Document CE168/12)**

69. Dr. James Fitzgerald (Director, Department of Health Systems and Services, PASB), introduced the document on this item, explaining that the COVID-19 pandemic had led to shortages and inequities in access to essential medicines, vaccines, personal protective equipment, and other health technologies and supplies vital for the control and management of an international health emergency. It had also highlighted the high dependence of Latin America and the Caribbean on imports of medical products from other Regions; the vulnerabilities of global supply chains; and the heterogeneity in the Americas in terms of COVID-19 vaccine research, development, and production capacity.

70. Dr. Fitzgerald emphasized that ensuring access to essential medicines, vaccines, and other critical health supplies required regional collaboration, coordination, and solidarity. Comprehensive sectoral and intersectoral policies were also needed to increase development and production capacities. A number of projects and initiatives in the Region had already helped to facilitate technology transfer and accelerate the development and fair distribution of COVID-19 vaccines. The policy paper aimed to promote intersectoral action and increase regional production and development capacities to improve access to medicines and other health technologies, protect national security, and stimulate economic recovery in the Region. It was built on three strategic lines of action: strengthening coherence in intersectoral action and governance in health, science and technology, and
industry; strengthening research, development, production, and logistical capacity; and strengthening regional and subregional collaboration and strategic partnerships.

71. In the ensuing discussion, delegates welcomed the policy paper, commending in particular its focus on promoting equal access to medicines, sharing experiences and good practices, and strengthening regional production and international cooperation. It was stressed that equal access to medicines and vaccines was fundamental to the right to health for all. Promoting generic medicines, increasing transparency of production costs at national and regional levels, and increasing local production through technology transfer were highlighted as possible strategies for fostering more equal access to medicines and health technologies. PAHO was urged to continue promoting the exchange of knowledge, information, and technology between Member States in order to facilitate decision-making and increase local development and production capacities. It was suggested that high-income countries should support those with fewer resources, including by providing capacity-building, technology transfer, and continuous training.

72. Delegates agreed that the COVID-19 pandemic had exposed the urgent need to strengthen and diversify global supply chains to facilitate equal access to health products, essential supplies, and raw materials in the Region. It was considered critical for PAHO and Member States to join forces to improve the Region’s capacity to respond to emergency situations, access the medicines and health technologies needed for the management of COVID-19 patients, and ensure effective vaccination programs. A representative of a nongovernmental organization urged Member States to promote sustainable financing mechanisms in support of research and development and initiatives to strengthen national or regional production of affordable medicines and to include medicines for the treatment of neglected tropical diseases endemic to the Region as priority products for local production.

73. Strong support was expressed for greater technical, multisectoral, and multilateral cooperation, including between PAHO, WHO, the World Intellectual Property Organization (WIPO), and the World Trade Organization (WTO). The critical work of industry in responding rapidly to the COVID-19 pandemic and developing vaccines was commended, and the importance of working with non-State actors was emphasized, as was coordination among government ministries and cooperation with lawmakers. Several delegates reaffirmed their countries’ commitment to the WTO Agreement on Trade-related Aspects of Intellectual Property Rights (TRIPS Agreement) and the Doha Declaration on the TRIPS Agreement and Public Health. The importance of the COVAX Facility and the COVID-19 Technology Access Pool (C-TAP) and Medicine Patent Pool initiatives was also underscored.

74. Several delegates outlined measures that had been taken by their Governments to strengthen the research, development, and production of medicines and health technologies. Further engagement with patent-holding companies was recommended in order to promote public-private partnerships, foster technology transfer, and facilitate the local production of medicines and health technologies. It was suggested that intellectual property waivers for COVID-19 vaccines, which was currently being discussed at the
WTO, should be incorporated into the document. One delegate expressed the hope that the comprehensive nature of the policy paper would obviate the need for an accompanying strategy and plan of action to be developed. The Bureau was requested to ensure that the document was shared in good time ahead of the 59th Directing Council in order to facilitate consultation with as broad a range of stakeholders as possible.

75. Dr. Fitzgerald agreed with delegates on the need for greater intersectoral action, involving not only the health, science and technology sectors, but also non-State actors, including the private sector, academia, and civil society. He noted that, since the onset of the COVID-19 pandemic, many countries had already made progress in that area, identifying national priorities and establishing coordination mechanisms between multiple stakeholders. He also pointed out that leadership at the highest levels of governance, concerted action by government ministries, and the involvement of lawmakers constituted critical components of efforts to increase production capacity. National regulatory authorities and the Pan American Network for Drug Regulatory Harmonization also had an essential role to play, not only in ensuring the rapid evaluation, quality, safety, and efficacy of medicines, but also in providing oversight of research and development and supporting increased production capacities.

76. Dr. Fitzgerald explained that the Bureau had attempted to strike a balanced approach in the policy document to the issue of intellectual property, at once recognizing the importance of intellectual property protection for the development of new medicines while also emphasizing Member States’ need to protect public health and to promote access to medicines for all. Concerning the linkages between the policy’s strategic lines of action and other global and multilateral initiatives, he explained that the Organization was making every effort to build solidarity and collective action across the Region. For example, it had been working with various organizations, including the Economic Commission for Latin America and the Caribbean (ECLAC) and the Community of Latin American and Caribbean States (CELAC), as well as the WHO World Local Production Forum and various industry sectors, to strengthen capacity and promote technology transfer in the Region. It was also liaising with the United Nations common system and the World Bank to ensure access to priority products.

77. As significant investment to meet the objectives of the policy paper would be required, the Bureau was engaging with private-sector stakeholders and national and international financial institutions, including the Inter-American Development Bank. Efforts were also under way with WHO and non-State actors, such as universities and representatives of industry, to facilitate the establishment of a COVID-19 mRNA vaccine technology transfer hub in the Region.

78. The Director noted that the pandemic had highlighted the Region’s heavy dependence on other regions for essential medicines and supplies. It was vital that the Region became more self-sufficient, not only in the context of the current COVID-19 pandemic, but also in the face of any future pandemics. However, achieving self-sufficiency would require more than technology transfer or the suspension of intellectual property rights. It would necessitate commitments at the highest political levels and
significant capacity-building investments in order to make universal health a reality and build solidarity across the Region.

79. During the Committee’s discussion of the proposed resolution, it was suggested that an additional operative paragraph should be added on the creation of a regional forum for discussion of the challenges and opportunities associated with the production of essential medicines and health technologies. Additional amendments aimed at simplifying and clarifying some wording and ensuring consistency with other WHO and PAHO documents were also proposed. The Executive Committee subsequently adopted the amended Resolution CE168.R4, recommending that the 59th Directing Council approve the policy document.

*One Health: A Comprehensive Approach for Addressing Health Threats at the Human-Animal-Environment Interface (Documents CE168/13 and CE168/13, Rev. 1)*

80. Dr. Marcos Espinal (Director, Department of Communicable Diseases and Environmental Determinants of Health, PASB) introduced Document CE168/13, explaining that the aim of the One Health policy was to foster coordination and collaboration among human, animal, plant, and environmental health programs in order to better prevent and prepare for current and future health challenges at the human-animal-environment interface. The policy put forward a collaborative, multidisciplinary, and multisectoral approach for achieving optimal health outcomes by recognizing the interconnections between people, animals, plants, and their shared environment. The One Health approach was intended to address a range of health threats, including diseases of zoonotic origin, antimicrobial resistance, and foodborne illnesses.

81. Dr. Espinal pointed out that the COVID-19 pandemic was the latest example of the devastating impact of zoonotic diseases on human society, not just in terms of health but also in economic terms, as evidenced by the 7% contraction in the gross domestic product (GDP) of Latin America and the Caribbean in 2020.

82. The One Health policy built on existing mandates and plans and on the experience of PAHO and other relevant organizations in working with stakeholders beyond the health sector. It included six strategic lines of action. The policy had benefited from input from various entities across the Bureau and from suggestions made by Member States during two informal consultations held in May 2021.

83. The Executive Committee welcomed the proposed policy and endorsed the One Health approach, underlining the need for multidisciplinary and multisectoral action to implement such an approach. While the Committee expressed support for the proposed strategic lines of action, Members felt that several aspects of the policy could be strengthened. For example, it was suggested that the policy should address several issues specific to the Region, such as illegal mining involving the use of toxic chemicals, which had negative consequences for food and water sources and therefore for human health; the use of agrochemicals and the need for research on their true impact and monitoring and control of their use; the need for integrated waste management and incentives to reduce the
use of polluting products and promote reuse of materials; and the need to improve air quality and reduce pollutants that were harmful to health.

84. It was also suggested that the document should place greater emphasis on utilizing the existing technical and human resource capacities in each country, including the expertise available at PAHO/WHO collaborating centers; sharing information; and conducting joint research in order to implement the One Health approach. One delegate expressed the view that, before the policy could be adopted and implemented, it would be necessary to coordinate with the other sectors involved in applying a One Health approach, in particular in order to ensure that adequate attention was given to social determinants of health, such as access to water and sanitation and to nutritious food.

85. It was pointed out that the policy did not adequately recognize the importance of working with local populations, including indigenous peoples, and ensuring that local knowledge was duly considered. The importance of protecting both human and wildlife health was also noted, and it was suggested that the policy should include a reference to the World Organisation for Animal Health (OIE) Wildlife Health Framework in order to highlight the vital role of wildlife in biodiversity and essential ecosystem services. The Bureau was asked to clarify how PAHO would contribute to the One Health High-level Expert Panel and was encouraged to work closely with WHO Headquarters, OIE, the Food and Agriculture Organization of the United Nations (FAO), and the United Nations Environment Programme (UNEP) in implementing the policy.

86. With regard to the proposed resolution annexed to Document CE168/13, it was pointed out that the wording of preambular paragraph 4 suggested that intensive agricultural production and exportation automatically increased the risk of zoonotic diseases, a statement that did not appear to be based on a risk assessment or supported by scientific evidence.

87. Dr. Espinal explained that the policy put forward a generic approach that could be adapted by countries to address issues of specific concern to them, such as illegal mining, use of agrochemicals, and other matters raised by the Executive Committee. He assured the Committee that the Bureau was fully aware that implementing the One Health approach would require collaboration across sectors and noted that, for that reason, it had sought to include representatives of the agricultural and environmental sectors and of national regulatory agencies in the Member State consultations held in May. For that reason, as well, the policy’s first strategic line of action acknowledged that the One Health approach could not be managed by any one entity or sector and called for an analysis and mapping of the complex interactions between the various sectors that must be involved. Dr. Espinal also pointed out that Annex C included a non-exhaustive list of the collaborating centers with which the Bureau proposed to work in order to promote research and training under the policy. Lastly, he noted that PAHO was working closely with FAO and OIE and was leading efforts within the “Tripartite” (formed by WHO, FAO, and OIE) to tackle antimicrobial resistance in various countries.
88. The Director affirmed that the One Health initiative brought together a multitude of government sectors, including health, agriculture, environment, and trade, as well as civil society, academia, and the private sector. However, it had not yet been possible to achieve a total commitment across all the sectors concerned. The Bureau was therefore working with countries to help them put in place broad multisectoral coalitions at the national level. It was vital to do so because, without strong collaboration across sectors, it would be impossible to address critical issues such as antimicrobial resistance or avert future pandemics.

89. A working group was formed to revise the document and the proposed resolution in order to incorporate the Executive Committee’s comments and suggestions. The Committee subsequently adopted Resolution CE168.R11, recommending that the 59th Directing Council approve the policy.

Reinvigorating Immunization as a Public Good for Universal Health (Document CE168/14)

90. Dr. Luis Andrés de Francisco Serpa (Director, Department of Family, Health Promotion and Life Course, PASB), introducing the policy document on this item, affirmed that immunization was a key pillar of public health, an indisputable human right, and one of the best health investments that money could buy. He recalled that the Region of the Americas had an enviable immunization record: through the Expanded Program on Immunization in the Americas, it had successfully eliminated several vaccine-preventable diseases, including poliomyelitis, measles, and neonatal tetanus. New vaccines, such as those for rotavirus, pneumococcus, and human papillomavirus, had been introduced, and countries had strengthened their immunization programs and surveillance systems with support from the Revolving Fund for Access to Vaccines. Nevertheless, over the past decade, national immunization programs had suffered a number of setbacks, including a decrease in vaccination coverage, inadequate long-term sustainable financing, less stringent epidemiological surveillance, and increased vaccine hesitancy linked to the rise of false information. Those setbacks had contributed to emerging outbreaks of vaccine-preventable diseases in the Region. Moreover, the COVID-19 pandemic had disrupted immunization programs and expanded existing gaps in vaccination coverage.

91. Dr. De Francisco Serpa noted that the policy document provided for a strategic framework with priority lines of action and new approaches aimed at reinvigorating immunization as a public good for universal health. It included an overview of the current situation, highlighted critical challenges, and proposed innovative strategies incorporating proven best practices and emerging technology and tools. Those strategies included leveraging artificial intelligence and georeferencing tools to identify unvaccinated population clusters and developing innovative communication approaches to build trust in vaccines and combat vaccine hesitancy. He pointed out that strong immunization programs were key not only to maintaining the advances already made but also to controlling current and future epidemics and pandemics. Lastly, he noted that issues related to COVID-19 vaccines and the COVAX Facility were addressed under the update on COVID-19 in the Region of the Americas (see paragraphs 178 to 193 below).
92. In the ensuing discussion, delegates expressed strong support for the policy, acknowledged the value of immunization as a public good for universal health, and reaffirmed their countries’ commitment to strengthening their national immunization programs. It was noted that the COVID-19 pandemic had underscored the vital role of vaccines in protecting public health and the risks associated with reduced vaccination coverage; it had also disrupted immunization programs and widened existing gaps in access to health. Concern was expressed regarding the spread of misinformation about vaccines, growing vaccine hesitancy, and the consequent resurgence of vaccine-preventable diseases. It was emphasized that a multistakeholder approach—involving governments, donors, civil society, and the pharmaceutical industry, among others—was needed to maintain hard-won gains, recover from the disruptions caused by the COVID-19 emergency, and increase access to vaccines for all.

93. Several delegates outlined the measures their countries had taken to bolster their national immunization programs, the progress they had achieved, and the challenges they continued to face. Of those challenges, countering misinformation, disinformation, and false information was highlighted as a serious and growing concern. It was recommended that the document should place greater emphasis on tackling that issue, including through information campaigns to encourage public engagement and dispel myths related to vaccines. The key role of civil society and communities in that endeavor was highlighted. Several other suggestions were made, including ensuring timely and equitable access to vaccines and health technologies across the Region; strengthening countries’ technical and institutional capacity-building; and expanding regional production to ensure equal access to vaccines and other strategic supplies throughout the Americas.

94. Delegates welcomed the policy document’s focus on best practices and innovative strategies, highlighting in particular the emphasis on digital intelligence and strong leadership. The policy’s alignment with the WHO Immunization Agenda 2030 was also welcomed. It was pointed out that expanding vaccination coverage would require new delivery methods and investments in scalable and resilient vaccination logistics, infrastructure, manufacturing, and supply chains—factors that the document did not consider. Clarification was sought on the source of information used in the policy document to support the link between immunization and educational attainment. Several delegates called for the development of a detailed plan of action to accompany the policy, while one delegate felt that the policy was comprehensive enough to render a plan of action unnecessary.

95. Dr. De Francisco Serpa agreed that combating misinformation and false information about vaccines was essential for building public trust in vaccines and science and combating vaccine hesitancy. For that purpose, the Bureau had developed a number of tools and courses to assist countries in developing communication plans and conveying authoritative information about vaccines and immunization. He pointed out that the media were a critical component of efforts to build confidence in vaccines, as were health workers. The Bureau had therefore been carrying out a series of activities for health workers and holding talks and seminars for journalists on how to use communication tools to present information on vaccines in a more objective and informative manner. He also
pointed out that it was vital to keep abreast of public opinion and ensure that official communications were up-to-date and addressed the latest questions raised and misinformation posted on social networks. With regard to the preparation of a plan of action, he indicated that, following the completion of the Plan of Action on Immunization for the period 2016–2020,⁴ a new plan was being developed. That plan would be aligned with the WHO Immunization Agenda 2030.

96. The Director observed that, while the Region had an impressive immunization record, it now faced a real and growing danger of the reemergence of the vaccine-preventable diseases that it had worked so hard to eliminate. She pointed out that the reduction in vaccination coverage was not due to the COVID-19 pandemic alone. Over the past 10 years, financial investments in immunization programs had fallen and the visibility afforded to immunization programs by high-level politicians had diminished. The pandemic had exacerbated existing vaccination coverage gaps and contributed to growing vaccine hesitancy. It had also had the effect of diverting human and financial resources from national immunization programs and reducing coverage of essential health services in general.

97. In the light of those challenges, the Bureau was strengthening its immunization program and urged Member States to do the same. She confirmed that a plan of action would be drawn up; however, as the plan would be developed in close collaboration with Member States and other partners, she did not believe that it would be necessary to submit it for formal approval by the Governing Bodies.

98. Following the incorporation of several amendments proposed with a view to simplifying and clarifying some wording in the proposed resolution contained in Document CE168/14, the Executive Committee adopted Resolution CE168.R15, recommending that the 59th Directing Council approve the policy.


99. Dr. James Fitzgerald (Director, Department of Health Systems and Services, PASB), introducing the strategy, noted that the COVID-19 pandemic had impacted health, lives, and livelihoods in the Americas, generating a social and economic crisis characterized by mass unemployment, increased impoverishment, and exacerbation of longstanding inequities. He pointed out that the path to recovery would require intensified action to control the pandemic, rapid and equitable deployment of COVID-19 vaccines, and mitigation of disruptions in essential health services caused by the pandemic. In order to transition from pandemic response to recovery, it would be necessary to focus on building sustainable and resilient health systems.

100. Dr. Fitzgerald noted that important empirical lessons had been learned during the pandemic that would inform future decisions and actions aimed at developing, strengthening, and enhancing the preparedness of health systems. For example, failure to

---

address longstanding structural deficiencies and chronic underinvestment in health systems would impact response capacity and public health outcomes in times of a future public health emergency. In addition, effective governance and leadership were critical to ensure coherent planning of public health interventions, preparedness and response. On the positive side, the pandemic had prompted significant increases in surge capacity and accelerated innovations to optimize the mobilization and utilization of limited resources to address health needs. Health service delivery had been reorganized and expanded in all 51 countries and territories of the Region through the adoption of digital health technologies and other innovations.

101. The strategy put forward in Document CE168/15 would build upon the policy on resilient health systems approved in 2016, while also incorporating the experience gained from the response to the pandemic. It comprised four strategic lines of action and would provide a framework to support Member States in accelerating the recovery and protection of lost public health gains and advancing towards more resilient, sustainable, and inclusive health systems during a potentially complex and protracted recovery period in the Americas.

102. The Executive Committee welcomed the proposed strategy and agreed that the pandemic had highlighted existing weaknesses and underscored the need to build more resilient health systems in order to protect public health gains and ensure the continued delivery of essential health services during future health emergencies. The Committee also agreed that the pandemic had demonstrated the need for sustained investment in health systems. The need to build on the lessons learned from the pandemic was emphasized. Several delegates drew attention to the importance of ensuring access to safe, efficacious, and high-quality medicines and other health products and the need to enhance capacity for national production of such products in order to avoid shortages and supply problems. The need to strengthen drug regulatory systems was also noted, as was the need to bolster the capacity of human resources and of health systems and services to adapt to emergency situations and to sudden large increases in demand. The need to protect the health workforce, including by ensuring adequate supplies of PPE, was stressed. It was pointed out that strengthening the resilience of health systems was essential to protect not only health but also social and economic development. It was also pointed out that the pandemic had set back progress on the Sustainable Development Goals, and the need to renew efforts to achieve the Goals was underlined.

103. The Committee expressed strong support for the proposed strategy and its lines of action. However, it was suggested that several aspects could be enhanced, including the need to ensure appropriate training of human resources in order to strengthen health systems based on the primary health care approach. It was also felt that the strategy should place greater emphasis on improving core capacities for public health risk assessment and on addressing social, economic, and environmental determinants of health and on the pandemic’s long-term health and economic impacts on children and young people. While

---

the issue of mental health was mentioned in the strategy, it was considered that it should figure more prominently.

104. A representative of a nongovernmental organization highlighted the impact of the pandemic on care for persons affected by neglected diseases and urged Member States to adopt and implement policies and initiatives focusing on the neglected diseases that disproportionately affected the Region.

105. Dr. Fitzgerald noted that many of the comments had highlighted the need to address both short-term needs and mid- to long-term objectives of health systems transformation based on the primary care approach. Those comments echoed similar comments made during the Member State consultations on the strategy, when many participants had emphasized the importance of strengthening capacity and addressing needs at the community level, including barriers to access for vulnerable and disadvantaged groups who had been disproportionately affected by the pandemic. He recalled that in 2019 the Director had launched the regional primary health care compact, which would provide useful guidance for the process of recovering lost public health gains and improving the resilience of health systems.

106. He had taken note of the comments regarding improvements to the strategy, including greater emphasis on the issue of mental health and improving core capacities for essential public health functions, and would ensure that the document was revised accordingly. Lastly, he pointed out that the strategy was related to the policies on the One Health approach (see paragraphs 80 to 89 above) and the policy on increasing production capacity for essential medicines and health technologies (see paragraphs 69 to 79 above), and assured the Executive Committee that, in implementing the strategy, the Bureau would ensure the necessary linkages with the work undertaken on those policies.

107. The Director affirmed that resilient health systems were crucial to the achievement of SDG 3 and related SDGs, to future pandemic preparedness and response, and to the transformation of health systems based on primary health care and the fulfillment of essential public health functions. Stressing the importance of public investment in health systems, she noted that the primary health care compact called for the allocation of at least 6% of GDP to public spending on health, with 30% of that spending invested in the first level of care. She also noted that, as highlighted in a joint report by ECLAC and PAHO, it would be essential to acknowledge the interconnectedness of health, the economy, and social systems as the Region strove to build back in the post-COVID era.

108. The proposed resolution contained in Document CE168/15 was amended to reflect comments and suggestions made during the discussion, and the Executive Committee

---


subsequently adopted Resolution CE168.R12, recommending that the 59th Directing Council approve the strategy.

**Administrative and Financial Matters**

*Report on the Collection of Assessed Contributions (Documents CE168/16 and Add. I)*

109. Mr. Xavier Puente Chaudé (Director, Department of Financial Resources Management, PASB) reported that one Member State was in arrears to the extent that it was now subject to Article 6.B of the PAHO Constitution. Ten Member States, Participating States, and Associate Members had paid their 2021 contributions in full, seven had made partial payments, and 25 Member States had yet to make any payments at all for 2021, although assessed contributions were due on 1 January of each year.

110. He noted that the Organization continued to face severe financial difficulties owing to significant delays in the payment of assessed contributions. Over the past decade, there had been a marked increase in the balance of assessed contributions that remained outstanding at the end of the financial year, with the amount rising from $23 million in 2011 to in excess of $80 million in 2019 and 2020. As of 21 June 2021, $12 million of the $105.3 million due on 1 January 2021 had been collected. A total of $139.3 million remained outstanding, of which $46 million related to prior years. Of the total amount, 86% was owed by just three Member States. To meet its commitments and carry out its essential technical cooperation activities, PAHO had already been forced to utilize $26.5 million of the $28.7 million available in the Working Capital Fund. He stressed that the timely receipt of assessed contributions was crucial to the implementation of the Organization’s program and budget and urged those Member States with pending contributions to pay them at the earliest possible opportunity.

111. In the ensuing discussion, concern was voiced about the high level of unpaid assessed contributions, which could jeopardize the Organization’s delivery of critical technical support and guidance during the current, unprecedented health crisis. It was acknowledged that the economic and social effects of the COVID-19 pandemic had likely contributed to delays in the payment of Member States’ assessed contributions. Nevertheless, it was underscored that Member States, Participating States, and Associate Members should make every effort to pay their contributions on a timely basis to ensure that the Organization could deliver vital assistance and carry out its program of work.

112. The Director thanked the Member States that had made timely payments and appealed to those that had yet to make their payments to do so as soon as possible. She pointed out that there had been no increase in assessed contributions for four consecutive bienniums, which meant that, in real terms, the Organization had seen a reduction in its purchasing power. While she recognized that the pandemic had caused economic difficulties for many Member States, the issue of unpaid contributions predated the health crisis by some years and put at risk the ability of the PAHO to deliver much-needed technical cooperation.
113. The Executive Committee adopted Resolution CE168.R1, thanking those Member States that had made payments in 2021 and strongly urging other Member States to pay their outstanding contributions as soon as possible.


114. Mr. Marcos Cantero (Mexico, Representative of the Subcommittee on Program, Budget, and Administration) reported that, after examining an overview of the Financial Report of the Director for 2020, the Subcommittee had expressed gratitude to the Bureau for its support during the pandemic and had urged Member States to pay their assessed contributions on time, in full, and without conditions in order to enable the Bureau to continue providing that critical support. The Bureau had been asked to provide information on what steps it had taken to address the recommendations made by the External Auditor in respect of the financial report for 2019, in particular those related to resolving inconsistencies in the application of policies on accounting for delays in the receipt of assessed contributions, impairment of receivable assets, and enhancing the financial report to provide a clearer picture of the Organization’s performance. The Bureau had also been asked to include a greater focus on financial trends and risk management in the financial report for 2020.

**Financial Report of the Director for 2020**

115. Mr. Xavier Puente Chaudé (Director, Department of Financial Resources Management, PASB) summarized the main elements of the Financial Report for 2020, including figures on total revenue and expenditure, collection of assessed contributions, voluntary contributions, and procurement on behalf of Member States, noting that the Organization had received an unmodified audit opinion from the External Auditor. He pointed out that 2020 had been a difficult year, marked by the impact of the COVID-19 pandemic and significant delays in the payment of assessed Member States’ contributions. Nevertheless, the Bureau had transitioned smoothly to telework and continued to operate effectively, and the financial year had been closed successfully.

116. He reported that the Organization’s total consolidated revenue in 2020 had amounted to approximately $1,340.1 million, a 12% increase with respect to 2019, due to large increases in revenue from procurement on behalf of Member States for COVID-19 supplies and extraordinary voluntary contributions for emergencies. While procurement through the Revolving Fund for Access to Vaccines (the Revolving Fund) continued to account for the largest share of procurement revenue, revenue from the Revolving Fund for Strategic Public Health Supplies (the Strategic Fund) had risen markedly in 2020 as a result of increased procurement of COVID 19 supplies. Although the collection of assessed contributions had improved in 2020 relative to 2019, the amount collected had still amounted to only 40% of the amount committed. A total of $84.6 million had been outstanding at year’s end, $4 million less than in 2019, but more than double the amount outstanding in 2018 and earlier years. The delays in receipt of assessed contributions had compelled the Bureau to implement extreme measures to reduce spending; it had also been
obliged to use the entirety of the balance in the Working Capital Fund and to borrow from other unrestricted funds.

117. Total consolidated expenditures for 2020 had amounted to $1,336.2 million, in comparison with $1,189.3 million in 2019. Purchases of supplies, commodities, and materials had represented the largest share of expenditure; procurement on behalf of Member States accounted for virtually all of those purchases. Personnel costs had accounted for $181.5 million, compared with $143.5 in 2019. The increase was due mainly to the actuarial revaluation of the after-service staff health insurance (ASHI) liability, which in turn was related to a significant drop in the discount rate. Staff salaries and entitlements had fallen from $134.4 million in 2019 to $130.7 million in 2020. Transfers and grants to counterparts had tripled in 2020 with respect to 2019 as a result of donations of large amounts of PPE during the pandemic. In contrast, travel expenses had declined dramatically, amounting to only $9.8 million, one fifth of the amount spent in 2018.

Report of the External Auditor for 2020

118. Mr. Damian Brewitt (Financial Audit Director–International, National Audit Office of the United Kingdom of Great Britain and Northern Ireland (NAO) introduced the report of the External Auditor, confirming that the Auditor’s opinion on the Organization’s financial statements had been unqualified, meaning that the audit had revealed no errors or weaknesses that had been considered material to the accuracy, completeness, or validity of the statements. He noted that obtaining an unqualified audit opinion in the context of the events of 2020 represented a significant achievement by all concerned.

119. Highlighting the main issues raised and the recommendations made in the audit report, he pointed out that, while PAHO continued to have positive overall reserves and fund balances, many of those resources were restricted for specific purposes. PAHO had increasingly subsidized funding for its regular activities from other sources. Internal borrowing was not sustainable, and the External Auditor recommended that the Organization should consider other options to fund cash deficits, including use of retained reserves of program support funds. The External Auditor recognized, however, that cash flow shortfalls could ultimately only be addressed through timely remittance of assessed contributions from Member States.

120. The audit report emphasized the need for a systematic approach to the identification of cost savings in response to Member State requests. Consideration should be given to innovative ways of delivering services, including realizing the potential of changes to work practices implemented during the pandemic and outsourcing of some support functions. In addition, given the significant long-term financial risk associated with the growth in employee benefit liabilities and PAHO Member States’ limited influence over the rules governing the WHO Staff Health Insurance Fund, the External Auditor believed that it was important to regularly consider the risks and benefits associated with ongoing participation by PAHO in that Fund.

121. Other recommendations put forward in the External Auditor’s report related to further improvements to financial reporting; strengthening of internal controls, including
identification, control, and monitoring of risks and systematic assessment of the lessons learned from the pandemic to inform the development of business continuity procedures; and management of PAHO’s procurement funds. In relation to the latter, Mr. Brewitt noted that PAHO’s partnership with UNICEF under the COVAX Facility had resulted in broader and deeper partnerships with other international buyers and that the External Auditor recommended that the Organization should assess the potential benefit of further pooling of technical resources and buying power with a view to reducing prices and strengthening supply of vaccines and other items. It also recommended the articulation of an overarching strategy for the procurement funds, aligned with PAHO’s mandate, to enhance accountability and enable Member States to measure performance more effectively.

122. The Executive Committee welcomed the unqualified audit opinion and the positive comments of the External Auditor on the Bureau’s internal control environment. The Committee commended the Bureau for its progress in implementing prior recommendations of the External Auditor and expressed support for the recommendations made in the 2020 report. Particular support was expressed for the recommendations to develop strategies for reducing costs and strengthening risk management. It was agreed that enhanced external evaluation of project performance was beneficial and that information on voluntarily funded activities should be further mainstreamed in PAHO reporting to Member States, especially information on significant financial or reputational risks. With regard to cost reductions, the Bureau was asked whether virtual meetings and training, remote working, and outsourcing of some functions were measures under consideration for the long term.

123. Support was also expressed for the recommendations concerning the Organization’s procurement funds. It was suggested that those recommendations should serve as the basis for developing a roadmap, in collaboration with Member States, to improve the performance of the funds and ensure transparency and accountability. The Bureau was asked to prepare such a roadmap for consideration by the Governing Bodies.

124. The Bureau was asked to express its views on the External Auditor’s recommendation regarding options such as making greater use of retained reserves to offset cash flow deficits. Concern was expressed about the increase in the employee benefit liabilities, which was seen as a financial risk for the Organization. The Bureau was asked to indicate if it had assessed whether the current approach to funding those liabilities was the best one; if not, it was requested to conduct such a review and report to the Directing Council on the findings. In addition, clarification was requested of a statement in the report indicating that post-employment benefits for key management personnel could not be reliably quantified. The Bureau was also asked to provide more information on how the new policy on preventing sexual exploitation and abuse would be implemented.

125. Mr. Puente Chaudé explained that the Bureau budgeted all funds received in program support costs in one biennium for the next biennium in order to avoid the risk that a sudden change in the volume of activity in one biennium would have an excessive effect on the budget for that biennium. The application of that prudent approach had made it
possible to maintain the Organization’s activities despite the significant delays in the payment of assessed contributions in 2019, 2020, and the first quarter of 2021. As to whether some of the program support funds could be used to help fully fund the Working Capital Fund, he noted that the Bureau expected that there would be a revenue surplus at the end of the current biennium, owing to the delays in receipt of assessed contributions and the consequent impossibility of effecting some expenditures. In accordance with the Organization’s Financial Regulations, any such surplus would automatically be allocated to the Working Capital Fund. He suggested that it would therefore be advisable to wait until the end of the biennium before contemplating other means of funding the Working Capital Fund.

126. He pointed out that the ASHI liability was a very long-term and volatile liability that was greatly influenced by changes in interest rates, which had been extremely low in 2020, but were expected to increase in 2021 and subsequent years. The amount of the liability was therefore expected to decrease. In addition, the Bureau had taken major steps in recent years to contain medical expenses, particularly among staff in the United States, and increase assets to ensure that the liability could be met. Those measures had resulted in an increase of $10 million in the assets available to meet the ASHI liability. The Bureau believed that the current arrangement with WHO was satisfactory and enabled it to achieve a much greater return on its assets than PAHO would achieve on its own.

127. Mr. Gerald Anderson (Director of Administration, PASB) confirmed that the Bureau planned to continue some of the new ways of working adopted during the pandemic. For example, it would implement a standard procedure for determining whether in-person meetings were necessary, which was expected to significantly reduce travel and per diem costs associated with future meetings. He also noted that the Bureau was already outsourcing some functions, such as processing of health insurance claims and support functions for the Organization’s procurement funds. Two organizational development initiatives would examine those pilot initiatives and assess how to integrate outsourcing approaches into the Bureau’s overall operations.

128. Mr. Philip MacMillan (Ethics Program Manager, PASB), responding to the question concerning implementation of the new policy on preventing sexual exploitation and abuse, pointed out that experience had shown that it was not sufficient merely to have a zero-tolerance policy; it was necessary to have a plan for implementing the policy and ensuring that any occurrences of sexual exploitation and abuse were reported. From his perspective, it would be necessary to carry out an awareness campaign to ensure that staff knew the details of the policy and felt free to report misbehavior without fear of retaliation. It would also be necessary to implement practical measures on the ground so that local populations would know how to report any unethical behavior by PAHO personnel and would feel confident that the Organization would take such reports seriously.

129. Dr. James Fitzgerald (Director, Department of Health Systems and Services, PASB), referring to the comments on the procurement funds, said that it was important to remember that those funds were technical cooperation mechanisms and, as such, were guided by strategies that were fully aligned with the Organization’s technical mandates.
For example, one of the core strategies of the Plan of Action on Immunization adopted in 2015\(^8\) was to ensure that Member States fully utilized the Revolving Fund for Access to Vaccines, and the Fund was also an important element in the new policy on reinvigorating immunization as a public good for universal health (see paragraphs 90 to 98 above). He assured the Executive Committee that the Bureau would take into account the External Auditor’s recommendations in the development of future work plans for the procurement funds.

130. Mr. Brewitt confirmed that the External Auditor would continue to review the actions taken to address its recommendations and to highlight areas in which improvements could be made. Responding to the question regarding post-employment benefits for key management personnel, he noted that both the pension and after-service health insurance schemes were pooled schemes and that costs by individual could therefore not be identified. That was a common feature of such schemes and was not cause for concern. He underlined the importance of keeping Member States apprised of the impact of changes to pension and insurance schemes, which in turn could affect long-term liabilities that could represent significant costs for the Organization in the future.

131. The Director expressed gratitude to Member States for the confidence they had placed in the Bureau to manage the Organization’s financial resources and emphasized that the Bureau took all audit recommendations seriously and was fully committed to ensuring the most effective and efficient use of resources, with due regard to compliance and risk management. It conducted monthly reviews of the financial situation and continually made adjustments as needed. The Bureau had also launched a number of organizational development initiatives aimed at improving its technical cooperation and its efficiency and effectiveness. Lastly, she pointed out that the availability of flexible funding, and consequently the Bureau’s ability to deliver technical cooperation, depended on the timely receipt of Member States’ assessed contributions.

132. The Executive Committee took note of the report.

**Appointment of the External Auditor of PAHO for 2022-2023 (Document CE168/17)**

133. Ms. Gabriela Gómez (Representative of the Subcommittee on Program, Budget, and Administration) reported that the Subcommittee had received an update on the appointment of the External Auditor for 2022-2023. It had been informed that, in keeping with past practice, the Bureau recommended the reappointment of the current External Auditor, the National Audit Office of Great Britain and Northern Ireland, for an additional term of two years. The Subcommittee had been further advised that the Bureau would initiate the process of seeking candidates for appointment as the External Auditor of PAHO for the 2024-2025 and 2026-2027 bienniums. The Subcommittee had recognized the high standard of excellence of the NAO and voiced support for its reappointment. At the same time, it had been highlighted that best practice among international organizations was to appoint an external auditor for a single term of four to six years.

134. In the Executive Committee’s discussion of the report, delegates conveyed their appreciation for the expertise and high caliber of work provided by the NAO, and expressed strong support for the NAO’s reappointment for an additional two-year term, recognizing the need to strengthen transparency and provide continuity during the current unprecedented situation. It was reiterated, however, that best practice among international organizations was to limit the appointment of the External Auditor to a single term of four to six years that would not be immediately renewable. It was noted that the NAO’s reappointment would still be within the recommended limit of six years; nevertheless, it was suggested that consideration should be given to amending PAHO’s Financial Regulations to reflect such term limits. It was hoped that a diverse pool of new candidates would be proposed for consideration for the 2024-2025 and 2026-2027 bienniums.

135. Mr. Xavier Puente Chaudé (Director, Department of Financial Resources Management, PASB) recalled that the Organization’s past practice had been to appoint the External Auditor for a period of four years, with the possibility of an additional two-year term if the Auditor had discharged its mandate satisfactorily and was willing to serve for another biennium. However, consideration would be given to amending the Financial Regulations to better reflect the recommended practice of appointment of the External Auditor for a single term.

136. The Director said that the Bureau highly valued the contributions and recommendations made by the NAO and looked forward to continuing the collaborative working relationship for a third and final biennium.

137. The Executive Committee took note of the report.

Update on the Master Capital Investment Fund (Document CE168/18)

138. Ms. Gabriela Gómez (Representative of the Subcommittee on Program, Budget, and Administration) reported that the Subcommittee had reviewed a report on the status of the Master Capital Investment Fund and its various subfunds. The Bureau had indicated that the prioritization of the response to the COVID-19 pandemic and the recruitment freeze imposed as a result of the Organization’s financial constraints had resulted in the underutilization of the subfunds during 2020, in particular the Real Estate Maintenance and Improvement Subfund and the Human Resources Strategy Subfund. The Subcommittee had also been informed that the Master Capital Investment Plan for PAHO Headquarters had been updated to include the capital investment requirements for the building located at 2121 Virginia Avenue and that there had been a reduction of almost $700,000 in net operating expenses as a result of the purchase of that building in 2019.

139. In the Executive Committee’s discussion of this item, the cost savings realized through the Organization’s acquisition of the Virginia Avenue building were recognized. The Bureau was asked to provide an analysis of the expenses, savings, and revenues associated with the building’s purchase in order to demonstrate that the objectives of the business case had been met, especially in the light of the repairs and renovations that the building required. An evaluation of the lessons learned from the new ways of working adopted during the pandemic, in particular their impact on workspace needs in the Virginia
Avenue building, was also requested. Information was sought on the methods being considered by the Bureau to ensure that a more strategic, longer-term approach to expenditure through its various subfunds was being taken.

140. Ms. María Teresa Angulo (Director, Department of General Services Operations, PASB) explained that the Organization was in the process of updating the 2014 survey of PAHO-owned properties and the reassessment of the real estate projects included in the Master Capital Investment Plan, thereby ensuring a comprehensive approach to the Organization’s capital investments in, and maintenance of, its real estate. A capital investment plan for the Virginia Avenue building was also being drawn up and would take into account office space requirements and the impact of teleworking arrangements.

141. Mr. Gerald Anderson (Director of Administration, PASB) added that, as a result of the lessons learned during the pandemic and the increased use of virtual technologies throughout the Region and at Headquarters, the Director had recently approved a new teleworking policy, in which the added value of teleworking arrangements for PASB personnel was recognized. He confirmed that a review of the use of the Virginia Avenue building was currently under way with a view to ensuring its inclusion in the Organization’s long-term real estate plans. Lastly, he clarified that PAHO had long owned the land at 2121 Virginia Avenue and that, in December 2019, had purchased the building located at the site, thereby ceasing the associated rental costs and achieving the cost savings outlined in Document CE168/18.

142. The Executive Committee took note of the report.

**Update on the Working Capital Fund (Document CE168/19)**

143. Ms. Gabriela Gómez (Representative of the Subcommittee on Program, Budget, and Administration) reported that the Subcommittee had been informed that the funding level in the Working Capital Fund had been $28.7 million as of 31 December 2020, $21.3 million below the authorized level of $50 million approved by the 58th Directing Council. The Bureau had explained that, as a result of unpaid assessed contributions amounting to $84.6 million, the Organization had been forced to utilize the full $28.7 million and a further $17 million from additional unrestricted resources in order to cover a net cash deficit of $45.7 million in 2020. In its discussion, the Subcommittee had expressed concern about the high level of unpaid assessed contributions, which had led to the depletion of the Working Capital Fund and could have a negative impact on the sustainability of program implementation. It had also emphasized that Member States should pay their contributions in full and on time to enable the Organization to continue providing support, especially in critical times such as the current COVID-19 pandemic.

144. In the Executive Committee’s discussion of the report, the Bureau was requested to conduct an in-depth analysis to identify whether any programmatic or other issues had increased the Organization’s budgetary requirements and had therefore partly contributed to the additional burden that had been placed on the Working Capital Fund. It was

---

emphasized that the Working Capital Fund should be used strictly to cover shortfalls in assessed contributions, and it was suggested that the Bureau should ensure that a highly efficient approach to budgeting was taken to avoid generating financing gaps that could lead to the depletion of the Working Capital Fund.

145. Mr. Xavier Puente Chaudé (Director, Department of Financial Resources Management, PASB) stressed that the Working Capital Fund was a mechanism used for the sole purpose of covering temporary cash shortfalls caused by delays in the receipt of assessed contributions from Member States, which were the source of funding for virtually all technical cooperation activities of the Organization.

146. The Director reiterated that the Working Capital Fund existed to cover gaps resulting from the late payment of assessed contributions. She pointed out that the requested analysis could therefore not be easily produced, since the depletion of the Working Capital Fund was not related to increased programmatic or other expenditures, but rather to the non-payment of Member States’ assessed contributions.

147. The Executive Committee took note of the report.

Report on the Status of the Emergency Loan from the Revolving Fund for Access to Vaccines to the Regional Revolving Fund for Strategic Public Health Supplies (Document CE168/20)

148. Ms. Gabriela Gómez (Representative of the Subcommittee on Program, Budget, and Administration) reported that the Subcommittee had been informed that, while it had not been necessary to use the emergency loan provision in 2020, it had been applied in January 2021 to support one Member State’s request for the emergency acquisition of medicines required for critical care management of COVID-19 patients. In order to continue to meet the demands of PAHO Member States during the pandemic and to facilitate access to essential medicines and public health supplies for COVID-19, the Bureau had proposed an extension of the internal emergency loan provision until 31 December 2023. The Subcommittee had expressed support for the proposal, but had emphasized the need to ensure that adequate controls were in place, that any loans made from the capital account of the Revolving Fund to the capital account of the Strategic Fund did not jeopardize Member States’ ability to procure COVID-19 and routine immunization vaccines, and that loans were reimbursed in a timely manner.

149. Dr. James Fitzgerald (Director, Department of Health Systems and Services, PASB), summarizing the information presented in Document CE168/20, recalled that the Executive Committee had adopted Resolution CESS1.R1 during its Special Session in May 2020, authorizing a short-term internal emergency loan of up to $50 million from the capital account of the Revolving Fund to the capital account of the Strategic Fund. Authorization of the loan had been requested to meet the increased projected needs for COVID-19-related medical supplies.

150. He reported that, as of 31 December 2020, medicines and supplies valued at a total of $235.7 million had been procured on behalf of 25 Member States through the Strategic
Fund—a threefold increase in the use of the Fund in comparison with 2019. Approximately 80% of requests for procurement of supplies through the Strategic Fund were pre-paid by the requesting Member States; the remainder were funded through a line of credit from the Strategic Fund. The emergency loan provision from the Revolving Fund to the Strategic Fund had now been utilized for two Member States for the emergency supply of personal protective equipment and medicines for COVID-19 patients in intensive care. In light of the evolving context of the pandemic, and in order to continue to meet the urgent demands for essential medicines and public health supplies of PAHO Member States, the Bureau proposed extending the emergency loan facility until 31 December 2023 or the date of a WHO declaration announcing the end of the pandemic, whichever occurred first.

151. In the Executive Committee’s discussion, delegates expressed agreement with the proposed extension to the emergency loan provision as a means of supporting Member States in accessing necessary COVID-19 medical supplies and safeguarding the right to health for all. At the same time, delegates emphasized the vital importance of ensuring that the appropriate managerial, financial, and analytical controls were in place to prevent any negative impact on the ability of PASB to support Member States participating in the Revolving Fund. The Bureau was asked to explain what action it was taking to ensure the long-term sustainability and adequate capitalization of the Strategic Fund. Clarification was sought as to whether the proposed resolution might make it possible for the emergency loan to be used for the procurement of supplies unrelated to the COVID-19 pandemic. Details of the timelines and criteria for determining the repayment of emergency loans were requested. The Bureau was asked to include in the next report a statement of accounts detailing the flow of capital between the Funds and including information disaggregated by country on the use of the Funds, in order to increase transparency and accountability.

152. In response to those comments, Dr. Fitzgerald stressed that the terms for the extension of loans under the proposed resolution—including with respect to the supplies that could be procured—would remained unchanged from Resolution CESS1.R1. Regarding the sustainability and capitalization of the Strategic Fund, he pointed out that the increased use of the Fund had raised the amount in its capital account to $26 million, up from only $10 million six years earlier. As a result, the Fund’s current level of capitalization and rate of growth were adequate to address Member States’ requirements for emergency supplies during the pandemic and to meet their regular priority programming needs outside the emergency context. He underscored that the effective management of the capital account, coupled with the increase in the capitalization level and the use of regular forecasting, had ensured the efficient utilization of the Strategic Fund, meaning that it had only been necessary to use the emergency loan facility twice. He clarified that, once a line of credit had been approved, the country concerned was expected to reimburse the amount provided within 30 days after receiving the purchased supplies. He had taken note of the additional information requested for inclusion in the next report.

153. The Director affirmed that the Bureau would take all necessary measures to ensure the integrity and sustainability of both the Strategic Fund and the Revolving Fund, while also enabling Member States to obtain critical health supplies and medicines during the current health emergency. She assured the Committee that the necessary controls were in place.
place to ensure the effective management of both Funds. The Bureau endeavored to meet the increased requests for support from the Strategic Fund through its capital account, only resorting to the emergency loan facility when necessary and guaranteeing the timely repayment thereof.

154. The Executive Committee adopted Resolution CE168.R10, approving the proposal for an extension of the internal emergency loan from the Revolving Fund to the Strategic Fund.

**Personnel Matters**

*Amendments to the PASB Staff Regulations and Rules (Document CE168/21)*

155. Ms. Gabriela Gómez (Representative of the Subcommittee on Program, Budget, and Administration) reported that the Subcommittee had considered several proposed amendments to the Staff Rules relating to revisions to the salary scale for professional and higher categories and the salaries for the posts of Director, Deputy Director, and Assistant Director. Those amendments related to decisions that had been taken by the seventy-fifth session of the United Nations General Assembly on the basis of recommendations by the International Civil Service Commission. A number of amendments had also been proposed to Staff Rules relating to payments and deductions, in particular to clarify how overpayments or underpayments of staff salaries, benefits, or pension contributions should be addressed.

156. In its discussion, the Subcommittee had sought clarification regarding the financial impact of the changes to the Staff Rules, the revisions to salaries, and the increased pension and health insurance liabilities. The Bureau had been requested to produce a table showing the financial implications of salary increases over the past six years; conduct an analysis of the impact of Resolution CESS1.R2, concerning the current financial situation and adjustments to the Organization’s strategic priorities; and carry out a review of the organizational structure of the Bureau and of the salaries of Executive Management. In response, the Bureau had explained that the revision of the salary scale had been carried out on a no-loss/no-gain basis, resulting in no change in net pay.

157. Dr. Luz Marina Barillas (Director, Department of Human Resources Management, PASB) emphasized that the revisions to the salary scale for the professional and higher staff categories, and in particular the salaries of the ungraded posts of Director, Deputy Director, and Assistant Director, were fully in line with the salary scales of the United Nations common system. She noted that, as had been requested by the Subcommittee, Document CE168/21 now contained tables showing the impact of salary modifications since 2017, the year the salary scale of the United Nations common system had been adopted. She explained that the financial implications associated with the increase in the base/floor salary scale were estimated at approximately $858,000 per year across the entire United Nations system and approximately $11,000 per year for PAHO.

158. In the Executive Committee’s discussion of the report, a delegate reiterated the request made during the 15th Session of the Subcommittee for the document to include an
analysis of the review of the organizational structure of the Bureau and of the salaries of Executive Management, called for in Resolution CESS1.R2.

159. In response, Dr. Barillas recalled that Resolution CESS1.R2 provided for the Director, in consultation with the Member State Working Group established pursuant to the Resolution, to prepare a packet of austerity measures, including a review of the organizational structure of PASB and of the salaries of Executive Management, in the light of the precarious financial situation that the Organization faced due to delays in the receipt of assessed contributions. She pointed out that the Organization’s financial situation had improved significantly in July 2020, thereby averting the “worst-case” financial scenario envisaged in Resolution CESS1.R2 and obviating the need for extreme cost reduction measures. As a result, the Member State Working Group had decided to refocus its work on the implications of the COVID-19 pandemic for the Organization’s technical cooperation priorities.¹⁰

160. The Director expressed concern that, despite the Bureau’s success in achieving significant cost savings and efficiencies, the salaries of Executive Management—which were fully in line with those of WHO and the United Nations common system—were continuously being questioned. She pointed out that the Organization provided technical cooperation requiring a high level of expertise and competence and that salaries commensurate with those requirements were necessary to attract and retain talent with the requisite skills and experience and to ensure the good management of the Organization.

161. The Executive Committee adopted Resolution CE168.R13, confirming the amendments to the Staff Rules concerning the salary scale of professional and higher categories of staff and establishing the salaries of the Director, Deputy Director, and Assistant Director, with effect from 1 January 2021, and confirming the amendments to the Staff Rules relating to payments, benefits, and deductions, with effect from 1 July 2021.

**PASB Human Resources Management (Document CE168/22)**

162. Ms. Gabriela Gómez (Representative of the Subcommittee on Program, Budget, and Administration) reported that the Subcommittee had received an update on the most important initiatives undertaken in the sphere of human resources during 2020, including the development and implementation of the Bureau’s revised human resources strategy, known as the “People Strategy 2.0.” The Subcommittee had commended the Bureau’s efforts to protect and support staff and maintain business continuity during the COVID-19 pandemic. It had also welcomed the progress made towards gender parity, but emphasized that additional efforts were still required. The use of certain types of contractual mechanisms due to the Organization’s financial situation had been highlighted as an area of concern.

163. Dr. Luz Marina Barillas (Director, Department of Human Resources Management, PASB), introducing the document, said that the People Strategy 2.0 was built on three main pillars—functional optimization, innovation, and agility—designed to optimize resource

efficiency, identify and bridge skills gaps, and promote career development, among other
goals. A number of initiatives were being taken as part of the People Strategy 2.0, while
drawing on the lessons learned during the COVID-19 pandemic, such as revising the
teleworking policy, launching a skills and competencies gap analysis, and implementing a
mentoring program.

164. She noted that, as soon as the COVID-19 pandemic had been declared, the Bureau
had prioritized the development of procedures and protocols to prevent or minimize staff
exposure to COVID-19. She emphasized that a business continuity plan and incident
management teams had already been established prior to the pandemic, and thus the
necessary platforms to enable teleworking had already been in place. An emergency
telework standard operating procedure had been launched for all duty stations to facilitate
business continuity while protecting the health, safety, and well-being of all PAHO
personnel. Administrative guidelines on the COVID-19 outbreak had also been published,
and counseling services, information sessions, and various special measures had been made
available to support PAHO staff.

165. As far as talent management was concerned, the Bureau had evaluated the options
available for the targeted, temporary recruitment of personnel, including the utilization of
the Junior Professional Officers program, United Nations Volunteers, and the services of
professionals from collaborating centers. There had been a noticeable decrease in 2020 in
fixed-term and temporary appointments, and an increase in the use of consultants, largely
due to the need to respond to the pandemic. Concerning gender parity, women occupied
51% of all fixed-term professional posts throughout the Organization; however, there was
still room for improvement at P4 level and above. In that regard, a mentoring program had
been introduced for staff members on the head of country office roster to improve the
gender balance in PWRs and promote succession planning. Staff mobility between the
PWR Offices and Headquarters had been curtailed during the pandemic, largely as a result
of the prevailing travel restrictions. Lastly, she reported that disciplinary measures had
been taken in a case of misconduct by an international consultant, whose contract had thus
been terminated.

166. In the Executive Committee’s discussion of this item, delegates voiced support for
the new People Strategy 2.0 and its alignment with the Organization’s strategic priorities.
The Bureau was requested to provide more information on the roadmap and budget for
implementing the People Strategy 2.0 and on the indicators being used to track progress.
The Bureau was also encouraged to continue its efforts to provide training and development
for staff and to achieve a gender balance throughout the Organization. Attention was drawn
to global discussions on tackling sexual exploitation and abuse, sexual harassment, and
abuse of authority through cultural and organizational change. It was noted with
satisfaction that PAHO had recently developed a policy on the subject, and its swift
implementation was encouraged.

167. Delegates expressed appreciation for the commitment and dedication of PAHO
staff during the COVID-19 pandemic. Further information was requested regarding the
insurance eligibility criteria for consultants hired in the context of the COVID-19 response.
While the use of junior professional officers, volunteers, and other collaborators to supplement the PASB workforce was considered to be a positive development, the Bureau was asked to ensure that an appropriate strategic framework was in place, in particular to protect data and preserve institutional memory. In a similar vein, information was sought on how the special program for succession planning accounted for the need to preserve institutional memory and on the process currently followed by staff leaving the Organization.

168. Dr. Barillas emphasized that PASB took the issue of sexual exploitation and abuse, sexual harassment, and abuse of power very seriously, and was committed to ensuring a respectful working environment for women. The Bureau’s conflict management system—which involved various mechanisms, such as the Ombudsperson, the Ethics Office, and the Office of Legal Counsel—addressed ethical issues and workplace concerns through staff training initiatives and awareness-raising. Regarding the preservation of institutional memory, she explained that action had been taken some years ago in that regard. All staff who were leaving, changing post, or retiring were required to submit a report to their supervisors, which was stored in a repository set up for that purpose. Lastly, the insurance eligibility criteria for contractors was determined by the terms of reference of the contract in question. She had taken note of the information requested for inclusion in the report to be submitted to the Directing Council.

169. The Director underscored her commitment to embedding a zero-tolerance approach to sexual harassment in the Organization. She stressed that all complaints were taken seriously and that the necessary mechanisms had been put in place to enable staff to report incidents in confidence. A top-down approach to nurturing a respectful working environment was taken, with managers expected to lead by example. Regarding the preservation of institutional memory, appropriate processes, mechanisms, and repositories were in place, and a staff member’s exit could not be approved until a satisfactory exit report had been received.

170. She pointed out that PAHO had greatly relied on contractors to expand its technical cooperation and support for Member States during the pandemic. She assured the Committee that the Bureau took its duty of care obligations seriously and applied them equally to contractors and regular staff, in line with WHO and United Nations duty of care requirements. She also assured the Committee that every effort would continue to be taken to recruit the best talent, strive for gender equality and a gender balance, and invest in the continuous development of PAHO personnel—women in particular—to ensure that staff had the competencies necessary for managerial positions, while also ensuring that they continued to be held accountable for the work they did and the resources they spent.

171. The Executive Committee took note of the report.

Statement by the Representative of the PAHO/WHO Staff Association (Document CE168/23)

172. Ms. Carolina Bascones (Representative of the PAHO/WHO Staff Association) began her statement by recalling all the families that had lost loved ones as a result of the
COVID-19 pandemic and paying tribute to the frontline health workers who had carried out essential activities throughout the pandemic. She reaffirmed the commitment of the staff and the Staff Association to serving Member States and to maintaining the Organization’s mission, which was more important than ever in the current context. She then highlighted some of the matters that the Staff Association wished to bring to the Committee’s attention in relation to four areas: fostering a respectful workplace, achieving gender equity and creating professional opportunities for staff, attracting and retaining personnel, and ensuring staff safety and well-being.

173. The Staff Association believed that progress in those four areas would enable PAHO to mount a better response to new challenges. For example, the Staff Association considered that the respectful workplace initiative should be revamped and adapted to the virtual work environment implemented in response to the pandemic. Ms. Bascones noted that the experience of the pandemic had demonstrated that virtual work was not only possible but offered numerous benefits in terms of efficiency and delivery of services. She also noted that the experience had required changes in attitudes and ways of working, including modernizing the workforce in the use of technology and modernizing the supervision model. With regard to attracting and retaining staff, she pointed out that one of the main functions of the Staff Association was to protect staff and ensure that international standards were respected, including standards relating to remuneration. She pointed out that the remuneration of members of the Bureau’s Executive Management was in line with international standards.

174. She concluded her statement by expressing gratitude to the Bureau’s Health and Well-being Unit, which had been an important source of information and support for staff during the pandemic. She also thanked the Director for her leadership and Mr. Gerald Anderson, Director of Administration, for his efforts to technologically modernize the Bureau, which had enabled staff to continue working virtually throughout the pandemic.

175. In the discussion that followed, delegates thanked the staff for their continued work, dedication, and resilience during the pandemic and expressed support for the Staff Association’s recommendations to align policies to reflect new telework realities, maintain workplace flexibilities in order to attract and retain staff, and promote gender equity and gender parity. The Bureau was again encouraged to step up efforts to increase gender parity in staffing at higher levels.

176. The Director said that she wished Member States to know that she viewed the Staff Association as a partner, not just in staff-related matters but generally in the work of the Bureau. She pointed out that staff and management did not agree on everything, but they were in full agreement on the importance of working in the best interests of the Organization.

177. The Committee thanked Ms. Bascones for her statement.
Matters for Information

_Update on COVID-19 in the Region of the Americas_ (Document CE168/INF/1)

178. Two presentations were made on this item, one by Dr. Jarbas Barbosa (Assistant Director, PASB) and the other by Dr. Ciro Ugarte (Director, Department of Health Emergencies, PASB). Dr. Ugarte began with an overview of the COVID-19 pandemic situation as of 20 June 2021, noting that, while cases had declined substantially in some countries of the Region, the Americas continued to account for a large proportion of global cases and deaths. The statistics clearly showed that active transmission of the virus was still occurring in the Americas. Moreover, new variants of the virus had been detected in all countries of the Region, with some reporting the circulation of up to four variants of concern.

179. He then highlighted some key challenges in various strategic areas, including surveillance, rapid response, and case investigation; points of entry, international travel, and transport; national laboratory capacity; infection prevention and control; case management; operational support and logistics; maintenance of essential health services and systems during the pandemic; and vaccination. In response to those challenges, the Bureau had, among other activities, provided ongoing technical guidance and support, shipments of personal protective equipment and testing and surveillance materials, and vaccines. Member States had also taken important steps to enhance their response capacity. For example, all 35 countries had a functioning multisectoral, multipartner coordination mechanism for COVID-19 and in-country laboratory capacity or access to an international laboratory that could provide results within 72 hours. An analysis of 12 countries indicated that there had been a 97.4% increase in the number of intensive care beds in those countries, an improvement which had undoubtedly saved many lives.

180. Dr. Barbosa presented information on the COVID-19 vaccine rollout in the Region and described some of the impacts of the pandemic on priority public health programs, noting that one of the most serious impacts had been disruptions to the delivery of essential health services, which had been reported by 97% of the countries in the Region. The service disruptions had been due to a mix of supply- and demand-related factors, including health workforce shortages, lack of PPE, disruption of supply chains, stockouts and unavailability of essential medicines, and community fear of seeking health care during the pandemic. Strategies for restoring or adapting service delivery included triaging to identify priorities, provision of home-based care, and the use of telemedicine, although there were barriers in regard to the latter, owing to lack of connectivity and Internet access in a number of communities in the Region.

181. With regard to the COVID-19 vaccine rollout, Dr. Barbosa reported that eight vaccines had received emergency use authorization from WHO to date. As of 18 June 2021, 49 of 51 countries and territories in the Region had introduced COVID-19 vaccines, and some 556 million doses had been administered, 37% of them in Latin America and the Caribbean. Around 22% of the population in Latin America and the Caribbean had received one dose and around 11% had been fully vaccinated.
182. While inequity in vaccine distribution was gradually decreasing, high-income countries continued to account for the vast majority of the doses administrated. To date, some 21 million doses had been provided to 31 countries and territories in the Americas through the COVAX Facility. Vaccine deliveries were expected to begin increasing in July 2021, boosting vaccine availability significantly by the last quarter of the year. In the meantime, it would be important for countries to ensure that the necessary preparations were in place, including addressing any logistical and cold-chain-related issues. It was also important to encourage and facilitate donations of vaccines, both bilaterally and through COVAX. Dr. Barbosa noted that, to that end, the Bureau was working with potential donor countries to overcome any logistical or regulatory barriers that might impede donations. It was also concluding negotiations with producers in order to develop a portfolio of vaccines for countries that wished to expand their access through the Revolving Fund for Access to Vaccines.

183. Dr. Barbosa and Dr. Ugarte concluded their joint presentation by highlighting some key messages and lessons learned from the pandemic response, with Dr. Barbosa noting the need to build resilient health systems that could continue to deliver essential health services while also mounting a response to a health emergency; the need for strategies to reduce access barriers highlighted and exacerbated by the pandemic; and the need for more effective global and regional efforts to address inequities in access to COVID-19 vaccines. Dr. Ugarte underlined the need to maintain public health and social measures, even where there was acceptable vaccination coverage. He pointed out that, in general, effective national responses had been both holistic and agile, with centralized leadership, coordination across sectors, clear decision-making based on scientific advice and efforts to foster public trust in such advice, and, crucially, the ability to change course rapidly in response to epidemiological changes and the emergence of new evidence. He also noted that the “infodemic” of misinformation had highlighted the need to make greater use of non-traditional media, including social media, in order to communicate with the public and counter false and misleading information.

184. The Executive Committee thanked the Bureau for the comprehensive report and voiced support for the strategic lines of action laid out therein and the recommendations regarding actions needed to improve the situation. Delegates expressed appreciation to the Bureau for its leadership in the response and its provision of technical guidance and other support. Various delegates described the measures their countries had taken in response to the pandemic, including strengthening detection and surveillance, enhancing laboratory capacity, increasing national capacity for production of essential medicines and critical supplies, and implementing digital health initiatives to facilitate the continued delivery of health services. Several also noted that their countries were conducting or participating in clinical trials of COVID-19 candidate vaccines. It was considered essential to draw on the lessons learned thus far in order to deal more effectively with the ongoing pandemic and, especially, in order to be better prepared to respond to future health emergencies.

185. The need to combat misinformation was underscored, as was the need to communicate public information on risks and prevention in simple and transparent
language. The Bureau was asked to produce guidance on the issue of vaccine hesitancy, which was a significant problem in the Region and an obstacle to controlling the pandemic.

186. Delegates were encouraged by the report’s finding that, by early June, almost all countries in the Region had introduced COVID-19 vaccines, but noted that there were still major inequalities and inequities in access, which were not only unfair but also contrary to the interests of the international community as a whole. It was considered that the COVAX Facility should distribute vaccines on the basis of epidemiological criteria and should step up efforts to make vaccines available to the countries of the Americas. The Bureau was urged to continue supporting donations of surplus vaccines. More information was requested about the possibility of developing a regional access strategy aimed at securing additional COVID-19 vaccines and pooling demand and resources from Member States. A delegate noted that the idea of introducing a global vaccine passport had been broached, but pointed out that the idea was not technically feasible, since vaccines were not yet available to all population groups. Moreover, vaccine passport requirements could lead to discrimination against individuals who could not be vaccinated because they had immunodeficiency disorders or other health conditions.

187. Dr. Ugarte acknowledged the immense efforts of Member States to adapt to the situation and strengthen their health systems, observing that the response to the pandemic had been a joint effort between national authorities and the Bureau, characterized by a spirit of great solidarity and a willingness to share information, which was crucial, as it enabled the Region to see what was happening, monitor cases, and make informed decisions. Much remained to be done to overcome the pandemic, but he believed that much had also been learned about how to work together to respond to future health emergencies.

188. Dr. Barbosa noted that many countries were still struggling to vaccinate their high-priority populations and agreed on the need to be more vocal about the need for equitable access to COVID-19 vaccines. He concurred with the view that the COVAX Facility should distribute vaccines on the basis of epidemiological criteria in order to reach countries with the most urgent needs, and he encouraged countries of the Region that were participating in the Facility to put forward a proposal for the adoption of that approach at the next meeting of the Board of Directors of Gavi, the Vaccine Alliance. He believed that the COVAX Facility was a good initiative; however, it lacked rules for equitable distribution of vaccines and imposed no consequences for producers for late delivery or other problems. Regarding the proposal for a regional access strategy, he explained that the general idea was to propose alternatives for addressing the vaccine needs of self-financing countries beyond the initial 20% supplied through COVAX.

189. He also agreed that vaccine hesitancy was a major problem and one that underscored the need for clear communication not only with the public but also with health care workers, who were seen as the most reliable source of health information in most countries. He reported that the Bureau was working with Caribbean countries that had developed some specific strategies for tackling the issue of vaccine hesitancy.
190. He commended the countries that were conducting or participating in vaccine trials and strengthening their internal production capacity, pointing out that increasing the Region’s capacity to manufacture vaccines and medicines would greatly reduce its vulnerability to the impacts of future health emergencies. He also expressed thanks to the countries that had offered vaccine donations and other critical support to increase access to vaccines.

191. The Director pointed out that, while the Americas had been the Region that had faced the greatest epidemiological challenges during the pandemic, it had also been a Region that had demonstrated extraordinary leadership and provided an excellent example of multisectoral coordination in the response. She noted that the Americas had led the way in many respects. For example, it had been the first to put countries on maximum alert and to ensure access to testing. At the same time, it had faced challenges in boosting response capacity and ensuring access to basic resources such as PPE. Now it faced limitations in access to vaccines. She emphasized that the Bureau and Member States must work with financial institutions in the Region to ensure that they understood the need to build the resilience required to end the current pandemic and be able to confront the next one.

192. She assured Member States that the Bureau would continue its advocacy efforts aimed at enabling countries to reach herd immunity, restart their economies, and restore livelihoods, noting that it was communicating regularly with political leaders and with the media to that end. In particular, it was pointing out that the relaxation of public health measures was fueling recent rises in transmission of the virus and stressing that it would only be possible to bring the pandemic under control by maintaining such measures while also ramping up the rollout of vaccines.

193. The Committee took note of the report.

Report on Strategic Issues between PAHO and WHO (Document CE168/INF/2)

194. Ms. Gabriela Gómez (Representative of the Subcommittee on Program, Budget, and Administration) reported that, after reviewing an earlier version of the report on strategic issues between PAHO and WHO, the Subcommittee had applauded PAHO’s close coordination with WHO on the response to the COVID-19 pandemic and its support for Member States’ participation in the COVAX Facility. PAHO’s engagement with the Independent Panel for Pandemic Preparedness and Response had been welcomed. The Subcommittee had underscored the need to ensure consideration of the regional perspective in the Panel’s work and the need for continued alignment between PAHO and WHO in the effort to translate the outcomes and lessons learned from the various global reviews at the regional level. The Subcommittee had also welcomed the establishment of the WHO Working Group on Sustainable Financing and requested information on the regional deliberations to be conducted on the issue. It had been suggested that the report to be presented to the Executive Committee should provide a more strategic analysis of areas of opportunity for coordination between PAHO and WHO, with a greater focus on the results of such collaboration.
195. In the Executive Committee’s discussion of the report, the Delegate of Canada read out a joint statement on behalf of a group of Member States (Argentina, Barbados, Brazil, Canada, Colombia, Costa Rica, Ecuador, Mexico, and the United States of America), inviting other Member States also to support the statement. He thanked PAHO for its leadership in preparing for and coordinating effective responses to public health emergencies and welcomed the adoption by the Seventy-fourth World Health Assembly (WHA) of Resolution WHA74.7, on strengthening WHO preparedness for and response to health emergencies, and Decision WHA74(16), requesting the Director-General to convene a special session of the World Health Assembly in November 2021 to consider the possibility of developing a WHO convention, agreement, or other international instrument on pandemic preparedness and response.

196. He noted that the Working Group on Strengthening WHO Preparedness and Response to Health Emergencies (WGPR) had been set up pursuant to Resolution WHA74.7 and that the United States had been appointed as one of the Vice-Chairs of the WGPR, representing the Region on the WGPR Bureau. He pointed out that the Region was uniquely positioned to offer strong insights and advice on strengthening WHO preparedness and response and called for active regional participation in the WGPR. He proposed that the WGPR should meet as soon as possible and then monthly thereafter in order to provide recommendations no later than 1 November 2021 and requested the Bureau to support the engagement of PAHO Member States in the working group by convening regular meetings to facilitate information-sharing and informal regional discussions.

197. Other delegates endorsed the joint statement, affirming that the working group and the upcoming special session of the WHA would afford an important opportunity to take decisive action to strengthen the global health architecture and address shortcomings that the pandemic had made apparent. It was considered that the reports and recommendations of the various independent review bodies—including the Independent Panel for Pandemic Preparedness and Response, the Independent Oversight Advisory Committee for the WHO Health Emergencies Program, and the Review Committee on the Functioning of the International Health Regulations—could provide valuable input for the deliberations of the WGPR, as could the collective experience and expertise of Member States from the Americas.

198. Echoing some of the comments made by the Subcommittee, delegates expressed gratitude for PAHO’s ongoing assistance as Member States continued to battle the pandemic and for its efforts to support countries in accessing COVID-19 vaccines through the COVAX Facility; highlighted the importance of ensuring a regional perspective in the various global review processes under way; and reiterated the suggestion that the report on strategic issues between PAHO and WHO should provide a more strategic analysis of areas of opportunity for coordination between the two organizations, with a greater focus on the results of such collaboration in order to provide guidance to Member States for decision-making. For example, it was pointed out that the report could provide an analysis of the most relevant elements of Resolution WHA74.7 for the countries of the Region.
Mr. Rony Maza (Director, Department of Planning, Budget, and Evaluation, PASB) pointed out that the report was intended to provide a synopsis of key issues and their implications. In response to the Subcommittee’s request, the Bureau had tried to be very strategic in highlighting issues of particular relevance to PAHO Member States. While conscious of the need to avoid presenting an overly lengthy report, it had endeavored to elaborate on the coordination between PAHO and WHO and on the results achieved in three main areas: governance, programmatic and managerial matters, and country focus. With regard to the latter, for example, it had provided information on how PAHO had contributed to the biennial report on WHO’s country presence and to the development of new guidelines for country cooperation strategies. It had also elaborated on PAHO’s engagement in the design of GPW13 and the development of the GPW results framework.

In relation to the WHO program budget for 2020-2021, the report noted that the Americas had been the first region to implement the WHO output scorecard approach. The findings of that exercise had informed the Region’s contribution to the midterm review of the program budget, which had reflected the regional contribution to the global health agenda and the achievement of the GPW13 targets. The report also noted that the Region had thus far received $138.3 million of the WHO allocation to the Region for base programs, $10 million more than had been received during the 2018–2019 biennium. That was one example of a tangible result of the ongoing coordination between PAHO and WHO. It also reflected Member States’ advocacy for the allocation of a fair share of the WHO budget to the Region. In addition, the report included numerous references, which Member States could consult if they wished to have further details on any aspect of PAHO’s coordination with WHO.

Lastly, Mr. Maza indicated that the Bureau would work with Mexico, one of the Vice-Chairs of the Member State Working Group on sustainable financing, and with the WHO Secretariat to organize the regional consultation on the topic, to be held during the 59th Directing Council in September.

Dr. Ciro Ugarte (Director, Department of Health Emergencies, PASB) noted that Resolution WHA74.7 was the result of a lengthy process of consolidating numerous proposals. It was a long and complex resolution, the implementation of which would cost an estimated $1.4 billion, of which $1.3 billion remained to be mobilized. He stressed the importance of active participation by Member States in the WGPR set up under the Resolution and in the discussions that would take place during the WHA special session to be held in November 2021. He acknowledged, however, that the time difference between Geneva and the countries of the Region would make participation in virtual consultations challenging, which was a concern, given the crucial decisions that would be taken in the next few months.

The Director assured the Executive Committee that the Bureau was keenly aware of the need to ensure that health authorities at the national level, and not just the staff of Member State missions in Geneva, could participate in global discussions on emergency preparedness and response and other issues. It stood ready to provide whatever support was needed to enable such participation. She pointed out that the Americas had much to
contribute, as it was the Region with the most extensive experience in emergency preparedness and response. She also noted that it was important to guard against over-centralization. While it was necessary to have a common policy and approach, and command and control must be ensured, it was essential also to ensure that regions and countries were well prepared to deal with all aspects of emergency response.

204. The Committee took note of the report.

**Implementation of the International Health Regulations (Document CE168/INF/3)**

205. Dr. Ciro Ugarte (Director, Department of Health Emergencies, PASB) summarized the information presented in Document CE168/INF/3, noting that it complemented the information in Document CE168/INF/1 (see paragraphs 178 to 193 above). The document presented information on the acute public health events of international concern reported between 1 July 2020 and 24 April 2021 and on the status of the core capacities of States Parties. He noted that, during the period covered, 60 acute public health events of potential international concern unrelated to the COVID-19 pandemic had been identified and assessed in the Region, representing one third of such events considered globally over the same time frame. It was encouraging to note that national authorities were increasingly the initial source of reporting of such events (67%) and that the average time for Member States to respond to requests for information by PAHO had significantly decreased. Some 44 events, affecting 20 States Parties and three territories in the Region, had been substantiated as being of international public health concern. In the vast majority of those events, the necessary investigation, verification, and assessment had been carried out by Member States, with support from PAHO, even while the pandemic had been in full swing.

206. Regarding the core capacities of States Parties, he noted that, for all 13 core capacities, the average regional scores for the Americas were the same as or above the global averages, with the lowest average score for radiation emergencies, which remained an area of weakness. He was concerned to note, however, that only 29 of the 35 States Parties in the Region had submitted their annual reports on implementation of the International Health Regulations (IHRs) to the Seventy-fourth World Health Assembly. Moreover, just nine States Parties in the Region had consistently submitted their reports since 2011. While recognizing that the demands of the COVID-19 pandemic had undoubtedly had an impact on the capacities of national authorities to meet reporting obligations, he emphasized that the status of the core capacities across the Region could not be analyzed without that information.

207. In the discussion that followed, delegates acknowledged the critical importance and binding nature of the IHRs and reaffirmed their countries’ commitment to their implementation. It was noted that the Regulations allowed for the implementation of additional health measures in response to public health emergencies, provided that they did not cause unnecessary interference with international traffic and trade. PAHO was therefore urged to support countries of the Region in calling for States Parties not to impose onerous measures, such as requiring a certificate of vaccination against COVID-19 as a
condition of entry, and to recognize vaccines approved by other countries’ regulatory agencies.

208. Delegates agreed on the need to evaluate the response to the COVID-19 pandemic and to consider how the Regulations could be strengthened so that the world would be better prepared to detect and respond to future pandemics and other health emergencies. Suggestions included increasing transparency in IHR Emergency Committee decision-making and introducing an intermediate level of alert for international health emergencies. It was noted that a possible WHO convention, agreement, or other international instrument on pandemic preparedness and response—to be discussed during the special session of the World Health Assembly in November (see paragraphs 194 to 204 above)—would have an impact on the future application and implementation of, and compliance with, the Regulations. Nevertheless, it was stressed that the adoption of any such agreement should not be allowed to lead to any backsliding in the progress already achieved; rather, it should serve to strengthen Member States’ involvement in setting the priorities of the multilateral health system.

209. Several delegates described the measures that had been taken at the national level to strengthen their core capacities and points of entry, with several noting that their countries had used joint external evaluations to highlight areas for improvement. The efforts of PAHO and Member States to implement their core capacity requirements and share public health information, including epidemiological alerts and updates, while meeting the competing demands of the pandemic response, were commended. Nevertheless, the low rate of submission of annual reports by States Parties in the Region was noted with concern. The inconsistencies and significant gaps in implementation of the Regulations, which had been brought to light by the pandemic, were also a source of concern.

210. Several specific potential measures to improve implementation and compliance with the Regulations were suggested, including measures to ensure more equitable global access to medicines and vaccines, mechanisms to address the situation of foreigners in a country when a public health event of international concern was declared, and policies for assisting vulnerable populations during such events. The increased use of existing tools, such as after-action reviews, simulation exercises, and peer-to-peer joint external evaluation exercises, was recommended. A delegate reported that her Government was in discussions with other WHO Member States about the potential benefits of a universal review mechanism for compliance with the Regulations and would be interested in an exchange of views with PAHO Member States on the subject.

211. In response to those comments, Dr. Ugarte observed that, in the past, countries reporting public health events of potential international concern in a timely and transparent manner had suffered economic consequences as a result of their efforts; unsurprisingly, delays in the reporting of such events had thus been commonplace. Noting that further capacity-building for PAHO Member States regarding risk communication was needed, he stressed the importance of prompt reporting of events of potential international concern and explained that information received from countries of the Region was immediately
analyzed to identify trends and swiftly turned into usable data and information for the benefit of the Bureau and Member States. Regarding vaccine certificates, Dr. Ugarte noted that the issue was the subject of ongoing discussions by the Bureau’s various technical groups. He pointed out that few countries were demanding vaccine certificates as the sole requirement for entry. Indeed, the vast majority were doing so in an effort to reduce other entry restrictions, such as the requirement to quarantine or present the results of a PCR test. Most countries also recognized any vaccine on the WHO list of vaccines authorized for emergency use.

212. He welcomed the measures taken by Member States to improve their implementation of the IHRs, several of which could serve as examples for other countries to follow. He agreed that a full independent analysis of the response to the COVID-19 pandemic was necessary, although he also pointed out that the Organization was currently still fully engaged in dealing with the health emergency. He was of the view that the potential new global initiatives currently being discussed would strengthen health security and ensure that the lessons learned and progress already achieved were not disregarded. Regarding the suggested measures to improve implementation and compliance with the Regulations, he agreed that the repatriation of foreigners, in particular health workers, during events of international public health concern was fundamental, and that joint efforts should be further strengthened to ensure global access to medicines and other health technologies.

213. The Director reaffirmed the Bureau’s commitment to supporting Member States in their implementation of the Regulations and in their response to public health emergencies. She welcomed Member States’ efforts to comply with the Regulations and to continuously improve their core capacities. She emphasized that full compliance with the Regulations was critical in order to ensure the identification of public health events of international concern and, as had been borne out during the current unprecedented health crisis, to prevent and respond to pandemics.

214. The Executive Committee took note of the report.

Closure of the Session

215. Following the customary exchange of courtesies, the President declared the 168th Session of the Executive Committee closed.

Resolutions and Decisions

216. The following are the resolutions and decisions adopted by the Executive Committee at its 168th Session:
Resolutions

CE168.R1: Collection of Assessed Contributions

THE 168th SESSION OF THE EXECUTIVE COMMITTEE,

Having considered the Report on the Collection of Assessed Contributions (Document CE168/16 and Add. I) presented by the Director;

Noting the current financial stress the Pan American Health Organization is facing as a result of the delay in receipt of assessed contributions;

Noting that the Bolivarian Republic of Venezuela is in arrears in the payment of its assessed contributions to the extent that it is subject to the application of Article 6.B of the Constitution of the Pan American Health Organization;

Noting that as of 21 June 2021, 25 Member States have not made any payments towards their 2021 assessments,

RESOLVES:

1. To take note of the Report on the Collection of Assessed Contributions (Document CE168/16 and Add. I) presented by the Director.

2. To commend the Member States for their commitment in meeting their financial obligations to the Organization by making efforts to pay their outstanding arrears of contributions.

3. To thank the Member States that have already made payments for 2021.

4. To strongly urge the other Member States to pay all their outstanding contributions as soon as possible to mitigate any impact on technical cooperation activities.

5. To request the Director to continue to inform the Member States of any balances due and to report to the 59th Directing Council on the status of the collection of assessed contributions.

(First meeting, 21 June 2021)
CE168.R2: Policy on the Application of Data Science in Public Health Using Artificial Intelligence and Other Emerging Technologies

THE 168th SESSION OF THE EXECUTIVE COMMITTEE,

Having considered the Policy on the Application of Data Science in Public Health Using Artificial Intelligence and Other Emerging Technologies (Document CE168/11),

RESOLVES:

To recommend that the 59th Directing Council adopt a resolution along the following lines:

POLICY ON THE APPLICATION OF DATA SCIENCE IN PUBLIC HEALTH USING ARTIFICIAL INTELLIGENCE AND OTHER EMERGING TECHNOLOGIES

THE 59th DIRECTING COUNCIL,

Having considered the Policy on the Application of Data Science in Public Health Using Artificial Intelligence and Other Emerging Technologies (Document CD59/ ____);

Bearing in mind Member States’ commitments with regard to the strengthening of information systems and data-driven solutions for improving health analysis and forecasting;

Recalling the principles enshrined in the report commissioned by the United Nations Secretary-General on mobilizing the data revolution for sustainable development;

Considering the need to accelerate progress towards the adoption of emerging technologies at all levels of the health sector;

Observing that Member States in the Region of the Americas have officially affirmed their commitment to health data management with the highest level of quality since 1954;

Recognizing the cross-cutting nature of this policy and its complementarity with the objectives of the Strategic Plan 2020-2025 of the Pan American Health Organization and the Sustainable Health Agenda for the Americas 2018-2023,
RESOLVES:

1. To approve the Policy on the Application of Data Science in Public Health Using Artificial Intelligence and Other Emerging Technologies (Document CD59/____).

2. To urge Member States, in accordance with their national contexts, needs, vulnerabilities, and priorities, to:

   a) strengthen institutional and health worker capacity at all levels to implement data science tools and methods, supporting, among other things, the appropriate management of big data, information, and knowledge through the application of emerging technologies to improve and streamline data processes for descriptive, prescriptive, and predictive health-related analyses to inform decision-making processes;

   b) increase, promote, and support the participation of indigenous peoples, Afro-descendants, and members of other ethnic groups, in the development and implementation of data science policies, considering data biases due to gender differences and other factors;

   c) as appropriate, prepare and implement national and subnational policies, plans, programs, and interventions informed by the regional Policy on the Application of Data Science in Public Health Using Artificial Intelligence and Other Emerging Technologies, making the necessary resources and legal framework available and focusing on the needs of at-risk populations in situations of vulnerability.

3. To request the Director to:

   a) provide technical support to Member States for the development and implementation of a regional roadmap for the incorporation of data science techniques and methods at the national, subregional, regional, and inter-institutional levels and facilitate technical cooperation both with and among countries for the preparation and implementation of their national policies;

   b) prioritize technical cooperation to assist countries in strengthening health analysis capacity, including the use of artificial intelligence and other emerging technologies;

   c) facilitate access to open educational materials, tools, networks, and scientific information for improving health worker capacity for data management and health analysis and for the use of artificial intelligence and other emerging technologies;

   d) report periodically to the Governing Bodies on the progress and challenges encountered in the implementation of this regional policy, as well as its adaptation to specific contexts and needs.

(First meeting, 21 June 2021)

THE 168th SESSION OF THE EXECUTIVE COMMITTEE,

Having considered the Roadmap for the Digital Transformation of the Health Sector in the Region of the Americas (Document CE168/10),

RESOLVES:

To recommend that the 59th Directing Council adopt a resolution along the following lines:

ROADMAP FOR THE DIGITAL TRANSFORMATION OF THE HEALTH SECTOR IN THE REGION OF THE AMERICAS

THE 59th DIRECTING COUNCIL,

Having considered the Roadmap for the Digital Transformation of the Health Sector in the Region of the Americas (Document CD59/___);

Bearing in mind the commitments that Member States have made for the strengthening of information systems for health, vital statistics, critical data management, digital literacy, and digital health;

Recalling the principles enshrined by the United Nations Secretary General’s Roadmap for Digital Cooperation;

Considering the need to accelerate progress toward inclusive digital health with emphasis on the most vulnerable populations, especially those in conditions of greater social, economic, geographic, or cultural vulnerability and population groups that are not digitally literate or lack internet access;

Observing that the Member States of the World Health Organization affirmed their commitment to digital health at the 71st World Health Assembly in 2018 by requesting development of a global strategy on digital health, which was approved by the 73rd World Health Assembly through Decision WHA73(28);

Recognizing the cross-cutting nature of this policy and its alignment with the objectives of the PAHO Strategic Plan 2020-2025 and the Sustainable Health Agenda for the Americas 2018-2030,

RESOLVES:

1.  To approve the Roadmap for the Digital Transformation of the Health Sector in the Region of the Americas (Document CD59/___).
2. To urge Member States, considering their own contexts and priorities, to:

a) strengthen institutional and community capacity at all levels to implement digital health solutions, helping, among other things, to support access to quality health services to produce interoperability standards with the capacity to generate sufficient quality data, and to generate evidence in the adoption of emerging technologies such as artificial intelligence and blockchain, among others, where determined beneficial;

b) increase, promote, and support the participation of indigenous peoples, Afro-descendants, Roma, and members of other ethnic groups in the development and implementation of digital transformation policies, considering gender and cultural differences;

c) as appropriate, prepare and implement national and subnational policies, plans, programs, standards, and interventions informed by the Roadmap for the Digital Transformation of the Health Sector in the Region of the Americas, making the necessary resources and legal framework available and focusing on the needs of at-risk populations in vulnerable situations.

3. To request the Director to:

a) provide technical support to Member States in the implementation of a coordinated Roadmap for the Digital Transformation of the Health Sector at the national, subregional, regional, and inter-institutional levels;

b) promote technical cooperation to assist countries in strengthening health system capacity to include digital health solutions in line with the Sustainable Development Goals and applicable international and regional human rights instruments;

c) facilitate the co-creation, production, and dissemination of tools, studies, and reports in support of national policies and digital health solutions;

d) report periodically to the Governing Bodies on the progress and challenges encountered in the implementation of the Roadmap for the Digital Transformation of the Health Sector in the Region of the Americas.

(Fourth meeting, 22 June 2021)

CE168.R4: Increasing Production Capacity for Essential Medicines and Health Technologies

THE 168th SESSION OF THE EXECUTIVE COMMITTEE,

Having reviewed the policy Increasing Production Capacity for Essential Medicines and Health Technologies (Document CE168/12),
RESOLVES:

To recommend that the 59th Directing Council adopt a resolution in the following terms:

INCREASING PRODUCTION CAPACITY FOR ESSENTIAL MEDICINES AND HEALTH TECHNOLOGIES

THE 59th DIRECTING COUNCIL,

Having reviewed the policy Increasing Production Capacity for Essential Medicines and Health Technologies (Document CD59/___);

Considering that one of the basic principles enshrined in the Constitution of the World Health Organization (WHO) is that “enjoyment of the highest attainable standard of health is one of the fundamental rights of every human being without distinction of race, religion, political belief, or economic or social condition” and that the “health of all peoples is a fundamental to the attainment of peace and security and is dependent upon the fullest co-operation of individuals and States”;

Recognizing that access to essential medicines and other health technologies is a global priority and fundamental to universal access to health and universal health coverage, and that some countries face access barriers due to factors such as limited manufacturing capacity and high prices, and that these problems may be exacerbated during public health emergencies or situations of overwhelming demand, such as during the COVID-19 pandemic;

Observing with concern the impact of transport and international trade restrictions on access to raw materials, intermediate inputs, and medicines and other health technologies, including access to substances subject to international control, such as sedatives and analgesics for intubation protocols during the treatment of patients with COVID-19;


1 Draft resolution presented to the 74th World Health Assembly, held from 24-31 May 2021 in Geneva, Switzerland.
Global strategy and plan of action on public health, innovation and intellectual property (WHA61.21 [2008]) and its priority actions;

Recalling the Agreement on Trade-related Aspects of Intellectual Property Rights (TRIPS Agreement), in its amended version, and also the Doha Declaration on the TRIPS Agreement and Public Health, issued by the World Trade Organization (WTO) in Doha in 2001, which states that intellectual property rights can and should be interpreted and implemented in a manner supportive of WTO members’ right to protect public health and, in particular, to promote access to medicines for all, and which recognizes the importance of intellectual property protection for the development of new medicines and the concerns about its effects on prices;

Recognizing that health is a precondition and result of sustainable development and calling for the participation of all relevant sectors in coordinated multisectoral action to urgently address the health needs of the population;

Recognizing that the creation and strengthening of national and regional capacity for the development and production of raw materials and essential medicines and other health technologies is important for improving their affordability and accessibility, and adequately responding to regional health needs, especially during health emergencies, and that this also contributes to health security and economic and social development;

Recognizing the importance of promoting competition to improve the availability and affordability of medicines and other health technologies consistent with public health policies and needs through, inter alia, the manufacture and introduction of generic versions, and especially of essential medicines, in developing countries;

Recognizing the importance of transparency, access to sustainable financing, strengthening of research, and development and transfer of technology under voluntary and mutually agreed terms, as well as the importance of voluntary initiatives such as the COVID-19 Technology Access Pool (C-TAP) and Medicines Patent Pool as mechanisms for building and strengthening national and regional capacity for the development and production of raw materials and essential medicines and other health technologies;

Recognizing the need for strengthened national regulatory systems convergent with international standards to help ensure appropriate oversight of the quality, safety, and efficacy of the raw materials, medicines, and other health technologies produced in the Region;

Recognizing that regional and subregional integration can stimulate production through the development of sustainable demand, including the needs of Member States with small markets, and reaffirming the importance of international cooperation and collaboration with regional agencies of the United Nations system and other international and domestic financial institutions,
RESOLVES:

1. To urge the Member States, considering their contexts, needs, vulnerabilities, and priorities, to:

   a) promote the implementation of comprehensive national multisectoral policies on essential medicines and other health technologies that include roadmaps for their implementation and the explicit statement of multisectoral priorities for development, production, and equitable universal access;

   b) create or strengthen multisectoral governance mechanisms with health sector participation to increase national research, development, innovation, and production capacity, defining roles, respecting sector competencies, and prioritizing attention to regional health needs, with the leadership of national authorities and the collaboration of academia, the private sector, civil society, and international organizations;

   c) strengthen national capacity for the development and production of raw materials and essential medicines and other health technologies, including the training of skilled human resources and, where applicable, the strengthening or development of national infrastructure and clusters that support research, development, innovation, and production activities to better meet health needs and priorities;

   d) strengthen the capacity of institutions with enabling and oversight functions for the medicines and other health technologies sector, including the strengthening of national health regulatory systems;

   e) develop or strengthen, as appropriate, a coherent policy environment for the health sector and the science and technology, industry, and trade sectors to encourage the promotion of research, development, innovation, technology transfer under voluntary and mutually agreed terms, and the production of quality raw materials, essential medicines, and other health technologies, promoting affordability and accessibility, transparency, effectiveness, and competitiveness, environmental protection, and the sustainability of projects;

   f) increase investment in science and technology for the production of raw materials, essential medicines, and other health technologies, and strengthen the incentives for industrial promotion and the use of public procurement that simultaneously fosters affordability, sustainability, competitiveness, development, and regional production;

   g) promote international dialogue and collaboration to make progress toward timely, universal, and equitable access to quality-assured, safe, effective, and affordable essential medicines and other health technologies, including their components and precursors, that are necessary for public health emergencies and long-term planning, while ensuring their fair distribution and eliminating unjustifiable access barriers through a joint effort to promote resilient supply chains.
2. To request the Director to:

a) provide technical cooperation to the Member States in developing and implementing comprehensive policies on essential medicines and other health technologies to help strengthen national capacity, meet multisectoral objectives, and improve access to essential medicines and other health technologies;

b) collaborate with the Member States, in coordination with the national health authorities, in promoting technology transfer under voluntary and mutually agreed terms, as well as intraregional activities in science, technology, and innovation, including networks of institutions devoted to research, development, and innovation, and collaboration with regional industrial associations and international financial institutions for economic and social development;

c) promote collaboration and the exchange of information and experiences among Member States with the participation of the health authorities, and prepare model lists to prioritize the needs for medicines and other health technology in the Region in order to guide investment and other incentives for increasing regional development and production;

d) continue to support the Member States by strengthening the capacity of national health regulatory systems to help ensure appropriate oversight of the safety, quality, and efficacy of medicines and other health technologies, including those produced in the Region, by promoting convergence, regulatory harmonization, and networks of national health regulatory authorities;

e) continue promoting transparency of prices and economic data along the value chain of medicines and other health technologies, including those produced locally, in order to foster affordability and access;

f) continue providing technical support—as appropriate and when requested, in collaboration with the national health authorities and competent international organizations like the World Trade Organization and the World Intellectual Property Organization, including support for policy processes—to countries that intend to make use of the provisions of the TRIPS Agreement, including the flexibilities recognized by the Doha Declaration on the TRIPS Agreement and Public Health, in order to promote access to pharmaceutical products;

g) promote, with the participation of the national health authorities, the development of a regional discussion platform on the challenges and opportunities involved in the production of essential medicines and health technologies, in coordination with the relevant agencies of the United Nations system and other relevant stakeholders—a platform which takes into account the deliberations of the WHO World Local Production Forum.

(Fourth meeting, 22 June 2021)
CE168.R5: Scale of Assessed Contributions for 2022-2023

THE 168th SESSION OF THE EXECUTIVE COMMITTEE,

Whereas in Resolution CE168.R6 the Executive Committee of the Pan American Health Organization (PAHO) has recommended that the 59th Directing Council approve the Proposed Program Budget of the Pan American Health Organization 2022-2023 (Document CE168/8); and

Taking into consideration that the PAHO Scale of Assessed Contributions for 2022-2023 (Document CE168/9) incorporates the new scale of quota assessments of the Organization of American States approved by its General Assembly for the years 2019-2023,

RESOLVES:

To recommend to the 59th Directing Council the adoption of a resolution along the following lines:

SCALE OF ASSESSED CONTRIBUTIONS FOR 2022-2023

THE 59th DIRECTING COUNCIL,

Whereas in Resolution CD59.R__ the Directing Council approved the Program Budget of the Pan American Health Organization 2022-2023 (Official Document__); and

Having examined the report of the Pan American Sanitary Bureau on the Scale of Assessed Contributions for 2022-2023 to be applied to Member States, Participating States and Associate Members of the Pan American Health Organization for the budgetary period 2022-2023 (Document CD59/__);

Bearing in mind the provisions of Article 60 of the Pan American Sanitary Code, which establishes that the assessed contributions of the Pan American Health Organization shall be apportioned among the Signatory Governments on the same basis as the contributions of the Organization of American States;

Taking into account Article 24(A) of the Constitution of the Pan American Health Organization, which states that the Organization shall be financed by annual contributions from its Member Governments and that the rate of these contributions shall be determined in conformity with Article 60 of the Pan American Sanitary Code;

Considering that the General Assembly of the Organization of American States has adopted a scale of quota assessments for the years 2019-2023;

Bearing in mind that the total assessed contribution level still needs to be determined,
RESOLVES:

1. To approve the following Scale of Assessed Contributions for 2022-2023 (Document CD59/__).

2. To request the Secretariat to present detailed amounts of the proposed gross and net assessment contributions to be paid by PAHO Member States, Participating States and Associate Members once the total assessed contribution level is determined.

<table>
<thead>
<tr>
<th>Member</th>
<th>Assessment Rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2022</td>
</tr>
<tr>
<td><strong>Member States</strong></td>
<td></td>
</tr>
<tr>
<td>Antigua and Barbuda</td>
<td>0.037</td>
</tr>
<tr>
<td>Argentina</td>
<td>3.458</td>
</tr>
<tr>
<td>Bahamas</td>
<td>0.054</td>
</tr>
<tr>
<td>Barbados</td>
<td>0.038</td>
</tr>
<tr>
<td>Belize</td>
<td>0.037</td>
</tr>
<tr>
<td>Bolivia</td>
<td>0.081</td>
</tr>
<tr>
<td>Brazil</td>
<td>14.359</td>
</tr>
<tr>
<td>Canada</td>
<td>11.297</td>
</tr>
<tr>
<td>Chile</td>
<td>1.631</td>
</tr>
<tr>
<td>Colombia</td>
<td>1.888</td>
</tr>
<tr>
<td>Costa Rica</td>
<td>0.295</td>
</tr>
<tr>
<td>Cuba</td>
<td>0.152</td>
</tr>
<tr>
<td>Dominica</td>
<td>0.037</td>
</tr>
<tr>
<td>Dominican Republic</td>
<td>0.309</td>
</tr>
<tr>
<td>Ecuador</td>
<td>0.463</td>
</tr>
<tr>
<td>El Salvador</td>
<td>0.088</td>
</tr>
<tr>
<td>Grenada</td>
<td>0.037</td>
</tr>
<tr>
<td>Guatemala</td>
<td>0.197</td>
</tr>
<tr>
<td>Guyana</td>
<td>0.037</td>
</tr>
<tr>
<td>Haiti</td>
<td>0.037</td>
</tr>
<tr>
<td>Honduras</td>
<td>0.050</td>
</tr>
<tr>
<td>Jamaica</td>
<td>0.061</td>
</tr>
<tr>
<td>Mexico</td>
<td>7.458</td>
</tr>
<tr>
<td>Nicaragua</td>
<td>0.037</td>
</tr>
<tr>
<td>Panama</td>
<td>0.220</td>
</tr>
<tr>
<td>Paraguay</td>
<td>0.100</td>
</tr>
<tr>
<td>Peru</td>
<td>1.158</td>
</tr>
<tr>
<td>Saint Kitts and Nevis</td>
<td>0.037</td>
</tr>
<tr>
<td>Saint Lucia</td>
<td>0.037</td>
</tr>
<tr>
<td>Member</td>
<td>Assessment Rate (%)</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Saint Vincent and the Grenadines</td>
<td></td>
</tr>
<tr>
<td>Suriname</td>
<td></td>
</tr>
<tr>
<td>Trinidad and Tobago</td>
<td></td>
</tr>
<tr>
<td>United States of America</td>
<td></td>
</tr>
<tr>
<td>Uruguay</td>
<td></td>
</tr>
<tr>
<td>Venezuela</td>
<td></td>
</tr>
</tbody>
</table>

**Participating States**

<table>
<thead>
<tr>
<th>Member</th>
<th>Assessment Rate (%)</th>
<th>2022</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>France</td>
<td></td>
<td>0.113</td>
<td>0.109</td>
</tr>
<tr>
<td>The Netherlands</td>
<td></td>
<td>0.037</td>
<td>0.044</td>
</tr>
<tr>
<td>United Kingdom</td>
<td></td>
<td>0.037</td>
<td>0.044</td>
</tr>
</tbody>
</table>

**Associate Members**

<table>
<thead>
<tr>
<th>Member</th>
<th>Assessment Rate (%)</th>
<th>2022</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aruba</td>
<td></td>
<td>0.037</td>
<td>0.044</td>
</tr>
<tr>
<td>Curaçao</td>
<td></td>
<td>0.037</td>
<td>0.044</td>
</tr>
<tr>
<td>Puerto Rico</td>
<td></td>
<td>0.060</td>
<td>0.058</td>
</tr>
<tr>
<td>Sint Maarten</td>
<td></td>
<td>0.037</td>
<td>0.044</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td><strong>100.000</strong></td>
<td><strong>100.000</strong></td>
</tr>
</tbody>
</table>

(Fifth meeting, 23 June 2021)

**CE168.R6: Proposed Program Budget of the Pan American Health Organization 2022-2023**

**THE 168th SESSION OF THE EXECUTIVE COMMITTEE,**

Having examined the *Proposed Program Budget of the Pan American Health Organization 2022-2023* (Document CE168/8);

Having considered the *Report on the 15th Session of the Subcommittee on Program, Budget, and Administration* (Document CE168/4);

Noting the efforts of the Pan American Sanitary Bureau (PASB or the Bureau) to propose a program budget that takes into account both the socio-economic considerations and the joint responsibility of Member States and the Bureau in achieving public health mandates;

Noting the efforts of PASB to propose a program budget that considers the evolving context and impact of the ongoing COVID-19 pandemic at global, regional and country level;
Bearing in mind Article 14.C of the Constitution of the Pan American Health Organization and Article III, paragraphs 3.4 and 3.5, of the Financial Regulations of the Pan American Health Organization,

**RESOLVES:**

To recommend to the 59th Directing Council the adoption of a resolution along the following lines:

**PROGRAM BUDGET OF THE PAN AMERICAN HEALTH ORGANIZATION 2022-2023**

*THE 59th DIRECTING COUNCIL,*

Having examined the Program Budget of the Pan American Health Organization 2022–2023 (*Official Document___*);

Having considered the report of the 168th Executive Committee (Document CD59/___);

Noting the efforts of PASB to propose a program budget that takes into account both the socio-economic considerations and the joint responsibility of Member States and the Bureau in achieving public health mandates;

Noting the efforts of PASB to propose a program budget that considers the evolving context and impact of the ongoing COVID-19 pandemic at global, regional and country levels;

Bearing in mind Article 14.C of the Constitution of the Pan American Health Organization and Article III, paragraph 3.5, of the Financial Regulations of the Pan American Health Organization,

**RESOLVES:**

1. To approve the program of work of the Pan American Health Organization (PAHO) with a budget of US$ 640.0 million\(^1\) for base programs and $48.0 million for special programs, as outlined in the Program Budget of the Pan American Health Organization 2022–2023 (*Official Document___*).

2. To encourage all Member States, Participating States, and Associate Members to continue to make timely payments of their assessed contributions in 2022 and 2023 and of arrears that might have accumulated in the previous budgetary periods.

---

\(^1\) Unless otherwise indicated, all monetary figures in this document are expressed in United States dollars.
3. To encourage Member States, Participating States, and Associate Members of the Pan American Health Organization to continue advocating for an equitable share of the World Health Organization’s (WHO) resources and specifically for WHO to fully fund the budget space allocated to the Region of the Americas.

4. To encourage Member States, Participating States, and Associate Members to make voluntary contributions that are aligned with the PAHO Program Budget 2022-2023, and where possible, to consider making these contributions fully flexible and un-earmarked.

5. To approve assessed contributions for the biennium 2022-2023 in the amount of $225.5 million composed of: a) $194.4 million in net assessments of Member States, Participating States, and Associate Members, which requires no increase over the last approved amount of net assessed contributions ($194.4 million), and b) $31,150,000 as a transfer to the Tax Equalization Fund, as indicated in the table below.

6. In establishing the contributions of Member States, Participating States, and Associate Members, assessed contributions shall be reduced further by the amount standing to their credit in the Tax Equalization Fund, except that credits of those states that levy taxes on the emoluments received from PASB by their nationals and residents shall be reduced by the amounts of such tax reimbursements by PASB.

7. To finance the approved base programs in the following manner and from the indicated sources of financing:

<table>
<thead>
<tr>
<th>Source of financing</th>
<th>Amount (US$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assessed contributions from PAHO Member States, Participating States, and Associate Members</td>
<td>225,550,000</td>
</tr>
<tr>
<td>Less credit from Tax Equalization Fund</td>
<td>(31,150,000)</td>
</tr>
<tr>
<td>Budgeted miscellaneous revenue</td>
<td>14,000,000</td>
</tr>
<tr>
<td>PAHO voluntary contributions and other sources</td>
<td>179,000,000</td>
</tr>
<tr>
<td>Funding allocation to the Region of the Americas from WHO</td>
<td>252,600,000</td>
</tr>
<tr>
<td>TOTAL</td>
<td>640,000,000</td>
</tr>
</tbody>
</table>

8. To authorize the Director to use all sources of financing indicated above to fund the PAHO Program Budget 2022-2023, subject to the availability of funding.

9. To request the Director to prepare a report on the expenditure amounts from each source of financing, and against the 28 outcomes outlined in the PAHO Program Budget 2022-2023, to be presented to the Governing Bodies in 2024.

(Fifth meeting, 23 June 2021)
CE168.R7: Assessed Contributions of the Member States, Participating States, and Associate Members of the Pan American Health Organization for 2022 and 2023

THE 168th SESSION OF THE EXECUTIVE COMMITTEE,

Whereas in Resolution CE168.R6 the Executive Committee has recommended that the 59th Directing Council approve the Proposed Program Budget of the Pan American Health Organization 2022-2023 (Document CE168/8);

Whereas in Resolution CE168.R5 the Executive Committee has recommended that the 59th Directing Council approve the Scale of Assessed Contributions for 2022–2023 (Document CE168/9);

Having considered the Report on the 15th Session of the Subcommittee on Program, Budget, and Administration (Document CE168/4),

RESOLVES:

To recommend to the 59th Directing Council the adoption of a resolution along the following lines:

ASSESSED CONTRIBUTIONS OF THE MEMBER STATES, PARTICIPATING STATES, AND ASSOCIATE MEMBERS OF THE PAN AMERICAN HEALTH ORGANIZATION FOR 2022-2023

THE 59th DIRECTING COUNCIL,

Whereas in Resolution CD59.R__ the Directing Council approved the Program Budget of the Pan American Health Organization 2022–2023 (Official Document__);

Considering that Article 60 of the Pan American Sanitary Code and Article 24(A) of the Constitution of the Pan American Health Organization provide that the scale of assessed contributions to be applied to Member States, Participating States, and Associate Members be determined on the basis of the assessment scale adopted by the Organization of American States;

Bearing in mind that the Directing Council, in Resolution CD59.R__, adopted the scale of assessments for the Member States, Participating States, and Associate Members of the Pan American Health Organization for the biennium 2022-2023,

RESOLVES:

To establish the assessed contributions of the Member States, Participating States, and Associate Members of the Pan American Health Organization for the financial periods 2022 and 2023 in accordance with the scale of assessments shown below and in the corresponding amounts, which represent an increase of 0% with respect to the biennium 2020-2021.
# Assessments of the Member States, Participating States, and Associate Members of the Pan American Health Organization for the Financial Period 2022-2023

<table>
<thead>
<tr>
<th>Membership</th>
<th>Assessment Rate (%)</th>
<th>Gross Assessments (US Dollars)</th>
<th>Credit from Tax Equalization Fund (US Dollars)</th>
<th>Adjustments for taxes imposed by Member States on Emoluments of PASB Staff (US Dollars)</th>
<th>Net Assessment (US Dollars)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2022</td>
<td>2023</td>
<td>2022</td>
<td>2023</td>
<td>2022</td>
</tr>
<tr>
<td><strong>Member States</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antigua and Barbuda</td>
<td>0.037</td>
<td>0.044</td>
<td>38,739</td>
<td>46,068</td>
<td>2,775</td>
</tr>
<tr>
<td>Bahamas</td>
<td>0.054</td>
<td>0.058</td>
<td>56,538</td>
<td>60,726</td>
<td>4,050</td>
</tr>
<tr>
<td>Barbados</td>
<td>0.038</td>
<td>0.044</td>
<td>39,786</td>
<td>46,068</td>
<td>2,850</td>
</tr>
<tr>
<td>Belize</td>
<td>0.037</td>
<td>0.044</td>
<td>38,739</td>
<td>46,068</td>
<td>2,775</td>
</tr>
<tr>
<td>Bolivia</td>
<td>0.081</td>
<td>0.086</td>
<td>84,807</td>
<td>90,042</td>
<td>6,075</td>
</tr>
<tr>
<td>Brazil</td>
<td>14.359</td>
<td>15.309</td>
<td>15,033,873</td>
<td>16,028,523</td>
<td>1,076,925</td>
</tr>
<tr>
<td>Chile</td>
<td>1.631</td>
<td>1.739</td>
<td>1,707,657</td>
<td>1,820,733</td>
<td>122,325</td>
</tr>
<tr>
<td>Colombia</td>
<td>1.888</td>
<td>2.013</td>
<td>1,976,736</td>
<td>2,107,611</td>
<td>141,600</td>
</tr>
<tr>
<td>Costa Rica</td>
<td>0.295</td>
<td>0.315</td>
<td>308,865</td>
<td>329,805</td>
<td>22,125</td>
</tr>
<tr>
<td>Cuba</td>
<td>0.152</td>
<td>0.162</td>
<td>159,106</td>
<td>169,630</td>
<td>11,397</td>
</tr>
<tr>
<td>Dominica</td>
<td>0.037</td>
<td>0.044</td>
<td>38,739</td>
<td>46,068</td>
<td>2,775</td>
</tr>
<tr>
<td>Dominican Republic</td>
<td>0.309</td>
<td>0.329</td>
<td>323,523</td>
<td>344,463</td>
<td>23,175</td>
</tr>
<tr>
<td>Ecuador</td>
<td>0.463</td>
<td>0.494</td>
<td>484,761</td>
<td>517,218</td>
<td>34,725</td>
</tr>
<tr>
<td>El Salvador</td>
<td>0.088</td>
<td>0.093</td>
<td>92,136</td>
<td>97,371</td>
<td>6,600</td>
</tr>
<tr>
<td>Grenada</td>
<td>0.037</td>
<td>0.044</td>
<td>38,739</td>
<td>46,068</td>
<td>2,775</td>
</tr>
<tr>
<td>Guatemala</td>
<td>0.197</td>
<td>0.210</td>
<td>206,259</td>
<td>219,870</td>
<td>14,775</td>
</tr>
<tr>
<td>Guyana</td>
<td>0.037</td>
<td>0.044</td>
<td>38,739</td>
<td>46,068</td>
<td>2,775</td>
</tr>
<tr>
<td>Haiti</td>
<td>0.037</td>
<td>0.044</td>
<td>38,739</td>
<td>46,068</td>
<td>2,775</td>
</tr>
<tr>
<td>Honduras</td>
<td>0.050</td>
<td>0.053</td>
<td>52,350</td>
<td>55,491</td>
<td>3,750</td>
</tr>
<tr>
<td>Jamaica</td>
<td>0.061</td>
<td>0.065</td>
<td>63,867</td>
<td>68,055</td>
<td>4,575</td>
</tr>
<tr>
<td>Membership</td>
<td>Assessment Rate (%)</td>
<td>2022</td>
<td>2023</td>
<td>2022</td>
<td>2023</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>---------------------</td>
<td>---------------------</td>
<td>---------------------</td>
<td>---------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2022</td>
<td>2023</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mexico</td>
<td>7.458</td>
<td>7.951</td>
<td>7,808,526</td>
<td>8,324,697</td>
<td>559,350</td>
</tr>
<tr>
<td>Nicaragua</td>
<td>0.037</td>
<td>0.044</td>
<td>38,739</td>
<td>46,068</td>
<td>2,775</td>
</tr>
<tr>
<td>Panama</td>
<td>0.220</td>
<td>0.235</td>
<td>230,340</td>
<td>246,045</td>
<td>16,500</td>
</tr>
<tr>
<td>Paraguay</td>
<td>0.100</td>
<td>0.107</td>
<td>104,700</td>
<td>112,029</td>
<td>7,500</td>
</tr>
<tr>
<td>Peru</td>
<td>1.158</td>
<td>1.235</td>
<td>1,212,426</td>
<td>1,293,045</td>
<td>86,850</td>
</tr>
<tr>
<td>Saint Kitts and Nevis</td>
<td>0.037</td>
<td>0.044</td>
<td>38,739</td>
<td>46,068</td>
<td>2,775</td>
</tr>
<tr>
<td>Saint Lucia</td>
<td>0.037</td>
<td>0.044</td>
<td>38,739</td>
<td>46,068</td>
<td>2,775</td>
</tr>
<tr>
<td>Saint Vincent and the Grenadines</td>
<td>0.037</td>
<td>0.044</td>
<td>38,739</td>
<td>46,068</td>
<td>2,775</td>
</tr>
<tr>
<td>Suriname</td>
<td>0.037</td>
<td>0.044</td>
<td>38,739</td>
<td>46,068</td>
<td>2,775</td>
</tr>
<tr>
<td>Trinidad and Tobago</td>
<td>0.149</td>
<td>0.159</td>
<td>156,003</td>
<td>166,473</td>
<td>11,175</td>
</tr>
<tr>
<td>United States of America</td>
<td>53.150</td>
<td>49.990</td>
<td>55,648,050</td>
<td>52,339,530</td>
<td>3,986,250</td>
</tr>
<tr>
<td>Uruguay</td>
<td>0.343</td>
<td>0.366</td>
<td>359,121</td>
<td>383,202</td>
<td>25,725</td>
</tr>
<tr>
<td>Venezuela</td>
<td>2.236</td>
<td>2.384</td>
<td>2,341,092</td>
<td>2,496,048</td>
<td>167,700</td>
</tr>
</tbody>
</table>

| Participating States           |                     |                     |                     |                     |                     |                                                                             |                     |                     |                                |
| France                         | 0.113               | 0.109               | 118,348             | 114,208             | 8,478               | 8,181                                                                     | 109,870             | 106,027             |
| The Netherlands                | 0.037               | 0.044               | 38,739              | 46,068              | 2,775               | 3,300                                                                     | 35,964             | 42,768             |
| United Kingdom                 | 0.037               | 0.044               | 38,739              | 46,068              | 2,775               | 3,300                                                                     | 35,964             | 42,768             |

| Associate Members              |                     |                     |                     |                     |                     |                                                                             |                     |                     |                                |
| Aruba                          | 0.037               | 0.044               | 38,739              | 46,068              | 2,775               | 3,300                                                                     | 35,964             | 42,768             |
| Curaçao                        | 0.037               | 0.044               | 38,739              | 46,068              | 2,775               | 3,300                                                                     | 35,964             | 42,768             |
| Puerto Rico                    | 0.060               | 0.058               | 62,822              | 60,624              | 4,500               | 4,343                                                                     | 58,321             | 56,282             |
| Sint Maarten                   | 0.037               | 0.044               | 38,739              | 46,068              | 2,775               | 3,300                                                                     | 35,964             | 42,768             |
| **TOTAL**                      | **100,000**         | **100,000**         | **104,700,000**     | **104,700,000**     | **7,500,000**        | **7,500,000**                                                            | **8,075,000**       | **8,075,000**       | **105,275,000**          |

(Fifth meeting, 23 June 2021)
CE168.R8: PAHO Award for Health Services and Leadership 2021

THE 168th SESSION OF THE EXECUTIVE COMMITTEE,

Having examined the Report of the Award Committee of the PAHO Award for Health Services and Leadership 2021 (Document CE168/5, Add. I);

Bearing in mind the provisions of the procedures and guidelines for conferring the PAHO Award for Health Services and Leadership (previously known as the PAHO Award for Administration), as approved by the 56th Directing Council (2018),¹

RESOLVES:

1. To congratulate the candidates for the PAHO Award for Health Services Management and Leadership 2021 for their professionalism and outstanding work on behalf of their countries and the Region.

2. On the recommendation of the Award Committee, to confer the PAHO Award for Health Services Management and Leadership 2021 to Dr. Joanne Liu of Canada, for her significant contributions to the Region through: a) her dedicated work assisting communities affected by the earthquake and cholera epidemic in Haiti; b) supporting health system strengthening efforts in Honduras; c) her leadership in health emergencies and crises responses around the world; and d) her commitment to delivering health services to those living in the most vulnerable situations, all of which encompass key PAHO values such as health equity and solidarity. Dr. Liu’s advocacy for global action in times of crises has helped to further the discussions on health emergency responses. Her work has influenced how countries in the Region, and around the world, implement and advance medical humanitarianism, and her work on health emergencies will continue to be influential - which is critical in the current COVID-19 pandemic context, and as we look towards “building back better”.

3. To transmit the Report of the Award Committee of the PAHO Award for Health Services Management and Leadership 2021 (Document CE168/5, Add. I), to the 59th Directing Council.

(Fifth meeting, 23 June 2021)

¹ The procedures and guidelines for conferring the Award were approved by the 18th Pan American Sanitary Conference (1970) and amended by the 24th Pan American Sanitary Conference (1994), by the Executive Committee at its 124th (1999), 135th (2004), 140th (2007), 146th (2010), and 158th (2016) sessions, and by the 56th Directing Council (2018).
CE168.R9: Appointment of One Member of the PAHO Audit Committee of PAHO

THE 168th SESSION OF THE EXECUTIVE COMMITTEE,

Considering that the 49th Directing Council, through Resolution CD49.R2 (2009), established the Audit Committee of the Pan American Health Organization (PAHO) to function as an independent expert advisory body to the Director of the Pan American Sanitary Bureau (PASB) and PAHO Member States;

Guided by the Terms of Reference of the Audit Committee, which establish the process to be followed in the assessment and appointment by the Executive Committee of the members of the PAHO Audit Committee;

Noting that the Terms of Reference of that Committee stipulate that members shall serve no more than two full terms of three years each;

Considering that a vacancy will exist in the PAHO Audit Committee,

RESOLVES:

1. To thank the Director of the PASB and the Subcommittee on Program, Budget, and Administration for their thorough work in identifying and nominating highly qualified candidates to serve on the PAHO Audit Committee.

2. To appoint Mr. Martín Guozden to serve as a member of the PAHO Audit Committee for a second term of three years from June 2021 through June 2024.

(Fifth meeting, 23 June 2021)

CE168.R10: Emergency Loan from the Revolving Fund for Access to Vaccines to the Regional Revolving Fund for Strategic Public Health Supplies

THE 168th SESSION OF THE EXECUTIVE COMMITTEE,

Noting Resolution CESS1.R1, Emergency Loan from the Revolving Fund for Access to Vaccines to the Regional Revolving Fund for Strategic Public Health Supplies, adopted during the May 2020 Special Session of the Executive Committee of the Pan American Health Organization (PAHO);

Considering the 45% increase in requests by Member States in 2020 for support from the Capital Account of the Regional Revolving Fund for Strategic Public Health Supplies (Strategic Fund) resulting in a 66% increase in total cumulative usage of the Capital Account;
Recognizing the continually increasing requests for support through the PAHO Strategic Fund to facilitate access to life-saving essential medicines and health supplies to combat COVID-19;

Noting that the capitalization level of the PAHO Strategic Fund may be insufficient to meet the future needs of Member States during the COVID-19 pandemic;

Acknowledging the establishment by the Pan American Sanitary Bureau (PASB) of the necessary planning and operational mechanisms, as well as the appropriate managerial and financial controls to ensure that the internal emergency loan provision has no impact on the ability of PASB to support Member States participating in the PAHO Revolving Fund for Access to Vaccines (Revolving Fund),

RESOLVES:

To authorize the Director to do the following:

a) provide an extension of the internal emergency loan consisting of a short-term, limited, rolling transfer of funds, up to a maximum of US$ 50 million,1 from the Capital Account of the Revolving Fund to the Capital Account of the Strategic Fund, to 31 December 2023 or to the date of a declaration by the World Health Organization on the end of the pandemic, whichever comes first;

b) continue to determine the amounts and timing of transfers to the Capital Account of the Strategic Fund, up to the maximum total loan amount of $50 million during the period of the approved resolution, based on the availability of funds in the Capital Account of the Revolving Fund and on the programmatic needs of the participating Member States for vaccines, syringes, and cold chain equipment and for emergency supplies including those for COVID-19;

c) continue to apply appropriate managerial, financial, and analytic controls to ensure that there is no negative impact on the ability of PASB to support Member States participating in the Revolving Fund;

d) report on an annual basis to the Executive Committee sessions on the status of this emergency loan, including its effectiveness and repayment status.

(Fifth meeting, 23 June 2021)

1 Unless otherwise indicated, all monetary figures in this report are expressed in United States dollars.
CE168.R11: One Health: A Comprehensive Approach for Addressing Health Threats at the Human-Animal-Environment Interface

THE 168th SESSION OF THE EXECUTIVE COMMITTEE,

Having reviewed the policy on One Health: A Comprehensive Approach for Addressing Health Threats at the Human-Animal-Environment Interface (Document CE168/13, Rev. 1),

RESOLVES:

To recommend that the 59th Directing Council adopt a resolution along the following lines:

ONE HEALTH: A COMPREHENSIVE APPROACH FOR ADDRESSING HEALTH THREATS AT THE HUMAN-ANIMAL-ENVIRONMENT INTERFACE

THE 59th DIRECTING COUNCIL,

Having reviewed the policy on One Health: A Comprehensive Approach for Addressing Health Threats at the Human-Animal-Environment Interface (Document CD59/__);

Bearing in mind that the COVID-19 pandemic has done much to reverse the gains achieved in recent decades on poverty reduction and on health and well-being in the Region of the Americas;

Recognizing that the health outcomes associated with health threats at the human-animal-environment interface such as zoonotic diseases, antimicrobial resistance (AMR), and food safety issues depend on policies and programs inside and outside the health sector and that strategies for the management of risks at the human-animal-environment interface need to include other sectors and disciplines to maximize impact and ensure sustainability;

Acknowledging that the socioeconomic development of the Region of the Americas has been supported by its increasing agricultural production and its role as a global food producer and exporter, thereby it is crucial to protect such achievements from the impact of zoonotic diseases, antimicrobial resistance, and food safety problems that not only endanger the health of the population, particularly the most vulnerable, but also hinder the socioeconomic development of communities and industries such as tourism and international trade in animal and animal products;

Cognizant that One Health is a collaborative, multidisciplinary, and multisectoral approach that can contribute to addressing health threats at the human-animal-environment interface,
RESOLVES:

1. To approve the policy on *One Health: A Comprehensive Approach for Addressing Health Threats at the Human-Animal-Environment Interface* (Document CD59/__).

2. To urge Member States, taking into account their contexts, needs, vulnerabilities, and priorities, to adopt, adapt, and implement this policy, and to:

   a) establish or strengthen current multidisciplinary, multisectoral, consensus-driven mechanisms for One Health governance, including policies and actions for the stewardship and finance of functional structures working across institutions and enabling coordination, communication, engagement, and collaboration, and for access to relevant knowledge and resources;

   b) foster multisectoral technical activities including strategic planning, emergency preparedness and response, rapid and transparent information, data and sample sharing, in accordance with relevant international agreements, integrated surveillance, laboratory strengthening, and other best practices, with demonstration projects to drive scientific evidence-based collaborative actions;

   c) incorporate a risk analysis approach, taking into account human behavior and other drivers, particularly those challenges that affect the systems on which society depends—health, agriculture/animal production, and environment;

   d) promote training and education of the workforce on One Health, adopt new technologies including digital solutions and scientific tools, and foster research agendas on the human-animal-environment interface.

3. To request the Director to:

   a) apply the One Health approach within the Pan American Sanitary Bureau through inter-programmatic actions fostering the effective use of the Pan American Health Organization’s comprehensive portfolio of knowledge, expertise, and access to stakeholders on health challenges such as food safety, zoonotic diseases, and AMR;

   b) coordinate, promote, and provide technical cooperation to support countries and territories in implementing One Health in collaboration with relevant human, animal, plant, and environmental health partners and stakeholders, including those from the social determinants field;

   c) secure political, managerial, administrative, and financial support for the implementation of One Health by advocating and promoting it, in collaboration with other international and regional entities from the fields of human, animal, and environmental health, as well as by mobilizing external resources;

   d) report to the Governing Bodies on the progress made and challenges faced in implementation of this policy in 2026 and 2031.

(Sixth meeting, 23 June 2021)

THE 168th SESSION OF THE EXECUTIVE COMMITTEE,

Having reviewed the proposed Strategy for Building Resilient Health Systems and Post-COVID-19 Pandemic Recovery to Sustain and Protect Public Health Gains (Document CE168/15),

RESOLVES:

To recommend that the 59th Directing Council adopt a resolution along the following lines:

STRATEGY FOR BUILDING RESILIENT HEALTH SYSTEMS AND POST-COVID-19 PANDEMIC RECOVERY TO SUSTAIN AND PROTECT PUBLIC HEALTH GAINS

THE 59th DIRECTING COUNCIL,

Having reviewed the Strategy for Building Resilient Health Systems and Post-COVID-19 Pandemic Recovery to Sustain and Protect Public Health Gains (Document CD59/\__\);

Recognizing that the COVID-19 pandemic has significantly impacted health, lives, and livelihoods in the Region of the Americas;

Considering that action by Member States is required to address the systemic and structural deficiencies in health systems and emergency preparedness and response that have been exposed by the pandemic, and aware of the potential benefits to be realized by rapidly adopting and consolidating health system innovations observed during the pandemic response;

Noting the urgency to invest and build resilience in health systems that fully address the social, environmental, and economic determinants of health as a means to protect, promote, and sustain health, advance social and economic development, and accelerate the recuperation of lost public health gains,

RESOLVES:

1. To approve the Strategy for Building Resilient Health Systems and Post-COVID-19 Pandemic Recovery to Sustain and Protect Public Health Gains (Document CD59/\__\).
2. To urge Member States, taking into account their contexts, needs, vulnerabilities, and priorities, to:

a) strengthen leadership, governance, and stewardship to implement the strategic lines of action of the Strategy for Building Resilient Health Systems;

b) advance in transforming health systems based on the primary health care approach, inclusive social participation, and a whole-of-government and whole-of-society approach, with intersectoral action to address the social, environmental, and economic determinants of health;

c) measure the institutional capacities of health authorities to perform essential public health functions and develop sectoral and intersectoral action plans to strengthen these functions, integrated into the country policy and budget cycle;

d) build and expand the capacities of health service delivery networks to improve access and overcome fragmentation, including capacities for management and coordination of the networks, planning and management of human resources, digital transformation and strengthening of information systems for health, availability and management of critical supplies, medicines, and other health technologies and infrastructure, community engagement, and the development of adaptable response plans;

e) increase and sustain public investments in health to support the transformation and strengthening of health systems toward the achievement of universal health, paying due attention to the development of capacities for implementation of the essential public health functions, including compliance with the International Health Regulations; and prioritize investments in the first level of care to support the delivery of comprehensive health services (both individual and population-based).

3. To request the Director to:

a) provide technical cooperation to Member States to strengthen capacities that contribute to the implementation of the Strategy for Building Resilient Health Systems;

b) exercise leadership to promote regional cooperation and dialogue in health and foster cooperation among countries and the sharing of knowledge and experiences;

c) report periodically to the Governing Bodies of PAHO on the progress made and challenges faced in the implementation of this strategy through a midterm review in 2026 and a final report in 2032.

(Sixth meeting, 23 June 2021)
CE168.R13: Amendments to the PASB Staff Regulations and Rules

THE 168th SESSION OF THE EXECUTIVE COMMITTEE,

Having considered the amendments to the Staff Rules of the Pan American Sanitary Bureau submitted by the Director in Annex A to Document CE168/21;

Acknowledging the recommendation of the International Civil Service Commission in its 2020 Annual Report to increase the base/floor salary scale for the professional and higher categories and pay protection points by 1.90% on a no-loss/no-gain basis, and the Pan American Sanitary Bureau’s implementation of that recommendation as of 1 January 2021;

Taking into consideration the actions of the Seventy-fourth World Health Assembly regarding the remuneration of the Regional Directors, Assistant Directors-General, and the Deputy Director-General based on the United Nations General Assembly’s approval of the amended base/floor salary scale for the professional and higher categories on a no-loss/no-gain basis;

Bearing in mind the provisions of Staff Rule 020 and Staff Regulation 3.1 of the Pan American Sanitary Bureau;

Recognizing the need for uniformity in the conditions of employment of staff of the Pan American Sanitary Bureau and the United Nations Common System Agencies,

RESOLVES:

1. To confirm, in accordance with Staff Rule 020, the Staff Rule amendments that have been made by the Director effective 1 January 2021 concerning remuneration of staff in the professional and higher categories and the Staff Rule amendments that have been made by the Director effective 1 July 2021 regarding payment and deductions; approval, reporting, and recording of leave and service time; sick leave; parental leave; and staff in posts subject to local recruitment.

2. To establish the annual salary of the Assistant Director of the Pan American Sanitary Bureau, beginning on 1 January 2021, at US$ 184,808 before staff assessment, with a corresponding net base salary of $137,473.

3. To establish the annual salary of the Deputy Director of the Pan American Sanitary Bureau, beginning on 1 January 2021, at $186,323 before staff assessment, with a corresponding net base salary of $138,473.

4. To establish the annual salary of the Director of the Pan American Sanitary Bureau, beginning on 1 January 2021, at $205,264 before staff assessment, with a corresponding net base salary of $150,974.

Appendix

1 Unless otherwise indicated, all monetary figures in this document are expressed in United States dollars.
Appendix

PROPOSED AMENDMENTS TO THE STAFF RULES
OF THE PAN AMERICAN SANITARY BUREAU

<table>
<thead>
<tr>
<th>The substantive amendments presented below shall apply to the specific articles indicated in each case:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>380. PAYMENTS AND DEDUCTIONS</strong></td>
</tr>
<tr>
<td><strong>380.1</strong> Salaries, allowances, and benefits vary according to the staff member’s duty station of assignment and may be adjusted under conditions established by the Bureau.</td>
</tr>
<tr>
<td><strong>380.2</strong> The normal pay period is from the first to the last day of any calendar month.</td>
</tr>
<tr>
<td>[…]</td>
</tr>
<tr>
<td><strong>380.8</strong> The right of the Bureau to claim from an individual any amount the Bureau may have overpaid will normally lapse one year after the overpayment error. The recovery of an overpayment will be governed by the facts of each case, and the affected individual will be notified in writing.</td>
</tr>
<tr>
<td><strong>380.9</strong> The right of an individual to claim from the Bureau any amount the Bureau may have underpaid will normally lapse one year after the underpayment error. The correction of an underpayment will be governed by the facts of each case, and the affected individual will be notified in writing.</td>
</tr>
<tr>
<td><strong>380.10</strong> In the case of overpayment or underpayment of pension contributions, the Bureau will reconcile any differences, which shall not be subject to any time limitation on adjustment or recovery. In the case of underpayment, the staff member’s contribution to the Staff Pension Fund will be deducted from the staff member’s salary in accordance with Staff Rule 380.6.1.</td>
</tr>
<tr>
<td><strong>380.11</strong> Nothing in this rule prevents the Bureau from correcting errors made when determining or recording a staff member’s benefits and entitlements, regardless of when the error occurred.</td>
</tr>
</tbody>
</table>
The substantive amendments presented below shall apply to the specific articles indicated in each case:

### 670. APPROVAL, REPORTING, AND RECORDING OF LEAVE AND SERVICE TIME

**670.1** The granting of leave under Staff Rules 625, 630, 640, and 650 is subject to the exigencies of service and must be approved in advance by authorized officials. The personal circumstances of the staff member shall be considered to the extent possible. It is the staff member’s responsibility to ensure that all leave taken is promptly reported and recorded.

**670.2** The Bureau may correct errors made when determining or recording a staff member’s leave benefits or service time, regardless of when the error occurred.

### 740. SICK LEAVE

**740.1** Staff members, except those excluded under Rule 1320 who are unable to perform their duties because of illness or injury, or whose attendance is prevented by public health requirements, may be granted sick leave with pay with the approval of the Staff Physician in the following amounts:

[...]

**740.1.5** The Bureau may correct errors made when determining or recording a staff member’s sick leave benefit, regardless of when the error occurred.

### 765. PARENTAL LEAVE

**765.3** Staff members holding fixed-term or service appointments shall be entitled to four weeks of parental leave. Eight weeks of parental leave will be granted in the case of:

[...]

**765.4** Staff members holding temporary appointments, as defined in Rule 420.4, shall be entitled to two weeks of parental leave. Four weeks of parental leave will be granted in the case of:

**765.4.1** Staff members in the professional and higher categories serving at a non-family duty station;

**765.4.2** Adoption of a child subject to conditions established by the Bureau and upon presentation of satisfactory evidence of the adoption.
The substantive amendments presented below shall apply to the specific articles indicated in each case:

1310. STAFF IN POSTS SUBJECT TO LOCAL RECRUITMENT

1310.2 All posts in the general service category are subject to local recruitment and, therefore, shall be filled, as far as possible, by persons recruited in the local commuting area of each office. The recognized place of residence for such locally recruited persons, irrespective of their nationality and of the length of time they may have been in the area, shall be determined as the place where the office concerned is located. Applicants to a vacant general service post must be citizens or permanent legal residents of the country of the duty station and able to legally work in the location of the duty station at the time their application is submitted to the Organization for consideration and, if selected, at the time of their appointment and thereafter. Except as specified under Rule 1310.4, the Organization will not sponsor a local work permit or visa for a staff member in the general service category.

(SEventh meeting, 24 June 2021)

CE168.R14: Non-State Actors in Official Relations with PAHO

THE 168th SESSION OF THE EXECUTIVE COMMITTEE,

Having considered the report of the Subcommittee on Program, Budget, and Administration Non-State Actors in Official Relations with PAHO (Document CE168/6);

Mindful of the provisions of the Framework of Engagement with Non-State Actors, adopted by the 55th Directing Council through Resolution CD55.R3 (2016), which governs official relations between the Pan American Health Organization (PAHO) and such entities,

RESOLVES:

1. To admit the following non-State actor into official relations with PAHO for a period of three years:
   a) Campaign for Tobacco-Free Kids.

2. To renew official relations between PAHO and the following nine non-State actors for a period of three years:
   a) Action on Smoking and Health;
   b) American Speech-Language-Hearing Association;
   c) Drugs for Neglected Diseases Initiative - Latin America;
d) Framework Convention Alliance;
e) InterAmerican Heart Foundation;
f) Latin American Federation of the Pharmaceutical Industry;
g) Latin American Society of Nephrology and Hypertension;
h) National Alliance for Hispanic Health;
i) Sabin Vaccine Institute.

3. To request the Director to:

a) advise the respective non-State actors of the decisions taken by the Executive Committee;
b) continue developing dynamic working relations with inter-American non-State actors of interest to the Organization in areas that fall within the program priorities that the Governing Bodies have adopted for PAHO;
c) continue fostering relationships between Member States and non-State actors working in the field of health.

(Seventh meeting, 24 June 2021)

CE168.R15:  Reinvigorating Immunization as a Public Good for Universal Health

THE 168th SESSION OF THE EXECUTIVE COMMITTEE,

Having reviewed the proposed policy document Reinvigorating Immunization as a Public Good for Universal Health (Document CE168/14), which sets out the approach of the Pan American Health Organization (PAHO) and a strategic framework for revitalizing immunization programs in the Region of the Americas,

RESOLVES:

To recommend that the 59th Directing Council adopt a resolution along the following lines:

REINVIGORATING IMMUNIZATION AS A PUBLIC GOOD FOR UNIVERSAL HEALTH

THE 59th DIRECTING COUNCIL,

Having reviewed the policy document Reinvigorating Immunization as a Public Good for Universal Health (Document CD59/___), which sets out PAHO’s approach and a strategic framework for revitalizing immunization programs in the Region of the Americas;
Considering that, despite the tremendous achievements of immunization programs in past decades, progress has stalled or even reversed in many countries in the Region, putting past achievements at risk;

Acknowledging that immunization is among the most cost-effective public health strategies available, and that in addition to its health benefits, immunization provides a high rate of return on investment, resulting in contributions to socioeconomic development and educational attainment;

Cognizant that this policy reflects and supports the commitment made by Member States to advance toward meeting the Sustainable Development Goals by 2030, the goals of the Sustainable Health Agenda for the Americas 2018-2030, and the goals of the Immunization Agenda 2030 of the World Health Organization,

RESOLVES:

1. To approve the policy Reinvigorating Immunization as a Public Good for Universal Health (Document CD59/___).

2. To urge Member States, according to their national context and priorities, to:
   a) adopt and implement the strategic lines of action of this policy to reinvigorate immunization programs through the implementation of innovative approaches and best practices, incorporating technological, communication, behavioral, and data analysis tools;
   b) declare vaccination as a public good and raise awareness among health care workers to advise individuals regarding vaccination, among parents and guardians to have their children immunized, and among individuals to be vaccinated, considering officially recommended immunization schedules;
   c) strengthen governance and leadership of immunization programs, combined with effective oversight, accountability, coalition building, regulation, and attention to system design, to ensure adequate and efficient implementation of this policy and progress toward universal health;
   d) ensure and protect immunization-specific budgets, including but not limited to the costs of vaccines and supplies, human resources, and immunization operations.

3. To request the Director to:
   a) provide technical cooperation and promote collaboration within and across all levels of the Organization and Member States in support of revitalized immunization efforts;
   b) promote and enhance constructive collaboration with other stakeholders relevant to the implementation of this policy— including but not limited to other international organizations, existing networks, programs, and collaborating centers—to pursue synergies and to increase efficiencies;
c) enhance coordination at regional and country levels to improve access to vaccines, diagnostic tests for laboratory networks supporting surveillance, and other key supplies relevant to primary health care, through the Revolving Fund for Access to Vaccines and the Regional Revolving Fund for Strategic Public Health Supplies;

d) report to the Governing Bodies on the progress made and challenges faced in implementation of this policy in 2027 and 2031.

*(Eighth meeting, 24 June 2021)*

**CE168.R16: Provisional Agenda of the 59th Directing Council, 73rd Session of the Regional Committee of WHO for the Americas**

**THE 168th SESSION OF THE EXECUTIVE COMMITTEE,**

Having examined the provisional agenda (Document CD59/1) prepared by the Director of the Pan American Sanitary Bureau for the 59th Directing Council of PAHO, 73rd Session of the Regional Committee of WHO for the Americas, presented as Annex A to Document CE168/3, Rev. 1;


Considering the extraordinary and unprecedented circumstances presented by the COVID-19 pandemic,

**RESOLVES:**

1. To approve the provisional agenda (Document CD59/1) prepared by the Director of the Pan American Sanitary Bureau for the 59th Directing Council of PAHO, 73rd Session of the Regional Committee of WHO for the Americas.

2. To hold the 59th Directing Council of PAHO, 73rd Session of the Regional Committee of WHO for the Americas, from 20 to 24 September 2021, and to request the Officers of the Executive Committee, in consultation with the Pan American Sanitary Bureau, to decide on an in-person or virtual format.

*(Eighth meeting, 24 June 2021)*
Decisions

Decision CE168(D1): Adoption of the Agenda

Pursuant to Rule 9 of the Rules of Procedure of the Executive Committee, the Committee adopted the agenda submitted by the Director (Document CE168/1, Rev. 2).

(First meeting, 21 June 2021)

Decision CE168(D2): Representation of the Executive Committee at the 59th Directing Council, 73rd Session of the Regional Committee of WHO for the Americas

Pursuant to Rule 54 of its Rules of Procedure, the Executive Committee appointed Costa Rica and Ecuador, its President and Rapporteur, respectively, to represent the Committee at the 59th Directing Council, 73rd Session of the Regional Committee of WHO for the Americas. The Committee appointed Haiti and the United States of America as alternate representatives.

(Eighth meeting, 24 June 2021)
IN WITNESS WHEREOF, the Delegate of Costa Rica, President of the Executive Committee, and the Director of the Pan American Sanitary Bureau, Secretary ex officio, sign the present Final Report in the Spanish language.

DONE in Washington, D.C., on this twenty-fourth day of June in the year two thousand twenty-one. The Secretary shall deposit the original texts in the archives of the Pan American Sanitary Bureau. The Final Report will be published on the webpage of the Pan American Health Organization once approved by the President.

Adriana Salazar González
President of the
168th Session of the Executive Committee
Delegate of Costa Rica

Carissa F. Etienne
Secretary ex officio of the
168th Session of the Executive Committee
Director of the
Pan American Sanitary Bureau
Annex A

AGENDA

1. OPENING OF THE SESSION

2. PROCEDURAL MATTERS
   2.1 Adoption of the Agenda and Program of Meetings
   2.2 Representation of the Executive Committee at the 59th Directing Council of PAHO, 73rd Session of the Regional Committee of WHO for the Americas
   2.3 Draft Provisional Agenda of the 59th Directing Council of PAHO, 73rd Session of the Regional Committee of WHO for the Americas

3. COMMITTEE MATTERS
   3.1 Report on the 15th Session of the Subcommittee on Program, Budget, and Administration
   3.2 PAHO Award for Health Services Management and Leadership 2021
   3.3 Non-State Actors in Official Relations with PAHO
   3.4 Appointment of One Member to the Audit Committee of PAHO

4. PROGRAM POLICY MATTERS
   4.1 Proposed Program Budget of the Pan American Health Organization 2022-2023
   4.2 Scale of Assessed Contributions 2022-2023
   4.3 Roadmap for the Digital Transformation of the Health Sector in the Region of the Americas
   4.4 Policy on the Application of Data Science in Public Health Using Artificial Intelligence and Other Emerging Technologies
4. PROGRAM POLICY MATTERS (cont.)

4.5 Increasing Production Capacity for Essential Medicines and Health Technologies

4.6 One Health: A Comprehensive Approach for Addressing Health Threats at the Human-Animal-Environment Interface

4.7 Reinvigorating Immunization as a Public Good for Universal Health

4.8 Strategy for Building Resilient Health Systems and Post COVID-19 Pandemic Recovery to Sustain and Protect Public Health Gains

5. ADMINISTRATIVE AND FINANCIAL MATTERS

5.1 Report on the Collection of Assessed Contributions


5.3 Appointment of the External Auditor of PAHO for 2022-2023

5.4 Update on the Master Capital Investment Fund

5.5 Update on the Working Capital Fund

5.6 Report on the Status of the Emergency Loan from the Revolving Fund for Access to Vaccines to the Regional Revolving Fund for Strategic Public Health Supplies

6. PERSONNEL MATTERS

6.1 Amendments to the PASB Staff Regulations and Rules

6.2 PASB Human Resources Management

6.3 Statement by the Representative of the PAHO/WHO Staff Association
7. MATTERS FOR INFORMATION*

7.1 Update on COVID-19 in the Region of the Americas

7.2 Report on Strategic Issues between PAHO and WHO

7.3 Implementation of the International Health Regulations

8. OTHER MATTERS

9. CLOSURE OF THE SESSION

Annex

---

* Due to the COVID-19 pandemic and according to the meeting of the Officers of the Executive Committee held on 19 April 2021, Final and Progress Reports listed in the Annex to this document will be published on the webpage of the 168th Session of the Executive Committee for information purposes.
### Annex

**Final Reports and Progress Reports on Policies, Strategies and Plans of Action Due for Reporting to the Executive Committee in 2021**

<table>
<thead>
<tr>
<th>Matters for Information</th>
<th>Document Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAHO/WHO Collaborating Centers</td>
<td>CE168/INF/4</td>
</tr>
</tbody>
</table>
## Matters for Information

### Progress Reports on Technical Matters:

<table>
<thead>
<tr>
<th>Number</th>
<th>Title</th>
<th>Document Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.</td>
<td>Plan of Action of Human Resources for Universal Access to Health and</td>
<td>CE168/INF/14(A)</td>
</tr>
<tr>
<td></td>
<td>(Resolution CD56.R5 [2018])</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Resolution CD52.R13 [2013])</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Resolution CD45.R9 [2004])</td>
<td></td>
</tr>
<tr>
<td>B.</td>
<td>Chronic Kidney Disease in Agricultural Communities in Central</td>
<td>CE168/INF/14(B)</td>
</tr>
<tr>
<td></td>
<td>America: Progress Report</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Resolution CD52.R10 [2013])</td>
<td></td>
</tr>
<tr>
<td>C.</td>
<td>Strategy and Plan of Action on Strengthening the Health System to</td>
<td>CE168/INF/14(C)</td>
</tr>
<tr>
<td></td>
<td>Address Violence against Women: Progress Report</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Resolution CD54.R12 [2015])</td>
<td></td>
</tr>
<tr>
<td>D.</td>
<td>Preventing Violence and Injuries and Promoting Safety: A Call for</td>
<td>CE168/INF/14(D)</td>
</tr>
<tr>
<td></td>
<td>Action in the Region: Progress Report</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Resolution CD48.R11 [2008])</td>
<td></td>
</tr>
<tr>
<td>E.</td>
<td>Plan of Action for the Sustainability of Measles, Rubella, and</td>
<td>CE168/INF/14(E)</td>
</tr>
<tr>
<td></td>
<td>Congenital Rubella Syndrome Elimination 2018-2023: Progress Report</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Resolution CSP29.R11 [2017])</td>
<td></td>
</tr>
<tr>
<td>F.</td>
<td>Plan of Action on Entomology and Vector Control 2018-2023: Midterm</td>
<td>CE168/INF/14(F)</td>
</tr>
<tr>
<td></td>
<td>Review</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Resolution CD56.R2 [2018])</td>
<td></td>
</tr>
<tr>
<td>G.</td>
<td>Cooperation for Health Development in the Americas: Progress Report</td>
<td>CE168/INF/14(G)</td>
</tr>
<tr>
<td></td>
<td>(Resolution CD52.R15 [2013])</td>
<td></td>
</tr>
</tbody>
</table>

### Resolutions and other Actions of Intergovernmental Organizations of Interest to PAHO:

<table>
<thead>
<tr>
<th>Number</th>
<th>Title</th>
<th>Document Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.</td>
<td>Seventy-fourth World Health Assembly</td>
<td>CE168/INF/15(A)</td>
</tr>
<tr>
<td>B.</td>
<td>Subregional Organizations</td>
<td>CE168/INF/15(B)</td>
</tr>
</tbody>
</table>
## Annex B

### LIST OF DOCUMENTS

**Official Document**

*OD362*  

**Working Documents**

- **CE168/1, Rev. 2 and CE168/WP**  
  Adoption of the Agenda and Program of Meetings
- **CE168/2**  
  Representation of the Executive Committee at the 59th Directing Council of PAHO, 73rd Session of the Regional Committee of WHO for the Americas
- **CE168/3**  
  Draft Provisional Agenda of the 59th Directing Council of PAHO, 73rd Session of the Regional Committee of WHO for the Americas
- **CE168/4**  
  Report on the 15th Session of the Subcommittee on Program, Budget, and Administration
- **CE168/5 and Add.I**  
  PAHO Award for Health Services Management and Leadership 2021
- **CE168/6**  
  Non-State Actors in Official Relations with PAHO
- **CE168/7**  
  Appointment of One Member to the Audit Committee of PAHO
- **CE168/8, Add. I and Add. II**  
  Proposed Program Budget of the Pan American Health Organization 2022-2023
- **CE168/9**  
  Scale of Assessed Contributions 2022-2023
- **CE168/10**  
  Roadmap for the Digital Transformation of the Health Sector in the Region of the Americas
- **CE168/11**  
  Policy on the Application of Data Science in Public Health Using Artificial Intelligence and Other Emerging Technologies
- **CE168/12**  
  Increasing Production Capacity for Essential Medicines and Health Technologies
**Working Documents (cont.)**

CE168/13 One Health: A Comprehensive Approach for Addressing Health Threats at the Human-Animal-Environment Interface

CE168/14 Reinvigorating Immunization as a Public Good for Universal Health


CE168/16 and Add. I Report on the Collection of Assessed Contributions

CE168/17 Appointment of the External Auditor of PAHO for 2022-2023

CE168/18 Update on the Master Capital Investment Fund

CE168/19 Update on the Working Capital Fund

CE168/20 Report on the Status of the Emergency Loan from the Revolving Fund for Access to Vaccines to the Regional Revolving Fund for Strategic Public Health Supplies

CE168/21 Amendments to the PASB Staff Regulations and Rules

CE168/22 PASB Human Resources Management

CE168/23 Statement by the Representative of the PAHO/WHO Staff Association

**Matters for Information**

CE168/INF/1 Update on COVID-19 in the Region of the Americas

CE168/INF/2 Report on Strategic Issues between PAHO and WHO

CE168/INF/3 Implementation of the International Health Regulations
Annex C

LIST OF PARTICIPANTS/LISTA DE PARTICIPANTES
OFFICERS / MESA DIRECTIVA

President / Presidente: Sra. Adriana Salazar González (Costa Rica)
Vice-President / Vicepresidente: Dr. Jean Patrick Alfred (Haiti)
Rapporteur / Relator: Dr. Fernando Jácome Gavilánez (Ecuador)

MEMBERS OF THE EXECUTIVE COMMITTEE / MIEMBROS DEL COMITÉ EJECUTIVO

BARBADOS

Head of Delegation – Jefe de Delegación
Hon. Jeffrey Bostic
Minister of Health and Wellness
Ministry of Health and Wellness
St. Michael

Delegates – Delegados
Dr. Kenneth George
Chief Medical Officer
Ministry of Health and Wellness
St. Michael

BRAZIL/BRASIL

Head of Delegation – Jefe de Delegación
Sr. Flávio Werneck Noce dos Santos
Assessor Especial do Ministro para Assuntos Internacionais em Saúde
Ministério da Saúde
Brasília

Delegates – Delegados
Sra. Cristina Alexandre
Chefe da Assesoria de Assuntos Internacionais em Saúde
Ministério da Saúde
Brasília

Sr. Indiara Meira Gonçalves
Assessora para Assuntos Multilaterais em Saúde
Ministério da Saúde
Brasília

BRAZIL/BRASIL (cont.)

Delegates – Delegados (cont.)
Sra. Mariana Darvenne
Assessora para Assuntos Multilaterais em Saúde
Ministério do Saúde
Brasília

Sr. Matheus Machado de Carvalho
Subchefe da Divisão de Cidadania
Ministério das Relações Exteriores
Brasília

Sr. Matheus Corradi de Souza
Assesor da Divisão de Cidadania
Ministério das Relações Exteriores
Brasília

Sr. Jackson Lima
Primeiro secretário, Representante Alterno do Brasil junto à Organização dos Estados Americanos
Washington, D.C.

CUBA

Head of Delegation – Jefe de Delegación
Dr. José Ángel Portal Miranda
Ministro de Salud Pública
Ministerio de Salud Pública
La Habana

Delegates – Delegados
Excma. Sra. Lianys Torres Rivera
Embajadora
Embajada de la República de Cuba
Washington, D.C.
## MEMBERS OF THE EXECUTIVE COMMITTEE / MIEMBROS DEL COMITÉ EJECUTIVO (cont.)

### CUBA (cont.)

**Delegates – Delegados (cont.)**

Dr. Néstor Marimón Torres  
Director de Relaciones Internacionales y Cooperación  
Ministerio de Salud Pública  
La Habana

Dra. Evelyn Martínez Cruz  
Jefe del Departamento de Organismos Internacionales  
Ministerio de Salud Pública  
La Habana

Sr. Pablo Berti Oliva  
Consejero  
Ministerio de Relaciones Exteriores  
La Habana

Lic. Martha García Hernández  
Segunda Secretaría  
Ministerio de Relaciones Exteriores  
La Habana

Sr. Asdrúbal de la Vega González  
Tercer Secretario  
Embajada de la República de Cuba  
Washington, D.C.

### COSTA RICA (cont.)

**Delegates – Delegados (cont.)**

Sra. Jennifer Ugalde  
Relaciones Internacionales  
Ministerio de Salud  
San José

Excm. Sra. Samy Araya Rojas  
Embajadora, Representante Alterna de Costa Rica ante la Organización de los Estados Americanos  
Washington, D.C.

Sra. Montserrat Vargas  
Despacho de la Viceministra de Asuntos Bilaterales  
Ministerio de Salud  
San José

Sr. Antonio Alarcón Zamora  
Ministro Consejero, Representante Alterno de Costa Rica ante la Organización de los Estados Americanos  
Washington, D.C.

Sra. Laura Raquel Pizarro Viales  
Ministra Consejera, Representante Alterna de Costa Rica ante la Organización de los Estados Americanos  
Washington, D.C.

Sra. Sofia Isabel Mitjavila  
Ministra Consejera, Representante Alterna de Costa Rica ante la Organización de los Estados Americanos  
Washington, D.C.

### COSTA RICA

**Head of Delegation – Jefe de Delegación**

Sra. Adriana Salazar González  
Jefe de Asuntos Internacionales en Salud  
Ministerio de Salud  
San José

**Delegates – Delegados**

Excm. Sra. Alejandra Solano Cabalceta  
Embajadora, Representante Permanente de Costa Rica ante la Organización de los Estados Americanos  
Washington, D.C.

### ECUADOR

**Head of Delegation – Jefe de Delegación**

Dr. Fernando Jácome Gavilanez  
Director Nacional de Cooperación y Relaciones Internacionales  
Ministerio de Salud Publica  
Quito
MEMBERS OF THE EXECUTIVE COMMITTEE / MIEMBROS DEL COMITÉ EJECUTIVO (cont.)

ECUADOR (cont.)

Delegates – Delegados

Excmo. Sr. Carlos Jativa Naranjo  
Embajador, Representante Permanente de Ecuador ante la Organización de los Estados Americanos  
Washington, D.C.

Sr. Marco Ponce  
Ministro, Representante Alterno de Ecuador ante la Organización de los Estados Americanos  
Washington, D.C.

HAITI/HAITÍ

Head of Delegation – Jefe de Delegación

Dr. Marie Gréta Roy Clement  
Ministre  
Ministère de la Santé publique et de la Population  
Port-au-Prince

Delegates – Delegados

Dr. Lauré Adrien  
Directeur Général  
Ministère de la Santé publique et de la Population  
Port-au-Prince

Dr. Jean Patrick Alfred  
Directeur de l'Unité de Planification  
Ministère de la Santé publique et de la Population  
Port-au-Prince

Dr. Johnny Calonges  
Directeur de l'Unité de Contractualisation  
Ministère de la Santé publique et de la Population  
Port-au-Prince

Dr. Ives Gaston Deslouches  
Directeur de Cabinet  
Ministère de la Santé publique et de la Population  
Port-au-Prince

HAITI/HAITÍ (cont.)

Delegates – Delegados (cont.)

Dr. Michaelle Erika Laforest  
Directrice des Ressources Humaines  
Ministère de la Santé publique et de la Population  
Port-au-Prince

Mr. Jean Bernard Henry  
Counselor, Alternate Representative of Haiti to the Organization of American States  
Washington, D.C.

Ms. Whedly Beautelus  
First Secretary, Alternate Representative of Haiti to the Organization of American States  
Washington, D.C.

MEXICO/MÉXICO

Head of Delegation – Jefe de Delegación

Dr. Hugo López-Gatell Ramírez  
Subsecretario de Prevención y Promoción de la Salud  
Secretaría de Salud  
México, D.F.

Delegates – Delegados

Sr. Marcos Cantero Cortés  
Titular de la Unidad de Análisis Económico  
Secretaría de Salud  
México, D.F.

Excma. Sra. Luz Elena Baños Rivas  
Embajadora, Representante Permanente de México ante la Organización de los Estados Americanos  
Washington, D.C.
MEMBERS OF THE EXECUTIVE COMMITTEE / MIEMBROS DEL COMITÉ EJECUTIVO (cont.)

MEXICO/MÉXICO (cont.)

Delegates – Delegados (cont.)

Lic. Alejandro Svarch Pérez
Comisionado Federal para la Protección contra Riesgos Sanitarios
Secretaría de Salud
México, D.F.

Lic. Ruy López Ridaura
Director General del Centro Nacional de Programas Preventivos y Control de Enfermedades
Secretaría de Salud
México, D.F.

Lic. Dwight Dyer Leal
Director General de Información en Salud
Secretaría de Salud
México, D.F.

Lic. José Luis Alomía Zegarra
Director General de Epidemiología
Secretaría de Salud
México, D.F.

Lic. Ricardo Cortés Alcalá
Director General de Promoción a la Salud
Secretaría de Salud
México, D.F.

Lic. José Luis Díaz Ortega
Encargado de la Dirección General del Centro Nacional para la Salud de la Infancia y la Adolescencia
Secretaría de Salud
México, D.F.

Lic. Martha Leticia Caballero Abraham
Encargada de la Dirección General de Relaciones Internacionales
Secretaría de Salud
México, D.F.

Mtra. Araceli Camacho Chairez
Directora de Políticas de Aseguramiento en Salud
Secretaría de Salud
México, D.F.

MEXICO/MÉXICO (cont.)

Delegates – Delegados (cont.)

Lic. Jose Gustavo Valle Mendoza
Subdirector de Gestión Interamericana
Secretaría de Salud
México, D.F.

Lic. Zulema Guerra Carpio
Jefa del Departamento para el Sistema Interamericano
Secretaría de Salud
México, D.F.

Lic. Maite Narváez Abad
Segunda Secretaria, Representante Alterna de México ante la Organización de los Estados Americanos
Washington, D.C.

SURINAME

Head of Delegation – Jefe de Delegación

Hon. Dr. Amar N. Ramadhin
Minister of Health
Ministry of Health
Paramaribo

Delegates – Delegados

Dr. Rakesh Sukul
Acting Director of Health
Ministry of Health
Paramaribo

Dr. Ritesh Dhanpat
Acting Deputy Director of Health
Ministry of Health
Paramaribo

Ms. Diana Koswal
Acting Deputy Financial Director of Health
Ministry of Health
Paramaribo

Mrs. Saskia Bleau
Acting Head of the Planning, Monitoring and Evaluation Department
Ministry of Health
Paramaribo
MEMBERS OF THE EXECUTIVE COMMITTEE / MIEMBROS DEL COMITÉ EJECUTIVO (cont.)

UNITED STATES OF AMERICA/ESTADOS UNIDOS DE AMÉRICA

Head of Delegation – Jefe de Delegación

Ms. Loyce Pace
Director
Office of Global Affairs
Department of Health and Human Services
Washington, D.C.

Delegates – Delegados

Ms. Mara Burr
Director, Multilateral Relations
Office of Global Affairs
Department of Health and Human Services
Washington, D.C.

Ms. Nerissa Cook
Deputy Assistant Secretary
Bureau for Global Health
United States Agency for International Development
Washington, D.C.

Mr. Ted Faris
Deputy Director
Office of Management, Policy, and Resources
Bureau of International Organization Affairs
Department of State
Washington, D.C.

Mr. Colin McIff
Deputy Director
Office of Global Affairs
Department of Health and Human Services
Washington, D.C.

Ms. Sarah Emami
Senior Global Health Officer
for Multilateral Relations
Office of Global Affairs
Department of Health and Human Services
Washington, D.C.

UNITED STATES OF AMERICA/ESTADOS UNIDOS DE AMÉRICA (cont.)

Delegates – Delegados (cont.)

Ms. Brittany Hayes
Global Health Officer for Multilateral Relations
Office of Global Affairs
Department of Health and Human Services
Washington, D.C.

Ms. Meghan Holohan
Acting Multilateral Affairs Team Lead
Bureau for Policy, Planning and Learning
U.S. Agency for International Development
Washington, D.C.

Mr. Jonathan Howard
Deputy Director
Office of Economic and Development Assistance
Bureau of International Organization Affairs
Department of State
Washington, D.C.

Ms. MacKenzie Klein
Global Health Officer
Office of the Americas
Office of Global Affairs
Department of Health and Human Services
Washington, D.C.

Ms. Gabrielle Lamoureille
Deputy Director, Multilateral Relations
Office of Global Affairs
Department of Health and Human Services
Washington, D.C.

Ms. Maya Levine
Senior Global Health Officer
Multilateral Relations
Office of Global Affairs
Department of Health and Human Services
Washington, D.C.

Ms. Marcela Lievano-Martinez
Global Health Officer
Office of the Americas
Office of Global Affairs
Department of Health and Human Services
Washington, D.C.
MEMBERS OF THE EXECUTIVE COMMITTEE / MIEMBROS DEL COMITÉ EJECUTIVO (cont.)

UNITED STATES OF AMERICA/ESTADOS UNIDOS DE AMÉRICA (cont.)

Delegates – Delegados (cont.)

Mr. Andrew Lorenz
Health Advisor
Office of Economic and Development Assistance
Bureau of International Organization Affairs
Department of State
Washington, D.C.

Ms. Heidi Mihm
Health Systems Advisor
Latin America and Caribbean Bureau
U.S. Agency for International Development
Washington, D.C.

Ms. Kristy Mordhorst
Health Advisor
Office of Economic and Development Assistance
Bureau of International Organization Affairs
Department of State
Washington, D.C.

Ms. Leandra Olson
Senior Global Health Officer
Multilateral Relations
Office of Global Affairs
Department of Health and Human Services
Washington, D.C.

Mr. W. William Schluter
Director
Global Immunization Division
Center for Global Health
Centers for Disease Control and Prevention
Washington, D.C.

Mr. Bradley Setser
Counselor to the U.S. Trade Representative
Office of the United States Trade Representative
Washington, D.C.

Mr. JP Shuster
Management Specialist
Office of Management, Policy, and Resources
Bureau of International Organization Affairs
Department of State
Washington, D.C.

Ms. Anne Snyder
Senior Global Health Officer
Office of Trade and Health
Office of Global Affairs
Department of Health and Human Services
Washington, D.C.

OTHER MEMBERS NOT SERVING IN THE EXECUTIVE COMMITTEE / OTROS MIEMBROS QUE NO FORMAN PARTE DEL COMITÉ EJECUTIVO

ARGENTINA

Sra. Carla Moretti
Directora Nacional de Relaciones Internacionales
Ministerio de Salud
Buenos Aires

Sra. Gabriela Ramirez
Asesora, Dirección Nacional de Relaciones Internacionales
Ministerio de Salud
Buenos Aires

Sra. Georgina Grigioni
Asesora, Dirección Nacional de Relaciones Internacionales
Ministerio de Salud
Buenos Aires

Lic. Andrea Polach
Asesora
Dirección Nacional de Relaciones Internacionales
Ministerio de Salud
Buenos Aires
OTHER MEMBERS NOT SERVING IN THE EXECUTIVE COMMITTEE / OTROS MIEMBROS QUE NO FORMAN PARTE DEL COMITÉ EJECUTIVO  (cont.)

BAHAMAS

Ms. Alarice Grant
Ministry of Health
Nassau

Dr. Cherita Moxey
Senior House Officer
Ministry of Health
Nassau

BELIZE/BELICE

Hon. Michel Chebat Jr. SC
Minister of Health and Wellness
Ministry of Health
Belmopan

BOLIVIA (PLURINATIONAL STATE OF/ ESTADO PLURINACIONAL DE)

Dra. María Renee Castro Cusicanqui
Viceministra de Promocion, Vigilancia Epidemiologica y Medicina Tradicional
Ministerio de Salud
La Paz

Dra. Ivet Campos
Responsable de Programa
Ministerio de Salud
La Paz

Dra. Lizeth Ganci
Jefa de Gestion de Riesgos, Emergencias y Desastres
Ministerio de Salud
La Paz

Dr. Ronald Nelson Machaca
Médico Cirujano
Ministerio de Salud
La Paz

CANADA/CANADÁ (cont.)

His Excellency Hugh Adsett
Ambassador, Permanent Representative of Canada to the Organization of American States
Washington, D.C.

Mr. Nicolas Palanque
Director, Multilateral Relations Division
Office of International Affairs for the Health Portfolio
Government of Canada, Ottawa

Ms. Lucero Hernandez
Manager, Multilateral Relations Division
Office of International Affairs for the Health Portfolio
Government of Canada, Ottawa

Ms. Jennifer Izaguirre
Policy Analyst
Office of International Affairs for the Health Portfolio
Government of Canada, Ottawa

Mr. William Wang
Policy Analyst
Office of International Affairs for the Health Portfolio
Government of Canada, Ottawa

Ms. Charlotte McDowell
Senior Development Officer and Alternate Representative of Canada to the Organization of American States
Washington, D.C.

Ms. Marissa de la Torre Ugarte
Policy Analyst
Global Affairs Canada
Inter-American Program
Ottawa

CHILE

Dr. Enrique Paris Mancilla
Ministro de Salud
Ministerio de Salud
Santiago
OTHER MEMBERS NOT SERVING IN THE EXECUTIVE COMMITTEE / OTROS MIEMBROS QUE NO FORMAN PARTE DEL COMITÉ EJECUTIVO (cont.)

CHILE (cont.)

Exmo. Sr. Issa Kort Garriga
Embajador, Representante Permanente de Chile ante la Organización de los Estados Americanos
Washington, D.C.

Dr. Francisco Adriañola Santibáñez
Coordinador de Asuntos Internacionales
Ministerio de Salud
Santiago

COLOMBIA (cont.)

Sra. Grecia Umbarila
Asesora, Grupo de Cooperación y Relaciones Internacionales
Ministerio de Salud y Protección Social
Bogotá

Sr. Luis Hincapié
Asesor, Coordinación de Asuntos Sociales
Dirección de Asuntos Económicos, Sociales y Ambientales
Ministerio de Relaciones Exteriores
Bogotá

COLOMBIA

Sr. Luis Alexander Moscoso
Viceministro de Salud Pública y Prestación de Servicios
Ministerio de Salud y Protección Social
Bogotá

Exmo. Sr. Aleandro Ordonez
Embajador, Representante Permanente de Colombia ante la Organización de los Estados Americanos
Washington, D.C.

Sra. Faride Carlier
Directora de Asuntos Económicos, Sociales y Ambientales
Ministerio de Relaciones Exteriores
Bogotá

Sra. Adriana Maldonado
Ministra Consejera, Representante Permanente Alterna de Colombia ante la Organización de los Estados Americanos
Washington, D.C.

Sra. Paola Bernal
Coordinadora, Grupo de Cooperación y Relaciones Internacionales
Ministerio de Salud y Protección Social
Bogotá

Sra. Ximena Valdivez
Coordinadora de Asuntos Sociales
Dirección de Asuntos Económicos, Sociales y Ambientales
Ministerio de Relaciones Exteriores
Bogotá

DOMINICAN REPUBLIC/REPÚBLICA DOMINICANA

Dr. Eddy Pérez Then
Asesor, Despacho del Ministro de Salud
Ministerio de Salud Pública
Santo Domingo

Dr. Eladio Pérez
Viceministro de Salud Colectiva
Ministerio de Salud Pública
Santo Domingo

Excmo. Sr. Josué Fiallo
Embajador, Representante Permanente de la República Dominicana ante la Organización de los Estados Americanos
Washington, D.C.

Sr. José Luis Domínguez
Ministro Consejero, Representante Alterno de la República Dominicana ante la Organización de los Estados Americanos
Washington, D.C.

Sr. Gerardo Guemez
Ministro Consejero, Representante Alterno de la República Dominicana ante la Organización de los Estados Americanos
Washington, D.C.
OTHER MEMBERS NOT SERVING IN THE EXECUTIVE COMMITTEE /
OTROS MIEMBROS QUE NO FORMAN PARTE DEL COMITÉ EJECUTIVO (cont.)

EL SALVADOR

Dr. Carlos Alvarenga Cardoza
Viceministro de Salud
Ministerio de Salud
San Salvador

Dr. Ronald Pérez Escobar
Director de Políticas y Gestión de Salud
Ministerio de Salud
San Salvador

GRENADA

H.E. Yolande Smith
Ambassador, Permanent Representative of Grenada to the Organization of American States
Washington, D.C.

GUATEMALA

Excm. Sra. Blanca Rita Claverie de Sciolli
Embajadora, Representante Permanente de Guatemala ante la Organización de los Estados Americanos
Washington, D.C.

Sr. Kenneth Rafael Marroquín
Subdirector de Política Multilateral para Organismos Regionales
Ministerio de Relaciones Exteriores
Ciudad de Guatemala

Sra. María Eugenia Ardón Quezada
Asesora del Despacho Ministerial
Ministerio de Salud y Asistencia Social
Guatemala

Sr. Mauricio R. Benard Estrada
Consejero, Representante Alterno de Guatemala ante la Organización de los Estados Americanos
Washington, D.C.

Sra. Lady Empreratriz Ramos Puac
Primer Secretario de la Subdirección de Política Multilateral de Organismos Regionales
Ministerio de Relaciones Exteriores
Ciudad de Guatemala

GUYANA

Hon. Dr. Frank Anthony
Minister of Health
Georgetown

Dr. Leslie Ramsammy
Advisor
Ministry of Health
Georgetown

Dr. Narine Singh
Chief Medical Officer
Ministry of Health
Georgetown

HONDURAS

Licda. Alba Consuelo Flores Ferrufino
Subsecretaria de Estado
Secretaría de Salud
Tegucigalpa

Dr. Nery Conrado Cerrato Ramirez
Subsecretario de Proyecto e Inversión
Secretaría de Salud e Inversión
Tegucigalpa

NICARAGUA

Dr. Carlos Sáenz Torres
Secretario General
Ministerio de Salud
Managua

Dr. Cristian Toledo
Director General de Vigilancia
Ministerio de Salud
Managua

Dr. Luis Urcuyo
Director General de Planificación y Desarrollo
Ministerio de Salud
Managua
### OTHER MEMBERS NOT SERVING IN THE EXECUTIVE COMMITTEE / OTROS MIEMBROS QUE NO FORMAN PARTE DEL COMITÉ EJECUTIVO (cont.)

#### PANAMA/PANAMÁ
- **Dra. Nadja I. Porcell Iglesias**
  - Directora General de Salud Pública
  - Ministerio de Salud
  - Ciudad de Panamá
- **Dr. Cirilo Lawson**
  - Director de Planificación de Salud
  - Ministerio de Salud
  - Ciudad de Panamá
- **Lic. Thays Noriega**
  - Directora de Asuntos Internacionales y Cooperación Técnica
  - Ministerio de Salud
  - Ciudad de Panamá
- **Dr. Luis Garrido**
  - Asesor del Ministro de Salud
  - Ministerio de Salud
  - Ciudad de Panamá
- **Lic. José Luis Vásquez**
  - Coordinador de la Dirección de Asuntos Internacionales
  - Ministerio de Salud
  - Ciudad de Panamá

#### SAINT KITTS AND NEVIS/SAINST KITTS Y NEVIS
- **Hon. Akilah Byron- Nisbett**
  - Minister of Health et al.
  - Ministry of Health
  - Basseterre
- **Dr. Hazel Laws**
  - Chief Medical Officer
  - Ministry of Health
  - Basseterre
- **Dr. Delores Stapleton-Harris**
  - Permanent Secretary
  - Ministry of Health
  - Basseterre

#### SAINT LUCIA/SANTA LUCÍA
- **Senator Hon. Mary Issac**
  - Minister for Health and Wellness
  - Ministry of Health and Wellness
  - Waterfront, Castries

#### TRINIDAD AND TOBAGO/TRINIDAD Y TABAGO
- **Ms. Anita Sohan**
  - Director, International Cooperation Desk
  - Ministry of Health
  - Port-of-Spain

#### URUGUAY
- **Dr. Daniel Salinas**
  - Ministro de Salud Pública
  - Ministry of Health
  - Montevideo
- **Dr. Miguel Asqueta**
  - Director General de Salud
  - Ministerio de Salud
  - Montevideo
- **Mag. Gabriela Gómez**
  - Directora de Relaciones Internacionales y Cooperación
  - Ministerio de Salud Pública
  - Montevideo
### OTHER MEMBERS NOT SERVING IN THE EXECUTIVE COMMITTEE / OTROS MIEMBROS QUE NO FORMAN PARTE DEL COMITÉ EJECUTIVO (cont.)

#### URUGUAY (cont.)
- Lic. Luis Galicia  
  Coordinador de Programas  
  Ministerio de Salud Pública  
  Montevideo

#### VENEZUELA (BOLIVARIAN REPUBLIC OF/ REPÚBLICA BOLIVARIANA DE) (cont.)
- Dr. Julio Francisco Colmenares  
  Director de Relaciones Multilaterales  
  Oficina de Integración y Asuntos Internacionales  
  Ministerio del Poder Popular para la Salud  
  Caracas

- Sr. Jhon Rafael Guerra Sansonetti  
  Consejero, Misión Permanente de la República Bolivariana de Venezuela ante la Organización de las Naciones Unidas  
  New York

- Sr. Jhon Rafael Guerra Sansonetti  
  Consejero, Misión Permanente de la República Bolivariana de Venezuela ante la Organización de las Naciones Unidas  
  New York

### PARTICIPATING STATES / ESTADOS PARTICIPANTES

#### FRANCE/FRANCIA
- Mrs. Anne Vidal de la Blache  
  Ambassador, Permanent Representative of France to the Organization of American States  
  Washington, D.C.

- Mrs. Alexandra LeBorgne  
  Political Advisor, Alternate Observer of France to the Organization of American States  
  Washington, D.C.

#### FRANCE/FRANCIA (cont.)
- Ms. Agathe Renault  
  Intern, Permanent Observer of France to the Organization of American States  
  Washington, D.C.

### OBSERVER STATES / ESTADOS OBSERVADORES

#### SPAIN/ESPAÑA
- Sra. Dña. Carmen Montón  
  Embajadora, Observadora Permanente de España ante la Organización de los Estados Americanos  
  Washington, D.C.

#### SPAIN/ESPAÑA (cont.)
- Sra. Dña. Concepción Figueroa  
  Observadora Permanente Adjunta de España ante la Organización de los Estados Americanos  
  Washington, D.C.
REPRESENTATIVES OF INTERGOVERNMENTAL ORGANIZATIONS / REPRESENTANTES DE ORGANIZACIONES INTERGUBERNAMENTALES

Caribbean Community/ Comunidad del Caribe
Dr. Douglas Slater
Dr. Karen Gordon-Boyle
Organization of American States/ Organización de los Estados Americanos
Ms. Maricarmen PLata

REPRESENTATIVES OF NONGOVERNMENTAL ORGANIZATIONS IN OFFICIAL RELATIONS WITH PAHO / REPRESENTANTES DE ORGANIZACIONES NO GUBERNAMENTALES EN RELACIONES OFICIALES CON LA OPS

American Public Health Association/ Asociación Americana de Salud Pública
Dr. Georges Benjamin
Ms. Vina HuLamm
Latin American Federation of the Pharmaceutical Industry/ Federación Latinoamericana de la Industria Farmacéutica
Sr. Rafael Díaz-Granados
Sr. Juan Carlos Trujillo de Hart

American Speech-Language-Hearing Association/Asociación Americana del Habla, Lenguaje y Audición
Mrs. Lily Waterston
Ms. Lemmieta McNeilly
Latin American Society of Nephrology and Hypertension/ Sociedad Latinoamericana de Nefrología e Hipertensión
Dr. Alejandro Ferreiro Fuentes
Sr. Guillermo Álvarez Estévez
Sr. Alfonso Cueto Manzano

Drug for Neglected Diseases Initiative/ Iniciativa Medicamentos para Enfermedades Olvidadas
Mr. Francisco Viegas Neves da Silva
Ms. Michel Lotrowska
National Alliance for Hispanic Health/ Alianza Nacional para la Salud Hispana
Ms. Marcela Gaitán

Inter-American Association of Sanitary and Environmental Engineering/ Asociación Interamericana de Ingeniería Sanitaria y Ambiental
Sr. Hugo Esteban Silva
Pan-American Federation of Nursing Professionals/ Federación Panamericana de Enfermeras Profesionales
Mg. Maria Concepcion Chavez

Inter-American Society of Cardiology/Sociedad Interamericana de Cardiología
Dr. Fernando Wyss Quintana
United States Pharmacopeial Convention
Mr. Victor Pribluda
Mr. Michael Schmitz
SPECIAL GUESTS / INVITADOS ESPECIALES

External Auditor, National Audit Office/Audit Externo, Oficina Nacional de Auditoría

Mr. Damian Brewitt
Mr. Simon Irwin

PAN AMERICAN SANITARY BUREAU / OFICINA SANITARIA PANAMERICANA

Director and Secretary ex officio of the Executive Committee/Directora y Secretaria ex officio del Comité Ejecutivo

Dr. Carissa F. Etienne

Advisors to the Director/Asesores de la Directora (cont.)

Dr. Heidi Jimenez
Legal Counsel, Office of the Legal Counsel
Asesora Legal, Oficina del Asesor Jurídico

Ms. Mônica Zaccarelli Davoli
Senior Advisor, Governing Bodies Office Asesora Principal, Oficina de los Cuerpos Directivos

Ms. Mary Lou Valdez
Deputy Director Directora Adjunta

Dr. Jarbas Barbosa Da Silva Jr.
Assistant Director Subdirector

Mr. Gerald Anderson
Director of Administration Director de Administración